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This thesis aims to further the use of value of information (VOI) methods in research 
prioritisation. It comprises seven chapters and a freely available online tool. The 
Chapter 1 provides an introduction to VOI and an overview of the methods that have 
thus far been developed to address the practical barriers to its use. Chapter 2 
illustrates the rapid VOI methods which are the focus of this thesis using a case 
study from one of six retrospective proposals provided by the national institute for 
health research (NIHR) trials and studies coordinating centre (NETSCC). This 
provides an estimate of the value of research in terms of research cost required to 
gain an additional unit of a disease specific binary outcome. Chapter 3 provides an 
approach to addressing the challenge of prioritising across disease areas by linking 
disease specific binary outcomes to a generic measure of health outcome: quality 
adjusted life years (QALYs). The implications of using a generic health outcome in 
research prioritisation are explored. Chapter 4 extends the methods from Chapters 2 
and 3 to allow for analysis of a wider range of outcomes (including continuous and 
survival outcomes) and develops a method for estimating the VOI provided by a 
feasibility studies. Chapter 5 introduces the online tool which implements each 
method described in previous chapters (https://shiny.york.ac.uk/rane/.) Chapter 6 
addresses the question of how to make early access decisions without a full 
economic model. Granting early access means that treatments can be quickly 
provided without delay. The cost of this is that it can remove the possibility of 
research. This chapter provides a framework for early access decisions which is built 
upon the rapid methods described in previous chapters. Chapter 7 concludes by 
providing a brief overview of the entire thesis and identifies avenues for future 
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Chapter 1  
 INTRODUCTION  
Empirical research provides the scientific foundation for modern medicine. Whether 
carried out by the public or private sector, budgets to fund research and the real 
resources to carry it out are limited. Research can take many forms such as 
randomised controlled trials (RCTs), observational studies, feasibility studies. 
Research prioritisation is the practice of choosing to fund certain research proposals 
at the expense of not funding others.  
Research prioritisation is an important activity. It was estimated that global 
investment in applied biomedical research was over US$97 billion (adjusted for 
purchasing power parity) in 2010 (Røttingen et al., 2013). Approximately 90% of 
this is spent in high income countries. For these high income countries, the same 
study estimated that 60% of health research and development investments are 
allocated by the business sector, 30% are allocated by the public sector and about 
10% are allocated by charity and non-profit organisations.  
Though the majority of research and development investments are made by the 
private sector, a substantial proportion is made by the public and charity sectors. 
There are two related reasons for the involvement of the public and charity sectors in 
health care research. The first, is because a large amount of health care is not 
delivered through pure private markets. This is due to a variety of reasons including 
but not limited to: incomplete information, equity concerns, increasing returns to 
scale and political history (Arrow, 1963; Culyer, 2012; Mooney, 2012). The second 
reason is that research carried out by the private sector can be seen as insufficient to 
meet health needs. Research decisions by the private sector are guided with regard to 
generating profits through sales of products. Research commissioning by public 
bodies is important in developed countries in areas in which expected profits are 
insufficient to incentivise adequate research investment. For example, research on 
antimicrobials (Rothery et al., 2018), novel indications for off patent drugs or new 
types of psychological therapy. Private incentives are especially inadequate to 
address medical need in low and middle income countries. In 2010, approximately 
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10% of global investment in biomedical research was spent in low and middle 
income and only 1% of all global research funding was allocated to the diseases most 
prevalent in low and middle income countries, such as tuberculosis and malaria, 
despite the fact that these diseases are responsible for more than 12% of the global 
burden of disease (Kieny et al., 2016; Røttingen et al., 2013). 
Research prioritisation by the public sector in developed counties is carried out by a 
range of national bodies. These include the patient centred outcome research institute 
(PCORI) in the United States (US), the Australian medical research advisory board 
(AMRAB) and the Canadian institute of health research (CIHR). In the United 
Kingdom research is prioritised by a branch of the national institute for health 
research (NIHR) called the NIHR evaluation, trials and studies coordinating centre 
(NETSCC). In developing countries research is funded and allocated by a mix of 
national aid organisations, charities and non-governmental organisations (NGOs) 
such as the UK department for international development (2018), Bill and Melinda 
Gates foundation (2018), European and developing countries clinical trials 
partnership (2018) and the US national institutes of health (2018).  
The research proposals which these bodies choose between must first be chosen 
before being presented to decision makers. This involves making research 
recommendations, i.e. choosing which research questions deserve attention in 
different disease areas. In the UK the James Lind alliance is an organisation which is 
dedicated to this question. It is a priority setting partnership which brings together 
patients, clinicians and carers to identify and prioritise unanswered questions across 
a range of disease areas (James Lind alliance, 2019). 
In making research prioritisation decisions on the basis of need in both developing 
and developed countries the aim is to fund research which will improve health 
outcomes. This is a complex task which requires scrutiny. Quantitative methods 
which estimate the health impact of research projects can improve the transparency 
and accountability of this process. To this end, a number of methods to aid research 
prioritisation have been proposed. A review by Fleurence and Torgerson (2004) 
identified five approaches to aid research prioritisation: subjective methods, burden 
of disease methods, clinical variations, payback methods and value of information 
(VOI) methods. A description and comparison of each of these approaches is beyond 
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the scope of this thesis, however this review concluded that VOI was the only 
approach which was consistent with the objective “to provide the most health 
benefits to the population that it serves within the budget constraint and while 
respecting equity considerations”. 
The aim of this PhD is to further the use of VOI in research prioritisation by 
developing and demonstrating methods to calculate VOI which fit within the 
practical constraints of the bodies responsible for decision making. The remainder of 
this chapter provides an introduction to VOI, a summary of the barriers to its wider 
use, an overview of the methods developed to address these barriers and finally a 
summary of the structure and contributions of this PhD. 
VOI is a method to estimate the value of reducing uncertainty before making a 
decision. It was originally developed in the 1950’s to address decision making in 
industrial engineering and then further developed in the 1960’s (Howard, 1966; 
Myers et al., 2012; Schlaifer and Raiffa, 1961).  
In the context of health, VOI has been developed as an approach to dealing with 
uncertainty in the economic evaluation of health technologies. Economic evaluation 
involves constructing an “economic model” or “decision analytic model” which is a 
mathematical model used to inform decision making by comparing the costs and 
health effects associated with the relevant treatment options (Briggs et al., 2006). By 
taking account of the likely costs and benefits of different treatment alternatives the 
optimal treatment choice can be identified in a way which takes account of budget 
constraints.  
The mathematical structure used to predict the relevant costs and benefits will 
depend on the disease being modelled and the data available. Decision trees 
represent possible prognosis (e.g. continued disease vs cure) using a series of 
pathways (Briggs et al., 2006; Drummond et al., 2015). Costs, health consequences 
and probabilities for each of the possible pathways are attached using the existing 
evidence. The expected benefits and costs of a given treatment can then be 
estimated. Decision trees are widely used but they are not well suited to capturing 
the natural history of more long term and/or chronic diseases (e.g. breast cancer). 
This is because with chronic diseases patients face a series of competing risks (e.g. 
different types of recurrence, death from breast cancer, death from natural causes) 
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and therefore a large number of possible pathways are required to represent this 
natural history. This complexity results in decision trees becoming “bushy” with 
many possible pathways. Markov models are used overcome this limitation. Markov 
models characterise disease natural history as a series of “states”. These represent the 
possible health states that can be experienced by a patient. In the case of breast 
cancer these may be; local recurrence, metastatic disease, death from breast cancer 
and death from natural causes. At each time point in the model there is a probability 
of moving from one state to another. Each state is associated with different costs and 
health consequences. Different treatments affect how patients move through between 
states and so Markov models can be used to estimate the expected cots and health 
consequences associated with different treatments (Briggs et al., 2006; Drummond et 
al., 2015)1.  
In addition to differences in model structure, there exist different types of economic 
evaluation in which different units used to capture treatment benefits. If benefits are 
kept in clinical outcomes (e.g. life years gained or dental cavity avoided) then this is 
known as a cost effectiveness analysis (CEA). This approach can be used when there 
is a single common effect which can be compared across treatment alternatives 
(Drummond et al., 2015). The output of this analysis is typically presented as the 
additional cost associated with an additional unit of outcome (e.g. £1,000 per dental 
cavity avoided). The limitation of CEA is that often decision makers need to 
compare the additional benefits of a more expensive treatment against the 
opportunity cost (i.e. the benefits foregone) associated with higher costs. This creates 
a difficulty as the health benefits foregone by increased costs may be in a different 
clinical area to the treatments assessed. To make an informed decision, the benefits 
gained must be compared to the benefits foregone and this is difficult to achieve in 
the absence of a generic measure of health outcome which captures health benefits 
across disease areas. Cost utility analysis (CUA) is often invoked to overcome this 
issue. In this approach health benefits are captured using a generic measure of health 
outcome such as quality adjusted life years (QALYs). These measures capture both 
length and quality of life and so can be used to capture the relative benefits of 
treatments across disease areas. Results are typically presented as the additional cost 
                                               
1 Other more complex model structures also exist but these are beyond the scope of the present thesis 
(Brennan et al., 2006). 
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associated with an additional QALY (e.g. £2,000 per QALY gained). There also 
exists another form of economic evaluation, cost benefit analysis (CBA) which 
converts all benefits into monetary terms. For example, the monetary value of an 
additional QALY may be used to convert a CUA into a CBA. In principle this could 
be used to compare the benefits in one sector of the economy such as health care to 
the benefits gained in another sector such as transport (UK Treasury, 2003). 
Regardless of the type of economic evaluation or the decision model structure, an 
economic evaluation will always contain uncertainties. For the purposes of this 
thesis it is important to distinguish between two types of uncertainty; structural 
uncertainty and input uncertainty (Strong, 2012)2. Structural uncertainty is the 
inherent uncertainty associated with constructing a mathematical approximation of 
reality. It reflects the fact that we cannot be certain that we have the “true” model i.e. 
a model that would correctly predict reality if the true values of our inputs were 
known (Strong, 2012). 
The second source of uncertainty is input uncertainty (also known as parameter 
uncertainty), this reflects the fact that the inputs to our decision model will have 
some uncertainty associated with them which can be expressed mathematically. For 
example relative treatment effects may be estimated from a clinical trial, in which 
case uncertainty will be captured by the standard error (SE). Reducing uncertainty in 
inputs helps inform decisions about the optimal intervention for subsequent patients 
and this has health consequences (Claxton, 1999; Eckermann and Willan, 2009; 
Wilson, 2015). 
For example, given existing evidence intervention A may be judged to be the optimal 
choice; however, due to uncertainty in the relative treatment effect, there is a chance 
that intervention B is in fact more effective. Therefore, when the existing evidence is 
uncertain there is always a chance that one of the alternative interventions could 
improve health outcomes to a greater extent than the intervention which is 
considered best on average. This means that there are adverse health consequences 
associated with uncertainty. The importance of this uncertainty is indicated by the 
scale of these health consequences. The scale is dependent on the likelihood that a 
                                               
2 There exist other forms of uncertainty such as “methodological” and “code” uncertainty but an 




particular intervention is not the most effective option, how much less effective it is 
likely to be (in terms of some measure of health outcome), and the size of the patient 
population facing the uncertain intervention choice.  
VOI methods calculate the expected health consequences of the current (input) 
uncertainty and these expected health consequences can be interpreted as an estimate 
of the health benefits that could be gained each year if the uncertainty surrounding 
treatment choice were resolved, i.e., it provides an expected upper bound on the 
health benefits of further research3. These potential expected benefits increase with 
the size of the patient population whose treatment choice can be informed by 
additional evidence and the time over which evidence about the effectiveness of the 
interventions is expected to be useful (see Chapter 2 for further explanation and 
illustration). 
As it estimates the value of reducing uncertainty VOI is well suited to the task of 
research prioritisation as it can be used to calculate the health gain from reducing 
uncertainty by funding specific research proposals. However, VOI can also be used 
in other applications which require trading off the benefits of additional information 
with the costs of acquiring information such as in the case of early access decisions. 
Granting immediate access to a new technology may provide expected health 
benefits but if further research is not possible with approval then the benefits of 
approval must be compared to the benefits of research foregone. VOI can provide a 
consistent and transparent approach to illustrating the consequences of this trade-off 
(see Chapter 5 for further details). 
Despite benefits to VOI and evidence that decision makers find the results useful in 
decision making (Bennette et al., 2016; Bindels et al., 2016; Carlson et al., 2018, 
2013; Claxton and Sculpher, 2006), there are a number of well documented barriers 
to its use in decision making these include: i) human resources, ii) time, iii) 
computing resources and iv) familiarity with methods. 
Human resources represent a barrier as VOI analysis is often based on the results of 
a decision analytic model which reports results in terms of costs and QALYs 
                                               
3 In this thesis VOI is used from a payer perspective to estimate the value of further research in terms 
of health outcomes. However, VOI can also be used from a manufacturer perspective in which case 
the benefits of further research will be in terms of expected profit (Willan, 2008).  
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(Meltzer et al., 2011; Myers et al., 2012). Constructing a full decision analytic model 
typically requires access to clinical expertise in addition to skills in critical appraisal 
and synthesis of evidence and decision modelling. In addition to access to skilled 
labour these models also require a large amount of time to construct and validate. 
Decision makers often operate within rigid timelines and so cannot easily delay 
decisions until a full economic model has been constructed. Even in cases in which a 
decision model exists, conducting VOI analysis using these models can demand 
access to substantial computing resources (Myers et al., 2012; Strong et al., 2015). 
This is due to simulations required to calculate VOI (discussed in Chapter 2). In 
order to reduce the computing resources required, important advances have been 
made in efficient calculation of VOI metrics (Brennan and Kharroubi, 2007; Heath et 
al., 2018, 2017; Jalal and Alarid-Escudero, 2018; Menzies, 2016; Strong et al., 
2015). However these methods facilitate the efficient calculation of VOI metrics 
given an economic model and so do not address the time and human resources 
required to build full economic models. Another barrier is familiarity with VOI 
methods which have been identified in a number of pilot studies (Bennette et al., 
2016; Bindels et al., 2016; Claxton and Sculpher, 2006; Fleurence and Meltzer, 
2013) Though economic modelling has become more widely understood and utilised 
in health care, decision makers remain relatively unfamiliar with VOI methods. This 
creates an important barrier to their uptake as results may be difficult to interpret and 
it is irresponsible to base decisions on methods which are poorly understood.  
In one respect this lack of familiarity reflects a catch-22 in which VOI methods are 
not utilised because decision makers are unfamiliar with the methods and decision 
makers are unfamiliar with the methods because they are not utilised (Heller, 1961). 
However it is also relevant to note that much academic work on VOI has been 
focused on developing technical extensions rather than on communicating the basic 
insights of the approach and making the methods more practical for use within 
existing decision making structures. 
In response to this collection of barriers Meltzer et al., (2011) have pioneered a 
“minimal modelling approach” in which VOI metrics can be calculated “without 
constructing a decision model of the disease and treatment process”. This minimal 
modelling approach aims to surmount the barriers described earlier by creating 
simple economic models which are easier to understand and do not require large 
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human, time or computing resources to calculate VOI metrics. The authors provide 
methods to calculate VOI in two scenarios. First is the case in which data from a 
clinical study is available which directly characterises uncertainty in both costs and 
outcomes and is sufficient to inform a decision about the benefits of alternative 
interventions. This requires that the study includes all the relevant treatment 
alternatives, follows individuals up to the point of death or to full recovery and 
collects information on a comprehensive measure of benefit such as QALYs. In this 
case the value of future research can be calculated by bootstrapping the results of the 
clinical study. The second scenario is one in which the treatments of interest are 
expected to affect quality of life only with negligible effects on survival. In these 
cases, if quality of life is directly measured by a clinical trial, then a survival model 
can be built which will allows for VOI to be calculated. A limitation of these 
approaches is that prior clinical studies do not always exist, not least studies which 
are sufficient to inform a decision about the benefits of all relevant treatments. It can 
also be difficult to access the individual patient data required to carry out the analysis 
described by Meltzer and colleagues. 
In providing support to a US based cancer research prioritisation group, Bennette et 
al., (2016) and Carlson et al., (2018) found that there did not exist any prior studies 
on which to base VOI analysis and so the Meltzer approach was not feasible in their 
context. In response, these authors developed a “hybrid between full decision 
analytic models and the conceptualization of ‘‘minimal modelling’’ by Meltzer and 
others.” This involved developing individual Markov models for each research 
proposal. The aim of these models is to relate changes in the primary endpoint to 
estimated lifetime costs and benefits (measured in QALYs). As model structure was 
kept simple it was possible to develop the required models for each research 
proposal within the time constraints of the prioritisation process. This approach is 
very well suited to cancer research prioritisation as the high level disease process is 
relatively similar across different types of cancer. The limitation of this approach is 
that research prioritisation bodies typically receive proposals from a range of disease 
areas and so must prioritise research across disease areas. To apply the approach of 
Bennette, Carlson and others to this prioritisation task would require a tool box of 
“disease specific minimal models” to address research proposals arising from a 
diverse pool of pathologies. 
24 
 
An alternative approach to calculating VOI metrics to aid research prioritisation 
across disease areas has been developed by Claxton et al., (2015a, 2013) and 
McKenna et al., (2016). This method is based on a simple decision tree and places 
the primary outcome at the centre of analysis. This means that this approach is not 
specific to any particular disease area. The primary outcome reported in existing 
studies, or a proposed new study, usually captures the most important aspects of 
health outcome. Uncertainty in the primary outcome is used as a starting point in 
order to understand the health consequences of uncertainty, e.g., the distribution of 
values describing uncertainty about the relative effect of an intervention on a specific 
endpoint. Starting with a primary outcome does not mean that other outcomes are 
unimportant, it simply places the focus on a specific outcome of interest as a starting 
point in order to establish the value of reducing uncertainty in that outcome. The 
health benefits of research, and the value of implementing the findings of existing 
evidence are expressed as the number of events avoided for a harmful outcome (e.g., 
death) or gained for a benefit outcome (e.g., cure). In situations where there are a 
number of other important aspects of outcome that are not captured in the primary 
outcome (e.g., adverse events, quality of life impacts or resource implications), a 
minimum clinical difference (MCD) in effectiveness in the primary outcome may be 
specified in order to capture these additional considerations. For example, a larger 
MCD in effectiveness in the primary outcome may need to be detected in a new 
research study before there is confidence that health outcomes will be improved. 
This is analogous to the concept of an effect size, which has been central to the 
design of clinical research and determines the sample size used in most clinical trials. 
Where the primary endpoint of a study is not sufficient to capture all valuable 
aspects of outcome, external evidence can be used to link the endpoint to a 
comprehensive measure of outcome. This is analogous to the hybrid minimal 
modelling approach described by Bennette et al., (2016) and Carlson et al., (2018) 
where intermediate endpoints may be mapped to a meaningful comprehensive 
measure of outcome through simple extrapolation or modelling efforts. Because 
these methods are simpler and quicker to calculate than the others they are referred 
to as “rapid methods”. 
Each of the approaches discussed attempt to simplify the task of creating decision 
models so that it is feasible to calculate VOI metrics within the time provided by 
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institutional constraints. In addition to reducing the expertise and time required, such 
simplification has the benefit of making the VOI methods easier to understand. 
However, simplification necessarily reduces the sophistication of the analysis. This 
induces the risk of over-simplification of complex clinical processes. Therefore, the 
extent to which the simplified approach adequately addresses the need for further 
evaluative research is an important consideration. This can be addressed by ensuring 
that the assumptions underpinning the analysis are made as explicit as possible and 
consideration is given to the likely impact that these assumptions might have on the 
findings. 
 CASE STUDIES 
In this thesis we develop the approach of Claxton, McKenna and others to address 
the diversity of research proposals received by prioritisation bodies. To motivate the 
appropriate methodological developments this work has been carried out with input 
and case studies from NETSCC. This reflects the intention of this work to make both 
an academic contribution and to provide practical methods usable by decision 
makers within the current institutional constraints. 
The NIHR is the main body that commissions and funds applied health and social 
care research in the UK. There are a number of NIHR funding streams, which 
include Programme Grants for Applied Research (PGfAR), Programme 
Development Grants, Research for Patient Benefit (RfPB), Health Technology 
Assessment (HTA), Efficacy and Mechanism Evaluation (EME), Health Services 
and Delivery Research (HS&DR), Public Health Research (PHR), Invention for 
Innovation (i4i), and NIHR Training Awards (NIHR, 2018a). Research prioritisation 
decisions are made in the vast majority of these programmes. However, for the 
purposes of this thesis, we focus on those made by the NETSCC HTA programme, 
which funds research that delivers information about the clinical and cost-
effectiveness of developments in health care technologies (including drugs, devices, 
procedures, diagnosis and screening) and the impact of treatment and tests to NHS 
patients. There are two main workstreams within the HTA programme: i) the 
researcher-led workstream, which offers researchers the opportunity to submit 
proposals on topics or research questions within the programme’s remit; and ii) 
the commissioned workstream, which invites applications in response to calls for 
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research on specific questions that have been identified and prioritised for their 
importance to the NHS and patients (NIHR HTA, 2018). Research proposals may 
include primary research, evidence synthesis, or feasibility and pilot studies.  
The assessments required for prioritising research will be demonstrated using a set of 
six historical proposals that were considered as part of the NIHR HTA programme. 
NETSCC provided the set of six retrospective proposals with all confidential and 
personal information removed including costing information (only total costs of the 
proposal were provided). The six proposals were specifically chosen to demonstrate 
the diverse variety of types of studies and broad spectrum of issues that NETSCC is 
typically asked to commission, including: i) feasibility studies; ii) complex multi-
arm adaptive trials; iii) disinvestment decisions associated with discontinuation of 
treatment; iv) inexpensive interventions; v) expensive trials; and vi) non-randomised 
safety trials. The six proposals are briefly summarised below: 
 Proposal 1 (P1): Trial of early versus late treatment of prophylaxis to reduce 
venous thromboembolism following traumatic brain injury. 
 Proposal 2 (P2): Trial discontinuation of a very high price medicine used for 
treating late stage cancer melanoma. 
 Proposal 3 (P3): Non-randomised safety trial discontinuation of a very high 
price medicine for treating atypical haemolytic uraemic syndrome. 
 Proposal 4 (P4): Complex multi-arm adaptive trial investigating treatments to 
modify the course of Alzheimer’s disease. 
 Proposal 5 (P5): Feasibility study investigating treatment for first episode 
psychosis in children and young people. 
 Proposal 6 (P6): Trial of a low cost educational booklet, which aims to 
provide information to family carers of patients with cancer to facilitate death 
in their preferred location. 
 
 OVERVIEW OF THESIS 
Chapter 2 introduces the place of VOI methods in research prioritisation in addition 
to outlining the rapid methods of research prioritisation which are the focus of this 
thesis. These methods were introduced by Claxton et al., (2015a) and are based 
around uncertainty in the primary outcome. The rapid method is illustrated for a 
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binary primary outcome (functional recovery) using a case study from one of six 
retrospective proposals provided by NETSCC. As no suitable studies exist on which 
to base the uncertainty in the primary outcome, a novel method for characterising 
uncertainty in the absence of available evidence is outlined. This provides an 
estimate of the value of research in terms of research cost required to gain an 
additional unit of a primary outcome (cost per additional unit of functional 
recovery). The results of applying this approach to the full set of six retrospective 
proposals are illustrated and the challenges of prioritising across research proposals 
without a common metric of value are discussed.  
Chapter 3 provides an approach to addressing the challenge of prioritising across 
disease areas by linking primary outcomes to a generic measure of health outcome 
such as QALYs. This approach has been described in Claxton et al., 2013 and 
McKenna et al., (2016) and is demonstrated here by applying it to the case study 
from Chapter 2. This provides an estimate of the value of research in terms of 
research cost required to gain an additional QALY. The result of applying this 
method to the full set of six NETSCC proposals is a table of research proposals 
which can be ranked in terms of value for money. As research budgets are limited, 
the benefits of a particular research proposal must be compared to the benefits of 
other research proposals which could have been funded with these resources. In 
order to reflect these trade-offs appropriately, we apply the “bookshelf” approach 
described by Culyer (2016) and Remme et al., (2017) to the research prioritisation 
task. This allows us to rank research proposals from highest to lowest health impact 
and so identify the “best buys” for decision makers. It also provides a basis to 
understand whether health outcomes could be improved by expanding the research 
budget relative to the budget for general health expenditure. This approach to 
research prioritisation also shows the population health implications for charitable 
and industry contributions to research funding. In addition, this chapter also explores 
issues of using research to change clinical practice and how to use information on 
relative prices to determine an appropriate MCD. 
Though the methods discussed in Chapters 2 and 3 can assist decision makers in 
addressing the key tasks of research prioritisation, they are directly applicable to 
only two of the six research proposals provided by NETSCC. Chapter 4 extends 
these methods to allow for analysis of binary primary outcomes when costs of 
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treatment depend on the primary outcome, continuous primary outcomes and 
survival primary outcomes. The analysis for each type of primary outcome is 
illustrated using a case study from the original six NETSCC proposals. Chapter 4 
also develops and applies a novel method for estimating the value of information 
provided by a feasibility/pilot studies. These are a research design which involves 
carrying out a small initial study to determine whether a larger comparative 
effectiveness research project (a “full trial”) is possible. This extension allows the 
expected health impact of proposals for feasibility/pilot studies to be compared 
directly to proposals for RCTs or other comparative effectiveness research which is 
essential if funding for feasibility/pilot studies and full trials come from the same 
research budget. 
The methods described in Chapters 2 to 4 provide a means to rapidly estimate the 
value of research for a range of primary outcomes for both comparative effectiveness 
research and feasibility/pilot studies. The “rapid approach” to VOI analysis is to 
provide decision makers with models which are practical, built around primary 
outcomes and are quick to implement. The aim of Chapter 5 is to introduce a tool 
which has been designed to reduce the technical barriers to implementation of VOI 
methods. This tool is called Rapid Assessment of Need for Evidence (RANE) is an 
important contribution of this PhD. RANE is open source, hosted by the University 
of York and is freely available for use at https://shiny.york.ac.uk/rane/. The RANE 
tool embeds the methods described in Chapters 2 to 4 and so allows users to quickly 
carry out VOI calculations to help inform research prioritisation decisions without 
having to code new models for each research proposal. This is vitally important as 
reducing the time and technical barriers to VOI analysis can facilitate its use more 
widely in the health system thus improving the transparency and accountability of 
research decision making. Chapter 5 reviews the software currently available for 
research prioritisation, provide an overview of the RANE tool and its capabilities 
and provides a step by step illustration of how to use the tool using a NETSCC 
proposal as an example.  
Chapter 6 extends beyond a HTA research funding panel setting (NETSCC) into a 
more comprehensive HTA decision making context in which approval and research 
decisions are made simultaneously. This chapter address the question of how to 
make early access decisions without a full economic model. There is pressure on 
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decision makers to allow early access to medications and devices with high prices 
when the evidence base is highly uncertain. The benefit of granting early access to 
new treatments which appear to be effective based on current evidence is that 
potentially worthwhile treatments can be quickly provided to patients without undue 
delay (Claxton et al., 2016; Eckermann and Willan, 2008a). However, the cost of 
granting early access is that it can reduce or remove the possibility of further 
research (Griffin et al., 2011). This implies a trade-off between expected health 
benefits for current patients from early access and health benefits to future patients 
from further research. The literature on conditional coverage of health technologies 
provides a coherent and transparent basis to trade-off price, uncertainty and effect 
size when making early access decisions and so can provide a basis to link evidence 
to pharmaceutical pricing (Claxton et al., 2008; Rothery et al., 2017). Conditional 
coverage recognises that decision makers can make not only approve or reject 
decisions but also have options such as “Only in Research” (OIR) and “Approval 
with Research” (AWR). The former only allows the use of new treatment in a 
research setting. The latter approves the treatment for widespread use on the 
condition that additional evidence is collected (Claxton et al., 2012; McKenna et al., 
2015; Walker et al., 2012). Currently the literature on conditional coverage assumes 
that decision makers have access to a full economic model. In this chapter we 
provide a framework for early access decisions which is built upon the rapid 
methods described in Chapters 2, 3 and 4. The approach is illustrated for a binary 
primary outcome using a case study from the set of six NETSCC proposals 
introduced in Chapter 2.  
Chapter 7 concludes by providing a brief overview of the entire thesis and identifies 





Chapter 2  
Rapid assessment of need for evidence: estimating 
the value of research in terms of cost per primary 
outcome 
 INTRODUCTION 
Research is central to the functioning of modern medicine but resources to fund it are 
limited. Therefore choices must be made about which research projects should be 
funded and which should not. Research prioritisation is the practice of choosing to 
fund certain research proposal at the expense of not funding others.  
There are a number of bodies worldwide which are charged with deciding which 
research projects to fund given limited budgets for research. These include national 
agencies such as NETSCC in the UK and the PCORI in the US, and international 
bodies such as the Bill and Melinda Gates foundation (2018) and the European and 
developing countries clinical trials partnership (2018). Value of information (VOI) 
analysis is a method which can potentially add to the transparency and accountability 
of the research prioritisation process by providing quantitative estimates of the value 
of different research proposals. The value of research is understood here as the health 
gain from reducing uncertainty in health care decision making. There is greater value 
in resolving the uncertainty in some clinical decisions rather than others as some 
decisions are more uncertain and have greater health consequences. These methods 
for calculating the value of research make use of the available evidence and will be 
described in detail in the next section. 
Historically VOI analysis has required building a full health economic model which 
reported results in terms of costs and quality adjusted life years (QALYs). A health 
economic model is a mathematical model which draws on a range of data sources to 
estimate the costs and health effects associated with an intervention over an 
appropriate time horizon (Briggs et al., 2006). Constructing such models typically 
requires a large amount of time and a range of expertise including clinical advisors 
and experts in decision modelling and evidence synthesis. For resource constrained 
resource prioritisation bodies this is an important barrier to their use. In response 
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Claxton et al., (2015a) have developed “rapid” methods to calculate VOI which are 
based around uncertainty in the most important clinical endpoint (the primary 
outcome). These methods can be applied to binary primary outcomes (i.e., an 
outcome which either occurs or it does not occur) to calculate the value of reducing 
uncertainty in the relative effect and the baseline probability of the primary outcome. 
They do not require a full economic model and so can provide a practical approach 
for decision makers to inform their decision making process. In this chapter we apply 
the VOI methods to estimate the benefit of research developed in Claxton et al., 
(2015a) to a retrospective set of proposals received by NETSCC to understand their 
implications for applied research prioritisation.  
First we outline the current processes used in identifying high priority research. 
Second, we outline the most important determinants of the health impact of research 
and how VOI takes account of these. Third we describe the need for rapid 
approaches to calculate VOI and the evidence required to carry out this analysis. 
Fourth, we apply the rapid approach to a case study from the set of 6 retrospective 
NETSCC proposals. As part of this we outline a method to characterise uncertainty 
in the absence of previous studies. Finally, we explore the implications of this 
approach when prioritising across a set of research proposals. 
 IDENTIFYING HIGH PRIORITY RESEARCH 
Research prioritisation involves developing a consensus on a number of priority 
areas to address key questions which need to be underpinned by future investment in 
research. The task involves assessing the value of the full range of research topics so 
that each topic can be compared against each other, or considered against numerous 
criteria. The resulting priorities are highly dependent upon the value of addressing 
the research question and the consensus opinion regarding how the research can 
improve the health of the population (patients, the health system and/or general 
public). Research funders have limited resources and the prioritised schedule of 
research must be traded against the available funding in order to identify high-
priority areas for further research. 
Figure 2.1 illustrates a typical research prioritisation process. The first step is topic 
generation, where topic ideas may come from the medical community, patients, 
academics, other stakeholders (such as the James Lind alliance), or research projects 
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identifying a future need for research in a particular area. Research ideas are then 
filtered and topics are generated for further consideration. Once topics are selected 
based on those that are expected to be important to patients, clinical practice, policy 
or decision makers, and where study outcomes could potentially lead to direct 
benefits to patients and/or the wider population, the topics are developed further. 
This may be via a commissioned workstream, where applicants are invited to 
respond to calls for research on specific questions, which have been identified 
and prioritised for their importance to the health system and patients, or via a 
researcher-led workstream, where researchers have the opportunity to submit 
proposals on the topic or research question.  
Once topics are selected, the second step to research prioritisation involves 
identifying and articulating, as far as possible, why the research question is important 
to patients and clinical practice in terms of improving health of the population. 
Health outcomes can be improved by either, conducting research to reduce 
uncertainties in the existing evidence base in terms of which interventions to use for 
the treatment, prevention or diagnosis of disease, or by implementing the findings of 
existing evidence about the best intervention to use. Therefore, the most important 
starting point is an understanding of how the existing literature or evidence supports 
the research question. New research should never be undertaken without knowledge 
of the existing evidence base, on the grounds that it would be considered unethical to 
enrol patients into a research study without prior knowledge of the effects of the 
interventions to be evaluated, e.g., enrolment into a RCT means that a certain 
proportion of patients are likely to be allocated to a suboptimal intervention 
(Chalmers and Nylenna, 2014; Ioannidis et al., 2014). The principle of equipoise 
implies that there must be genuine uncertainty over whether an intervention will be 
beneficial. Therefore, participants of a research study should never knowingly be 
offered less than the best intervention for their condition. Despite this basic 
requirement, however, Cooper et al., (2005) found that only 46% of a sample of 24 
responding authors of trial reports included in a Cochrane review were aware of the 
relevant existing reviews at the time when they were designing their new studies. 
The NIHR’s Health Technology Assessment Programme routinely requires research 
proposals to include a summary of why the research is important in terms of 
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improving the health of the population and how the existing literature supports the 
proposal.  
Once research questions requiring prioritisation are identified, the third step involves 
prioritising the proposals over other topics that could be commissioned with the 
same resources. The approach used for this purpose varies by different decision 
making bodies. One common approach is to attach an overall score to research 
proposals based on meeting certain criteria under different categories. For example, 
the NIHR Invention for innovation (i4i) panel in the UK attaches an overall score to 
proposals based on an assessment of: the expertise and track record of the applicants; 
the importance of the research area; the expected impact on NHS practice; and the 
quality of the project plan, including value for money. This score is based on a scale 
from 0 to 10, with 0 representing research that has poor or little merit compared with 
other research; 5 representing research that is comparable with other research; and 10 
representing research that has exceptional benefit compared with other research 
(NIHR, 2015). Similar overall scores are also used in other NIHR programs such as 
Research for patient benefit (RfPB) and Efficacy and mechanism evaluation (EME) 
(NIHR, 2019a, 2019b). A second categorisation approach involves the use of a 
“traffic light” system of colours to indicate the status of each research proposal 
relative to the others. For example, red may indicate fair existing knowledge on a 
topic and a ranking of lower priority compared to other research; amber may indicate 
existing knowledge could improve and research is comparable with other topics; 
while green may indicate a knowledge gap exists and further research is definitely 
warranted compared with other research.  
A third approach is to explicitly assess the ‘value’ of each research proposal using a 
specific metric of value, which can be used to directly compare the research 
proposals to each other. For example, the metric of value may be net QALYs gained 
representing the net health impact of an intervention on population health.4 This third 
                                               
4 Quality-adjusted life years (QALYs) gained is a generic measure of disease burden, which 
incorporates the impact of an intervention relative to a comparator in terms of both the quality and 
quantity of life lived. The cost per QALY gained provides a useful summary measure of how much 
additional resource is required to achieve the measured improvement in health (quality and quantity of 
life lived) of the intervention relative to the comparator.  The net impact of the intervention on health 
outcomes overall is judged relative to the likely health opportunity costs, which is the health that is 
forgone elsewhere in other health care programmes by diverting resources to the intervention, rather 
than other uses. The value of a research proposal can be expressed as the scale of the potential net 
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approach explicitly quantifies the value of the additional information generated by 
each of the proposed research projects competing for the same limited resources. By 
the VOI associated with each proposal, it is possible to identify those which offer the 
greatest return in terms of net health impact after taking account of the costs of 
research. When the value of all research proposals are assessed using the same 
metric of value, a straightforward exercise can be used to rank the proposals in order 
of value to determine the areas of highest priority. 
A combination of ‘scoring’ approaches may also be pursued in order to prioritise 
between the research proposals. Importantly, the process of research prioritisation 
should aim to be as transparent as possible so that there is clear justification and 
rationale for the funding of research. Once research proposals are ranked in order of 
priority, the final step involves selecting the proposals for funding based on the 
available research budget. The total budget should be focused on the high-priority 
areas as identified by the ranking process, with any remaining budget left to pursue 
other policy focused evidence-based research.  
The process by which research is identified as high-priority usually involves 
extensive and structured stakeholder engagement in order to secure both the best 
possible evidence base for the task, as well as identifying the “best buys” from the 
available research budget. These deliberations have a direct bearing on the topics 
that are selected as priority areas and, consequently, the manner in which the 
research is conducted. The selected priority areas should be reviewed on a regular 
basis in order to ensure that the proposed research delivers on the promised question 
and is of continued relevance. This will help ensure that resources are not wasted, 
which could be used elsewhere to identify and address new research opportunities.  
Establishing the potential benefits of new research to help inform its priority level 
requires a number of considerations; some of which represent value judgements, 
while others represent scientific beliefs about the evidence to date. Value judgements 
are made when more weight is placed on a particular outcome compared with 
another, while scientific beliefs are reasonably held views about a particular state of 
the world and the degree of uncertainty or knowledge about it. No quantitative 
                                                                                                                                     
health impact of the intervention on health outcomes overall, i.e., the difference between QALYs 
gained by the intervention and QALYs that could have been gained elsewhere with the additional 
resources which are required to fully implement the intervention. 
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analysis or scoring approach that establishes the value of a research proposal, no 
matter how well it is conducted, will be sufficient to capture all aspects of scientific 
and social value relevant to making decisions about research priorities; largely 
because these aspects can be readily disputed. The more relevant question is whether 
they offer a practical and useful starting point for deliberation so that a consensus 
opinion can be reached, and whether they add to the transparency and accountability 




Figure 2.1: Illustration of a research prioritisation process in which research 
projects are chosen based on their value to the health system. 
 
 THE HEALTH BENEFITS OF RESEARCH 
Research is important for improving health outcomes since it can resolve existing 
uncertainty about the effectiveness of the interventions available for the treatment, 
prevention or diagnosis of disease. Resolving uncertainty helps inform decisions 
about the optimal intervention for subsequent patients. For example, on the balance 
of existing evidence, a particular intervention may be judged to be the most effective 
option; however, due to uncertainty in the evidence base, there will be a chance that 
the other alternative interventions used for the same condition are in fact more 
effective. Therefore, when the existing evidence is uncertain there is always a chance 













Proposals selected for 















that one of the alternative interventions could improve health outcomes to a greater 
extent than the intervention judged to be the most effective on average. This means 
that there are adverse health consequences associated with uncertainty. The 
importance of this uncertainty is indicated by the scale of these health consequences. 
The scale is dependent on the likelihood that a particular intervention is not the most 
effective option, how much less effective it is likely to be (in terms of some measure 
of health outcome), and the size of the patient population facing the uncertain 
intervention choice. 
A judgement about the level of uncertainty in the existing evidence base can come 
from a systematic review of what is already known or being researched about a 
particular topic: a meta-analysis or statistical modelling approach that combines the 
results from multiple studies in an effort to increase power over individual studies 
and improve estimates of the size of effect (Chalmers and Nylenna, 2014; Higgins 
and Green, 2011); expert elicitation where relevant experts are asked to provide their 
judgement regarding the magnitude of effect size (O’Hagan et al., 2006; Soares et 
al., 2011); meta-epidemiological studies that adopt a systematic review or meta-
analysis approach to examine the impact of study design characteristics on effect size 
(Bae, 2014; Rhodes et al., 2015); or a combination of these sources.  
The level of uncertainty in the decision arises from the range of plausible values that 
the outcome of interest can take. This is usually represented by the confidence 
interval (CI)5, or standard error (SE), around the mean or median estimate of effect. 
A wide CI implies a large amount of uncertainty; however, it is only when the CI 
crosses the line of no difference between the alternative interventions that this 
uncertainty creates the potential for adverse health consequences, i.e., only the 
consequences of uncertainty that will change the decision are important. For 
example, uncertainty about the estimate of treatment effect only matters in so far as 
it influences the decision; if the decision is the same for all plausible values of the 
treatment effect then the uncertainty is unimportant. 
As an example, consider the evidence on the use of corticosteroids following 
traumatic brain injury (TBI) before the large definitive trial of CRASH (CRASH trial 
                                               
5 Technically, a Bayesian interpretation required to estimate the value of research as described in this 
report, therefore this may considered a credible interval (CI).  
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collaborators, 2005). Before CRASH, a meta-analysis of 19 RCTs indicated that the 
effects of corticosteroids (CS), compared with not using them, on death and 
disability were unclear. The odds ratio for death was 0.93 in favour of the use of CS, 
but with a 95% CI crossing the line of no difference (odds ratio equal to one) from 
0.71 to 1.18 (see bottom panel of Figure 2.2) (Claxton et al., 2013). This uncertainty 
means that every decision about the use of CS following TBI is associated with a 
chance that it may not have be the most effective treatment choice. Based on a 
Bayesian interpretation of the CI, there was a 75% chance that CS were effective and 
improved survival; however, there was a 25% chance that CS resulted in excess 
deaths per annum (see top panel of Figure 2.2). This uncertainty can be translated 
into the consequences for patient outcomes in number of expected deaths per annum, 
by combining the uncertain estimate of relative effect with an estimate of the 
baseline risk (derived from either the control arms of the trials, or from an external 
source on baseline risk relevant to the population of interest) and multiplying by the 
incidence of TBI per year (8,800 individuals). In this case, the expected (average) 
number of deaths per annum due to uncertainty in the use of CS following TBI was 
39 additional deaths per year and is represented by the grey section in Figure 2.2. 
This estimate of the consequences of uncertainty is derived from the fact that there is 
a low probability of a large increase in deaths with CS (say, greater than 500), 
compared to a larger probability of smaller increases in deaths (say, below 100). The 
average over these consequences gives the number of deaths per annum due to 
uncertainty in the use of CS.  
The expected health consequences can be interpreted as an estimate of the health 
benefits that could be gained each year if the uncertainty surrounding treatment 
choice were resolved, i.e., it provides an expected upper bound on the health benefits 
of further research, which would confirm whether CS following TBI increases or 
reduces the number of deaths per annum. These potential expected benefits increase 
with the size of the patient population whose treatment choice can be informed by 
additional evidence and the time over which evidence about the effectiveness of the 
interventions is expected to be useful.  
The health benefits that can be gained through research are called the “information 
value”. The information value will vary between research proposals as some 
intervention decisions will be associated with large uncertainty and large health 
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consequences, while others may have large uncertainty but with relatively modest 
consequences (e.g., wide CI but with less decision uncertainty). Some decisions will 
be associated with modest uncertainty but with very important health consequences, 
while others will have small uncertainty with modest consequences. The value of 
information for a particular decision will depend on both the level of uncertainty and 
the consequences of this uncertainty. By quantifying the value of conducting further 
research in this way, the potential information value of a particular research proposal 








Figure 2.2: Uncertainty in the outcome of mortality from the use of CS 
following traumatic head injury. The upper panel shows the range of plausible 
outcomes associated with the use of CS in terms of deaths. The lower panel 
illustrates the 95% CI which generates the upper panel. The impact of 
implementing CS following traumatic head injury based on existing evidence is 
illustrated on each panel. CS, corticosteroids. CI, confidence / credible interval. 
 
 THE HEALTH BENEFITS OF IMPLEMENTING THE FINDINGS OF EXISTING 
RESEARCH 
Funding research is not the only way to improve health outcomes. It is also possible 
to improve health outcomes by ensuring that the intervention option that is expected 
to be best based on the findings of existing evidence is implemented into clinical 
practice. In fact, the improvements in health outcomes from implementing the 
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findings of existing evidence, which is known as the “implementation value”, may 
be greater than the potential improvements in health outcomes through conducting 
further research (Claxton et al., 2013). 
Drawing a distinction between information value and implementation value is 
important because conducting further evaluative research is not the only way to 
change clinical practice or improve health outcomes. The results of a new research 
study may influence clinical practice and may contribute to the implementation of 
research findings, but this is not the only, or the most effective way to do so. There 
are other mechanisms (e.g., more effective dissemination of existing evidence) and 
policies which are within the remit of other bodies (e.g., incentives and sanctions) to 
affect implementation. Therefore, conducting research to influence implementation, 
rather than because there is real value in acquiring additional evidence itself, may be 
inappropriate as there is limited research capacity and this could be used elsewhere 
to conduct research in areas where there are genuine uncertainties. Conducting 
research can also have negative health effects for those patients enrolled in research 
and allocated to interventions that are expected to be less effective (e.g., patients 
enrolled to the suboptimal arm of a clinical trial). 
Figure 2.2 illustrates the implementation value in the outcome of mortality from the 
use of CS following TBI. On the balance of existing evidence, the odds ratio of 0.93 
favours the use of CS. Treating all patients with CS following TBI compared to 
usual care is expected to be worth 168 deaths avoided per annum. However, prior to 
CRASH, approximately 12% of patients receiving CS following TBI in the UK, 
while 88% did not receive CS (McKenna et al., 2016). If clinical practice were to 
switch fully to CS to reflect the balance of existing evidence, we would expect to 
observe (167 x 88% =) 147 fewer deaths per annum. This represents the expected 
value of implementation efforts to change clinical practice, which is the difference 
between the expected value of a decision based on existing evidence that is fully 
implemented and the expected value of a decision with implementation at its current 
level (i.e., 12% in the case of CS following TBI). Implementation efforts can be 
difficult and costly to reverse if the results of subsequent research find that the 
intervention is not as effective as the previous evidence suggested (Claxton et al., 
2016; Eckermann and Willan, 2008a). Therefore, in some circumstances 
(particularly, if there is a complete absence of evidence) it may be better to delay the 
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use of the intervention until additional research is undertaken. This may involve 
collecting a small amount of information to inform beliefs where there is no existing 
evidence before committing to changing practice or funding a large clinical trial. 
 THE TIME HORIZON FOR RESEARCH DECISIONS 
The information generated by research will not be valuable indefinitely because 
future changes are expected to occur over time that impact on the value of 
information. For example, new and more effective interventions may become 
available, making the current intervention and comparators obsolete and possibly 
rendering information about their effectiveness irrelevant to future clinical practice. 
Research may also fundamentally change our understanding of disease processes, 
e.g., the mechanisms that cause resistance to antibiotics, thereby impacting on the 
future value of the information generated by research that is commissioned today. 
Furthermore, other evaluative research may already have been commissioned by 
other bodies or health systems, which may resolve much of the uncertainty. 
Therefore, the actual time horizon for evidence generated by research will depend on 
the anticipated shelf-life of the alternative interventions and expected future changes 
over time. 
The actual time horizon for research decisions is unknown since it is a proxy for a 
complex and uncertain process of future changes (Philips et al., 2008). However, 
some judgement about the time horizon is required in order to make decisions about 
research priorities. This assessment is possible based on historical evidence and 
judgements (e.g., beliefs elicited from experts) about whether a particular area of 
research is likely to experience these changes. Information about clinical trials or 
studies that are already planned or underway may be obtained from various trial 
registries, applications for marketing authorisation, and funding bodies. Where there 
are limited or no data available, sensitivity or scenario analyses should be undertaken 
to highlight the extent to which the value of information is influenced by the time 
horizon. The health benefits of research should also be discounted over this time 
horizon so that more weight is given to decisions that are informed by the research in 




 SIZE OF THE POPULATION THAT CAN BENEFIT FROM RESEARCH  
The health benefits of research depend on the size of the population that can benefit 
from the new information. The size of the beneficiary population is typically derived 
using epidemiology data based on an understanding of the decision making context 
and the scale of the health care decisions that are likely to be affected by the new 
research. Those who could potentially benefit from new information include the 
prevalent cohort with the disease in question and/or the future incident cohorts over 
the appropriate time horizon for the research decision.  
The health benefits of research will not be realised until the study is completed and 
the results become available. Therefore, the eligible population, based on prevalence 
and/or incidence, is usually adjusted to reflect the time it will take for the study to 
complete. If treatment decisions cannot be reversed, then it is only those patients 
incident after the research reports that will realise any of the potential benefits. 
However, some study participants who are enrolled in the optimal intervention arm 
will receive the benefits of the best intervention while the study is conducted 
(McKenna and Claxton, 2011).  
The size of the beneficiary population that can benefit from research also depends on 
whether decisions are made at a local, national or international level, and the extent 
to which information is valuable across jurisdictions and populations (Eckermann 
and Willan, 2009; Woods et al., 2018). When decisions are made at a local level, it is 
usually with reference to the health benefits for a specific local population subject to 
resources available in the local setting. However, information generated by publicly 
funded research is a public good. Therefore, in some instances, information is more 
generalisable and the health benefits from a local research activity may be realised 
over a much broader population, e.g., at national or international levels, or wider risk 
group of individuals. In this case, the global value of research may be assessed 
(Eckermann and Willan, 2009). In other circumstances, research may offer the 
potential to inform multiple decisions, e.g., improved surveillance data may inform 
investment decisions across a range of prevention and treatment decisions, which 





 INFORMING RESEARCH PRIORITIES 
The health benefits of research provide an estimate of the extent to which research 
can potentially reduce the occurrence, and expected consequences, of uncertainty in 
the decision between alternative interventions. Acquiring information through 
research, however, can be costly. Therefore, the expected benefits of research must 
be compared to the costs of conducting the research. The costs of research include 
the fixed and variable costs of conducting the research activity and the costs that fall 
on the health care system, e.g., NHS support costs associated with implementing the 
research activity. These costs can be in terms of resources (use of more expensive 
treatments in research) or in terms of health (enrolling patients to a treatment which 
is expected to be suboptimal). The expected benefits of research must be greater than 
the costs of the research for the activity to be considered as potentially worthwhile; it 
is only when the costs of the research exceed the expected benefits that research can 
be completely ruled out. This criterion is used as a first hurdle to identify research 
that is potentially worthwhile.  
The costs of research should include a consideration of the health opportunity costs 
associated with the research expenditure. This means that the health gain from the 
research should be compared to the health that could have been gained elsewhere by 
making the resources available for other health care activities (i.e., the health 
opportunity costs is the health that is forgone elsewhere by resources not being 
available for other activities because they are accommodating the costs of the 
research activity). Therefore, the expected net impact of the research activity on 
health outcomes is judged relative to the likely health opportunity costs. Recent 
empirical work in the UK has estimated the relationship between changes in NHS 
expenditure and health outcomes (Claxton et al., 2015b; Lomas et al., 2018). This 
work suggests that the NHS spends approximately £15,000 to gain one QALY and 
£100,000 to avoid one death. Using these estimates, if the proposed research costs £2 
million, this means that the cost of the research could have been used to gain 
approximately 133 QALYs or avoid 20 deaths elsewhere in the NHS. If these 
opportunity costs of research are substantially less than the expected benefits of the 




Once it is established that the expected health benefits of research are sufficient to 
regard a particular research proposal as potentially worthwhile, the second important 
question is whether the research should be prioritised over other topics (or research 
proposals) that could be commissioned with the same resources. Insofar as there is 
funding dedicated to research activities, e.g., a dedicated research funding pot held 
by NETSCC specifically for new research to support NHS decision making, the 
opportunity costs incurred by the research funder is the funding (and associated 
health benefits) that are diverted away from other types of research in order to fund 
the specific activity. Most research funding bodies have limited resources and, 
therefore, it is likely that not all potentially worthwhile research projects can be 
commissioned. In this case, the benefits of some research projects must be foregone 
in order to commission others. Therefore, estimates of the costs and potential health 
benefits of research projects competing for limited resources can be helpful to inform 
the priority level of each proposal. If a research funder is concerned with the total 
health of the population served by the research budget, then they can identify the 
research that generates the most health per expenditure and order proposals in order 
of value for money. The research funder works down the ordered list, funding all 
proposals until the research resources run out. It the research funding available to 
decision makers runs out before all worthwhile research projects have been funded 
then this provides a case for increasing research funding. 
It is important to highlight that research prioritisation decisions require an 
assessment of the expected health benefits of research before the actual results of the 
research that will be reported in the future are known. Therefore, it might seem 
intuitive to look back at the historical proposals and ask whether a particular research 
prioritisation decision was correct based on the results of the research. However, this 
use of hindsight is inappropriate because the findings of the research represent only 
one realisation of the uncertainty that could have been found when the decision to 
prioritise and commission research was taken. For example, the expected health 
benefits of conducting a trial on the use of CS following TBI based on the evidence 
prior to CRASH was estimated to be 1,375 deaths averted over the 15 year time 
horizon. With an expected research cost of £2.2 million the value of CRASH was 
estimated to be (£2.2 million/1,375 =) £1,600 per death averted (McKenna et al., 
2016). Given that the NHS spends around £100,000 to avert one death (Claxton et 
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al., 2015b), this suggests that the CRASH trial was worthwhile. As it turns out, the 
trial was worthwhile to avoid unnecessary deaths with a definitive finding that CS 
increase the risk of death following TBI (CRASH Collaborators, 2005). However, it 
would be inappropriate to say whether the Medical Research Council that funded the 
CRASH trial made the ‘right’ decision to commission CRASH in the year 2000 only 
because it showed a surprising and consequential result. This is because i) the value 
of the other research proposals which were on the table for consideration on the day 
that CRASH was funded are unknown; ii) the actual findings of the CRASH trial 
represent only one realisation of the uncertainty that could have been found when the 
decision to prioritise and commission research was taken. Therefore, it is important 
to evaluate the quality of decisions based on the information that was available when 
the decision was made i.e. without the benefit of hindsight6.  
                                               
6 It is also important to bear in mind the distinction between implementation value and information 
value discussed in Section 2.2.2. The effect of the results of CRASH on motivating changes in 
practice should distinguished from the uncertainty that it resolved, especially when research funding 
is limited and there are other mechanisms for changing practice.  
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 RAPID ASSESSMENT OF THE NEED FOR EVIDENCE 
 THE NEED FOR A RAPID APPROACH 
The health benefits of research have traditionally been established within a net 
benefit framework used to assess uncertainty surrounding a decision to adopt or 
reimburse a health technology into the health care system. This typically requires the 
construction of a decision-analytic model, which brings together relevant evidence 
on short and long-term costs and health outcomes for the intervention and 
comparators under consideration, and facilitates the synthesis of data from a variety 
of sources in order to assess the cost-effectiveness of the intervention and the need 
for further evaluative research. However, institutions with a responsibility for 
making research prioritisation and commissioning decisions are often restricted by 
the time and resources required to generate decision models, making traditional 
modelling efforts unsuitable for integration into the research prioritisation process. 
This partly arises as a consequence of the fact that those institutions with the remit 
for making reimbursement decisions are often separated from those responsible for 
prioritising and commissioning research.  
The need for a practical and feasible method within the time and resource constraints 
of a deliberative process of research prioritisation has called for the development of 
‘rapid’ or minimal modelling approaches. These approaches allow for rapid 
estimation of the health benefits of research without the need for constructing a full 
disease and/or decision-analytic model. This involves simplifying or omitting 
components of the full modelling approach in order to produce information on the 
value of research in a timely manner. A rapid approach can offer a quick and 
practical means for estimating the health benefits of research in a matter of days, 
rather than weeks or months. The approach may also be viewed as offering a 
transparent and efficient method for setting research priorities and may provide a 
workable interface, whereby analysts and stakeholders could potentially validate key 
inputs and assumptions about the existing evidence base in real time as part of the 
deliberative process (see Chapter 5 for user friendly rapid VOI tool). The approach 
may also be relevant to different types of health care systems and decision making 
contexts, including those that do not explicitly include economic considerations in 
their decision making process. For example, for those institutions, the expected 
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health benefits of research may be assessed using a metric of value that is based on 
health outcomes alone rather than economic considerations. 
 RAPID APPROACHES FOR ESTIMATING THE HEALTH BENEFITS OF 
RESEARCH  
Minimal modelling has been proposed in the literature as a method for rapid 
estimation of the value of research (Meltzer et al., 2011). This can be performed if a 
prior clinical study is available that directly characterises uncertainty in 
comprehensive measures of health outcome (e.g., both costs and QALYs) and is 
sufficient to inform a decision about the benefits of alternative interventions (Meltzer 
et al., 2011). This may be achieved in studies that follow patients up to the point of 
death or to full recovery, while recording all relevant outcomes between the 
interventions such that a comprehensive measure of benefit can be assessed. The 
drawback to this approach is that in many cases the required clinical studies do not 
exist and so this analysis cannot be carried out. Extending the minimal modelling 
approach Bennette et al., (2016) propose a method to map progression free survival 
to a meaningful comprehensive measure of outcome by constructing a simple 
economic model with relatively few parameters for each research proposal. This 
approach has been applied successfully in cancer research prioritisation in the USA 
(Bennette et al., 2016; Carlson et al., 2018). A limitation of this approach is its 
specificity to oncology and the time and expertise required to construct a customised 
decision model for each research proposal. 
The rapid approach for estimating the health benefits of research that is proposed in 
this thesis places the focus on a primary outcome of interest. The primary outcome 
reported in existing studies, or a proposed new study, usually captures the most 
important aspects of health outcome. Uncertainty in the primary outcome is used as a 
starting point in order to understand the health consequences of uncertainty, e.g., the 
distribution of values describing uncertainty about the relative effect of an 
intervention on a specific endpoint. Starting with a primary outcome does not mean 
that other outcomes are unimportant, it simply places the focus on a specific outcome 
of interest as a starting point in order to establish the value of reducing uncertainty in 
that outcome. For example, mortality was taken as the primary outcome to 
understand the health consequences of uncertainty in the evidence available before 
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the CRASH trial. In this case, the expected health benefits of research were 
expressed in terms of number of deaths averted for the outcome of mortality. The 
health benefits of research, and the value of implementing the findings of existing 
evidence, can be expressed as the number of events avoided for a harmful outcome 
(e.g., death) or gained for a benefit outcome (e.g., cure).  
In situations where there are a number of other important aspects of outcome that are 
not captured in the primary outcome (e.g., adverse events, quality of life impacts or 
resource implications), a minimum clinical difference (MCD) in effectiveness in the 
primary outcome may be specified in order to capture these additional 
considerations. For example, a larger MCD in effectiveness in the primary outcome 
may need to be detected in a new research study before there is confidence that 
health outcomes will be improved. This is analogous to the concept of an effect size, 
which has been central to the design of clinical research and determines the sample 
size used in most clinical trials. The required effect size does not represent what is 
expected to be found by the research, but instead it represents the improvement in 
the primary outcome that would need to be detected for the new treatment to be 
considered worthwhile and to have an impact on clinical practice. For the example of 
CS for use in TBI, if CS is more expensive than the current standard of care, then a 
MCD of 2% may be required. This implies that the probability of death must 
decrease by at least 2% for the new treatment to be worthwhile relative to the current 
standard of care.  
Specifying a MCD is one way to implicitly account for the other aspects of outcome 
that are not captured in the primary outcome. This may be used as part of the 
deliberative process to assess whether the proposed research is a priority at a MCD 
that is regarded as sufficient to account for these other aspects of outcome. Where 
the primary endpoint of a study is not sufficient to capture all valuable aspects of 
outcome, external evidence can be used to link the endpoint to a comprehensive 
measure of outcome7. This is analogous to the minimal modelling approach 
described above where the primary endpoint is mapped to a meaningful 
comprehensive measure of outcome through simple extrapolation or modelling 
efforts. The translation to a comprehensive and comparable measure of health 
                                               
7 Section 3.3.4 describes a method to inform the appropriate size of the MCD with reference to a 
comprehensive measure of health outcome, such as QALYs. 
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outcome such as QALYs enables the health benefits of research to be compared 
directly across diverse clinical areas. This helps to address the difficult, but 
unavoidable question, in research prioritisation about how to estimate and compare 
the health benefits of research across diverse disease areas (see Chapter 3). 
 
The notable limitation associated with the approach described above, or any of the 
minimal modelling approaches is the possible over-simplification of complex 
clinical processes. Therefore, the extent to which the simplified approach adequately 
addresses the need for further evaluative research is an important consideration. This 
can be overcome by ensuring that the assumptions underpinning the analysis are 
made as explicit as possible and consideration is given to the likely impact that these 
assumptions might have on the findings. 
 
 THE MINIMUM EVIDENCE REQUIRED TO ESTABLISH THE HEALTH 
BENEFITS OF RESEARCH 
The minimum evidence required to conduct a rapid assessment of the need for 
research are described below for a binary outcome measure8. 
Primary outcome measure 
The primary outcome measure or endpoint captures the most important aspect of 
health outcome. The health benefits of research are expressed in terms of ‘benefits 
gained’ or ‘harms avoided’ depending on whether the outcome is a benefit or harm. 
Alternative endpoints can also be used to consider the impact of additional evidence 
on different aspects of outcome. Where the primary outcome is not sufficient to 
capture all valuable aspects of outcome, a MCD in the primary outcome may be 
specified in order to implicitly account for these other unquantified aspects of 
outcome and/or costs. 
Relative effectiveness 
An estimate of the relative effectiveness of the intervention is required for the 
primary outcome, along with an estimate of its uncertainty. This is usually expressed 
in terms of an odds ratio or relative risk, with a 95% CI (or SE) representing the 
                                               
8 The methods for continuous or survival primary outcomes have slightly different evidence 
requirements.  These outcomes are discussed in detail in the Chapter 4. 
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range of plausible values that the quantity can take. Importantly, some judgement 
about the uncertainty in this estimate based on what is already known must be made 
in order to determine whether additional evidence is required. This judgement can 
come from a systematic review and standard meta-analysis of the available existing 
evidence or from alternative sources such as expert elicitation or meta-
epidemiological studies (see Section 2.4.4). If an estimate is unavailable or 
considered inadequate, alternative values can be used to represent different 
judgements about the uncertain estimate of relative effect. 
Baseline event rate 
An estimate of the baseline event rate in the absence of the intervention is required. 
This is used to obtain an estimate of the absolute effect of the intervention on the 
primary outcome by applying the relative measure of effect to the baseline risk. The 
baseline probability of an event is also likely to be uncertain. This may be informed 
by the event rate in the control arms of the trials in the meta-analysis informing the 
relative intervention effect or, alternatively, from external evidence or judgements 
relevant to the target population. 
Incidence per annum 
An estimate of the number of patients facing the uncertain choice between 
alternative interventions is required in order to establish the size of the benefits to the 
target population. 
Minimum clinical difference (MCD) in primary outcome 
Specifying a MCD in the primary outcome that is required for the results of research 
to have an impact on clinical practice is one way to incorporate concerns that the 
primary outcome does not capture all important aspects of outcome and/or costs. The 
MCD represents the improvement in the primary outcome that would need to be 
detected for the new treatment to be considered worthwhile and to have an impact on 
clinical practice. Specifying a MCD is one way to implicitly account for the other 
aspects of outcome that are not captured in the primary outcome. 
Costs of the proposed new study 
Some assessment of the likely costs of the proposed new study is required in order to 
establish whether the expected benefits of the study are sufficient to justify the 
expected costs. It can also be used to establish whether the proposed study represents 
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a priority compared to other research that could be commissioned using the same 
resources. 
Duration of the proposed new study 
An assessment of the duration of time it will take for the proposed research to be 
conducted and for the results to report is required since the health benefits of 
research decline the longer it takes research to report. This might be informed by an 
assessment of study sample size, expected recruitment rates, or historical experience 
from conducting similar types of studies.  
Length of time for which new evidence is expected to be valuable 
The information generated by new research will not be valuable indefinitely because 
other changes occur over time. For example, over time new and more effective 
interventions become available, which will eventually make those currently available 
obsolete. This means that new information about effectiveness is only relevant for a 
specific amount of time. A judgement about the length of time that the evidence 
from the proposed new study might be valuable is required in order to estimate the 
expected benefits over an appropriate time horizon. This judgement could be 
informed by historical evidence or experience about whether a particular research 
area is likely to see future innovations and/or other evaluative research reporting. 
Discount rate  
When a time horizon greater than one year is considered, discounting should be used 
to reflect the fact that resources committed today could be invested at a real rate of 
return to provide more resources in the future. Guidance from the UK Treasury 
suggests the use of a discount rate of 3.5% per annum (HMT Green Book, 2013). 
 
 RAPID ESTIMATION OF THE HEALTH BENEFITS OF RESEARCH 
The health benefits of research to resolve uncertainty in the primary outcome are 
estimated by sampling from the uncertain distributions of relative effect and baseline 
event rate (i.e., from the range of plausible values specified by the CI or standard 
error on these quantities) and multiplying by the number of patients per annum 
whose treatment choice is to be informed by the decision. Each sampled value from 
the distributions is interpreted as one possible realisation of how patient outcomes 
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might turn out in practice, as supported by the existing evidence, i.e., each sampled 
value represents one possible ‘true’ value of how patient outcomes could turn out. 
Repeating this process many (e.g., 50,000) times creates a distribution of the health 
consequences of uncertainty, which is expressed in terms of the primary outcome 
measure9. For example, if the primary outcome is mortality, the consequences of 
uncertainty are expressed in terms of number of deaths per annum. The distribution 
of consequences tells us the chance of making an ‘incorrect’ decision due to 
uncertainty in the existing evidence base, while the number of patients affected by 
the decision provides the scale of the health consequences per annum. The average 
over this distribution provides an expected upper bound on the health benefits that 
could be gained by conducting further research to resolve this uncertainty. 
The process for the estimation of the health benefits of research is illustrated using 
the CRASH example introduced in Section 2.2.1. Table 2.1 shows 5 random (equally 
likely) samples taken from independent distributions of relative effect (odds ratio for 
the intervention relative to a control) and baseline risk (control) for a primary 
outcome of mortality.10 These are combined with the incident population (8,800 
patients per annum) to understand the absolute health consequences of the decision. 
The last row of Table 2.1 represents the average across the 5 sampled values. For the 
5 sampled values, the balance of evidence based on what is already known about the 
intervention and control indicates that the intervention is expected to reduce the 
number of deaths per annum by 80 compared with the control. This is because the 
expected odds ratio for death is 0.96 which is in favour of the intervention (column 
A). As a consequence, the mean absolute number of deaths for the intervention is 
2,669 per annum (column E) compared with the baseline risk for the control of 2,749 
deaths per annum (column D). This indicates that implementing the intervention 
would be worth (2,749 – 2,669 =) 80 deaths averted per year. 
Though current evidence favour the intervention, there is a possibility that the 
intervention would increase rather than reduce mortality – this is seen in Table 2.1 
for the sampled realisations 4 and 5, where the odds ratio for the intervention is 
                                               
9 Analytic solutions to calculation VOI without simulations are possible, however this becomes 
challenging in situations in which more than two treatments are being compared (Claxton, 1999; 
Schlaifer and Raiffa, 1961; Willan and Pinto, 2005). 
10 Correlation in outcomes between baseline risk and intervention effectiveness should be preserved 
where possible. For example, a multivariate or bivariate meta-analysis may be more appropriate to 
account for the dependence between multiple and possibly correlated outcomes (Riley, 2009). 
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greater than one. The expected health consequences of this uncertainty depends on 
the likelihood that the intervention is less effective than the control, how much less 
effective it is, and the size of the eligible population. The chance that the intervention 
is less effective is simply the chance of observing an odds ratio of greater than one, 
which is 40%, i.e. in 2 out of the 5 samples. The resulting consequences of this 
uncertainty is the number of additional deaths incurred if the intervention is used 
instead of the control in these instances (realisations 4 and 5 of column G). The 
expected health benefits of additional evidence to resolve this uncertainty is a 
weighting of the consequences of the uncertainty by the likelihood of them 
occurring, which is the average of the consequences of uncertainty across the 
sampled realisations (i.e., the average of column G). Therefore, the expected upper 
bound on the health benefits of research to resolve uncertainty is 48 deaths averted 




Table 2.1: Rapid estimation of the health benefits of additional evidence for a primary outcome of mortality 
        
Deaths per annum for an incidence  
of 8,800 eligible patients 


































(=F if A>1) 
  [A] [B] [C] [D] [E] [F] [G] 
Sample 1 0.83 0.6 0.5 3,300 2,933 -367 0 
Sample 2 0.91 0.54 0.49 3,086 2,894 -192 0 
Sample 3 0.95 0.49 0.47 2,894 2,814 -80 0 
Sample 4 1.05 0.35 0.37 2,281 2,377 95 95 
Sample 5 1.08 0.33 0.36 2,183 2,329 146 146 
Average 0.96 0.46 0.44 2,749 2,669 -80 48 





It should be noted that the estimate of the value of additional research (48 deaths per 
year) and the value of implementation (80 deaths per year) reported in Table 2.1 are 
estimates which result form only 5 samples. This process should be repeated a large 
number of times in order to propoerly characterise the consequences of uncertianty 
in the odds ratio and baseline odds of deaths. After 50,000 samples it is estimated 
that the consequences of uncertainty are 39 deaths per year and the value of 
implemtation is 170 deaths per year. These estimates are different to those in Table 
2.1. This difference is a result of chance and shows why a large number of 
simulations are necessary. This method is equivalent to doing a probabilistic 
sensitivity analysis on a decision tree in which the payoffs are quantified in terms of 
the primary outcome (mortality). 
2.3.4.1 Using MCD to capture other aspects of outcome 
If there are other important aspects of outcome that are not captured in the endpoint 
of mortality, then a MCD may be specified. Due to increased costs of the 
intervention a MCD of 0.5% deaths averted per annum may be required meaning that 
clinical practice should only change if the results of the new study indicate that at 
least (8,800 x 0.5% =) 44 additional deaths are averted per year with the new 
treatment. Therefore, the gross expected gain from the intervention of 80 deaths 
averted per year can be adjusted using the MCD to estimate the net health benefits of 
implementing the new treatment which are (80 -44 =) 36 deaths averted per year. 
The value of research will also be affected by taking account of the MCD to estimate 
the net health benefits of the intervention. Table 2.2 shows uncertainty in gross 
deaths per annum for the control and the intervention (column D and E). Column H 




Table 2.2: Rapid estimation of the health benefits of additional evidence for a 
primary outcome of mortality taking account of MCD = 44 deaths per annum 
Deaths per annum for an incidence  
of 8,800 eligible patients   






Net deaths per 
annum for 













(=I if I>0) 
[D] [E] [H] [I] [J] 
3,300 2,933 2,977 -323 0 
3,086 2,894 2,938 -148 0 
2,894 2,814 2,858 -36 0 
2,281 2,377 2,421 139 139 
2,183 2,329 2,373 190 190 
2,749 2,669 2,713 -36 66 
 
Column J of Table 2.2 shows the net health consequences of uncertainty. The net 
health consequences of uncertainty are larger than the gross health consequences of 
uncertainty in column G of Table 2.1. This is because the MCD penalises the new 
intervention and as the new intervention is expected to be superior to the current 
treatment, this makes the decision more uncertain. The adjustment for MCD has 
increased the expected upper bound on the health benefits of additional research 
from 48 to 66 deaths averted per year. Figure 2.3 below extends Figure 2.2 to 
graphically illustrate the effect on the value of research of increasing the MCD from 





Figure 2.3: The effect of increasing the MCD for CS on the value of additional 
research in traumatic head injury. The upper panel shows the range of 
plausible outcomes associated with the use of CS with an MCD of zero. The 
upper panel shows the range of plausible outcomes associated with the use of 
CS with an MCD of 1.8%. A larger MCD in this case increases the uncertainty 
in the decision and so is associated with a larger value of additional research. 
CS, corticosteroids. MCD, minimum clinical difference. 
 
As shown above, increasing the MCD from 0% to 1.8% adds 158 deaths11 to the use 
of CS each year to take account of differences between the treatments. This shifts the 
distribution of net outcomes with CS to the right. This means that there is a greater 
chance of increasing the number of net deaths with CS and so makes the decision 
                                               
11 (0.018 – 0) x 8,800 = 158 
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more uncertain. This increase in uncertianty is represented by a larger gray area in 
Figure 2.3. 
Deciding on an appropriate MCD requries trading off the health benefits of the 
priamry outcome with any other outcomes which the primary outcome does not 
capture (secondary outcomes). An explicit method to inform the MCD is provided in 











 APPLICATION OF THE RAPID EVIDENCE GENERATION APPROACH 
TO A RETROSPECTIVE SET OF RESEARCH PROPOSALS  
 ASSISTING NIHR PANEL AND BOARD RESEARCH PRIORITISATION 
DECISIONS 
In the sections that follow, the methods described in Section 2.3 are applied to the P1 
case study from the six NETSCC proposals introduced in Section 1.2. The same 
assessments are completed for all six proposals (Chapter 4 for analysis of P2-P5 and 
Chapter 5 for analysis of P6). Each proposal used to illustrate different issues that are 
encountered when establishing the need for research, and to illustrate the types of 
scientific value judgements that are required in each context.  
 
 PROPOSED TRIAL OF EARLY VERSUS LATE TREATMENT OF PROPHYLAXIS 
TO REDUCE VENOUS THROMBOEMBOLISM FOLLOWING TRAUMATIC BRAIN 
INJURY 
2.4.2.1 Why is the research needed? 
P1 is for a proposed RCT to examine the efficacy and safety of early (before end of 
day 3) pharmacological thromboembolism prophylaxis (PTP) compared with late 
(from day 8 onwards) PTP following traumatic brain injury (TBI). PTP, which is a 
blood thinner that is used to protect against serious blood clots following TBI, is 
established standard practice in the UK. However, there is uncertainty about the 
optimal timing of initiation of the treatment.  Early PTP has an associated risk of 
worsening intracerebral haemorrhage (ICH), while late PTP has an increased risk of 
venous thromboembolism (VTE) (including deep vein thrombosis, DVT) impacting 
on recovery and patient outcomes. A summary of the research question and proposed 




Summary of proposal 1 
Research question: Does early pharmacological thromboembolism prophylaxis 
(PTP) after traumatic brain injury (TBI) improve functional recovery at 6 months?   
Intervention:  Early PTP (before end of day 3 after TBI) with Dalteparin 5000u. 
Control: Late PTP from day 8 onwards with Dalteparin 5000u, representing 
standard care until intensive care unit (ICU) discharge. 
Outcomes:   
Primary outcome - Functional recovery and mortality at six months after TBI, 
assessed by the Glasgow Outcome Scale Extended (GOSE). 
Secondary outcomes - DVT; pulmonary embolism; ICH expansion; pneumonia; 
heparin induced thrombocytopaenia; length of stay in ICU. 
Proposed study: RCT to examine the efficacy, cost-effectiveness and safety of early 
PTP in 1300 patients after TBI measured by functional recovery at 6 months.   
Duration of proposed study: 5 years 
Costs of proposed study to NETSCC: £2,854,000 
NHS support and treatment costs: £490,000 





 EVIDENCE REQUIRED TO ESTABLISH THE HEALTH BENEFITS OF 
RESEARCH FOR PROPOSAL 1 
Primary outcome measure 
The primary outcome for the proposed trial is functional recovery and mortality at 
six months after TBI, as measured by the Glasgow Outcome Scale Extended 
(GOSE). The GOSE is a scale for functional outcome that rates patient status into 
one of eight categories: dead (GOSE of 1), vegetative state (GOSE of 2), lower 
severe disability (GOSE of 3), upper severe disability (GOSE of 4), lower moderate 
disability (GOSE of 5), upper moderate disability (GOSE of 6), lower good recovery 
(GOSE of 7), or upper good recovery (GOSE of 8).   
The health benefits associated with the proposed trial are estimated by comparing the 
percentage of patients who are expected to be functionally recovered at 6 months in 
the early PTP and late PTP treatment groups. For simplicity, and following the 
approach used by other authors (Nichol et al., 2015), the GOSE is dichotomised such 
that a patient with a GOSE score of ≥5 is defined as functionally recovered, while 
those with a GOSE score of 1-4 are classified as not having functionally recovered.  
Relative effectiveness 
An estimate of the relative effectiveness of early PTP compared with late PTP, based 
on what is already known about the interventions, is required for the primary 
outcome of functional recovery, along with an estimate of its uncertainty. The 
proposal summarises the existing evidence to date based on three systematic reviews 
that have been conducted examining the efficacy and safety of PTP following TBI. 
However, none of these reviews have considered the primary outcome of functional 
recovery. The evidence from the reviews included a number of small studies that 
assessed VTE rates and ICH progression in patients treated with early (< 72 hours) 
versus late (> 72 hours) thromboprophylaxis (Chelladurai et al., 2013; Jamjoom and 
Jamjoom, 2013). These studies concluded that there is insufficient evidence to 
comment on the effectiveness of early compared with late VTE prophylaxis and its 
effect on ICH progression. The Brain Trauma Foundation Guidelines also report 
insufficient evidence to recommend a preferred drug, dose or timing of initiation of 
PTP following TBI. UK neurological critical care units were surveyed as part of a 
Delphi panel and this identified the timing of PTP as an important research question 
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for clinicians in the management of TBI. In summary, this means that there is no 
existing evidence reported on the primary outcome of GOSE of the proposed trial 
and there is no quantitative estimate of uncertainty in relative effectiveness of the 
interventions. In order to quantify the benefits of the proposed RCT, an explicit 
estimate of uncertainty for the relative difference between early and late PTP in the 
primary outcome of functional recovery is required. In the absence of this 
information, some judgement about the uncertainty or range of plausible values that 
the quantity can take is required, approaches to address this are outlined in Section 
2.4.4. 
Baseline event rate 
An estimate of the baseline event rate for late PTP is required. This is used to obtain 
an estimate of the absolute effect of early PTP on the primary outcome of functional 
recovery by applying the estimate of relative effectiveness of early PTP compared 
with late PTP to the baseline risk. Although event rates for VTE and proximal DVT 
were reported in P1, the baseline event rate for the primary outcome of functional 
recovery for late PTP was not reported in the proposal. The baseline event rate was 
derived from the placebo arm of a recent multicentre RCT (EPO-TBI), which 
examined the effects of erythropoietin compared with placebo on neurological 
recovery, mortality, and VTE in patients with TBI (Nichol et al., 2015). The primary 
outcome assessed at 6 months was the proportion of patients with GOSE of ≥5 (i.e., 
proportion of patients functionally recovered). Under the assumption that the placebo 
arm of this trial is a close approximation to standard of care of late PTP, the baseline 
event rate for functional recovery is 55.1% (=162 patients out of 294 at risk who 
achieved GOSE ≥5 with placebo). In order to reflect uncertainty in this estimate, a 
beta distribution based on 162 events out of a sample of 294 patients at risk was used 
(Briggs et al., 2006). This results in a 95% CI of 49% to 61%. 
Incidence per annum 
The expected health benefits of additional evidence depend on the size of the patient 
population whose treatment choice is to be informed by the evidence. Sauerland and 
Maegele (2004) estimate an approximate annual incidence of TBI in the UK of 
8,800. Therefore, the impact of uncertainty on the absolute number of functional 
recoveries per year is estimated based on an annual incidence of 8,800. 
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Minimum clinical difference (MCD) in primary outcome 
The proposed trial is designed based on the primary outcome of functional recovery. 
Therefore, the benefits of the proposed research and implementation efforts to 
change clinical practice are expressed in number of functional recoveries gained. 
However, functional recovery may not necessarily be the only relevant outcome for 
assessing the value of the proposed study. For example, early PTP incurs additional 
treatment costs compared with late PTP, i.e., 5 additional days of treatment costs. 
The drug cost of Dalteparin 5000u is relatively cheap at £2.82 per dose (BNF, 2018), 
over an additional 5 days this incurs a cost of £14.10 per person, which is equivalent 
to an additional cost of £124,000 (= £14.10 x 8,800) per year to the NHS. Specifying 
a MCD required to change clinical practice is one way to incorporate concerns about 
increased costs and/or potential adverse events that are not captured in the primary 
outcome. As additional per patient costs are small, then the required MCD will also 
be small. For illustrative purposes, since early PTP is more costly than late PTP it 
might be required to demonstrate a 1% increase in the number of functional 
recoveries, in addition to those expected when everything else is considered equal.  
Costs of the proposed new study 
Some assessment of the likely costs of the proposed RCT is required in order to 
establish whether the expected benefits of the study are sufficient to justify the 
expected costs. For NETSCC costs are divided into two categories. “Research costs” 
which fall on the research budget (i.e. they are borne by NETSCC) and cover the 
costs organising the research project such as research team payments, administrative 
support, travel costs and dissemination costs. “NHS support and treatment costs” fall 
on the general health system (NHS) budget and include the costs associated with 
using experimental treatments as part of the research. For P1, the research costs are 
estimated to be £2,854,000, while the NHS support and treatment costs are 
£490,000. 
Duration of the proposed new study 
Some assessment of the duration of time it takes for the proposed research to be 
conducted and for the results to report is required since the health benefits of 
research decline the longer it takes research to report. For P1, the RCT is expected to 
take 5 years to complete and report.  
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Length of time for which new evidence is expected to be valuable 
The information generated by new research will not be valuable indefinitely because 
other changes occur over time. A judgement about the length of time that the 
evidence from the proposed new study might be valuable is required in order to 
estimate the expected benefits over an appropriate time horizon. It is anticipated that 
the new information for P1 might be valuable for a long time span of 15 years since 
standard practice in TBI appears to move relatively slowly. Alternative scenarios 
may be used to assess the impact of longer or shorter durations on the health benefits 
of the proposed research. 
Discount rate  
A discount rate of 3.5% per annum is used based on Guidance from the UK Treasury 
(HMT Green Book, 2013). 
 
 INFORMING A JUDGEMENT ABOUT RELATIVE EFFECTIVENESS IN THE 
ABSENCE OF EXISTING EVIDENCE 
When deciding about the need for research, some judgement about the level of 
existing uncertainty (e.g., estimate of standard error) for relative effect of the 
alternative interventions is required. An explicit quantification of uncertainty in the 
relative effect for the primary outcome is required for use in VOI analysis12. Ideally, 
in addition to being based on any existing studies, this estimate should take account 
of expert knowledge about the disease process, clinical intuition and any relevant 
weaknesses in the evidence base e.g. from unrepresentative sampling or failure to 
blind participants. Making such explicit and quantified statements about uncertainty 
is challenging; however, this judgement must be made when prioritising research, 
either implicitly or explicitly. None of the six proposals received by NETSCC (listed 
in Section 2.4.1) reported a suitably explicit quantitative summary of the current 
level of uncertainty in the primary outcome. Unfortunately, this omission is not 
unique to this particular set of research proposals. Bennette et al., (2016) also found 
that none of the 9 proposals investigated as part of a US oncology research 
prioritisation exercise reported uncertainty in the primary outcome. This is likely 
because the currently most common approach to medical statistics (Frequentism) 
                                               
12 In more technical terminology, this is a Bayesian concept called a “prior” and reflects the state of 
the decision maker’s knowledge given the current state of the evidence. 
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does not place emphasis on explicitly quantifying current levels of uncertainty, even 
though this is central to making decisions about the need for additional research. The 
first step to establishing whether additional research is required should always 
include a systematic review of what is already known about the interventions 
(Chalmers et al., 2014). It would be inappropriate and potentially unethical to fund 
research when sufficient evidence already exists to inform a decision about 
alternative interventions, especially if an experimental research design such as an 
RCT is required. However, it is recognised that for many decisions a review of the 
existing literature will show that there have not been any suitably similar studies 
carried out. In this case, there are a number of options available to inform a 
quantitative judgement of the uncertainty in the existing evidence base: 
Expert opinion or expert elicitation 
This is the process whereby relevant experts are asked to provide their judgement 
regarding the magnitude of a given quantity and its uncertainty. In its simplest form, 
this could involve asking experts for their ‘best guess’ estimates, but more formal 
methods of expert elicitation are readily available that involve asking for 
probabilistic belief statements about unknown quantities and using formal processes 
to combine judgements from multiple experts (Mason et al., 2017; O’Hagan et al., 
2006; Wilson et al., 2018). Where some limited data may be available for a given 
quantity, expert elicitation may be used to supplement this information, and a large 
literature exists on expert elicitation in Bayesian statistics (O’Hagan et al., 2006). 
The elicitation task need not be complex to aid decision making. In utilising rapid 
methods to aid research prioritisation in the US, (Carlson et al., 2018) developed a 
questionnaire consisting of two questions to inform uncertainty in relative effect: 
Question 1. “What is the probability that the new treatment is equivalent or better 
than the control arm for the primary outcome?” Question 2.” What is the probability 
the new treatment offers a substantial improvement over the control arm in the 
primary outcome?” 
Statistical modelling or extrapolation 
In the absence of information on a particular quantity in a population of interest, it 
may be possible to extrapolate data from other sources in order to inform the 
quantity in the population of interest. For example, in a recent National Institute for 
Health and Care Excellence (NICE) technology appraisal of biological therapies for 
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chronic plaque psoriasis in children and young people, data from the adult 
population on the relative effectiveness of the biological therapies was used to 
complement the limited evidence base for these treatments in children and young 
people (Duarte et al., 2017). It is also possible to reflect the uncertainty involved in 
the extrapolation process. 
Meta-epidemiological studies  
This is a rapidly developing area of research in which large databases of RCTs and 
meta-analyses are reviewed to describe the distribution of research evidence to 
inform a specific question and to understand heterogeneity between studies and 
control for potential bias (Bae, 2014). It may be used to assess the impact of study 
characteristics on treatment effect estimates and to identify possible effect modifiers. 
Meta-epidemiological studies provide a useful quantitative analysis of historical 
study results that may be used to empirically inform judgments about plausible 
effects for interventions where study results are judged to be exchangeable. For P1, a 
meta-epidemiological approach was used to inform a quantitative judgement about 
uncertainty in relative effectiveness in the absence of alternative information. This 
study utilised the meta-epidemiological analysis by Djulbegovic et al., (2012), which 
examined the likelihood that new treatments being compared to established 
treatments in randomised trials would be superior13. The analysis examined 743 
publically funded RCTs across a diverse range of conditions and involved 297,744 
patients. The results of the study found that, on average, new treatments were 
slightly more likely to have favourable results than established treatments for the 
primary targeted outcome, i.e., slightly more than half of publically funded RCTs 
demonstrate an improvement in the primary outcome for new treatments compared 
with established practice, while slightly less than half demonstrate less favourable 
outcomes. The magnitude of effect on primary outcomes indicates that new 
treatments favour established practice with an average odds ratio of 0.91.14 A kernel 
density analysis showed that the pooled trial results were approximately symmetrical 
                                               
13 In prioritising research in a US oncology setting Bennette et al., (2016) also draw on the meta-
epidemiological analysis by Djulbegovic et al., (2012) to address a lack of data on relative treatment 
effects.  The approach taken by Bennette and colleagues makes use of the judgements implied in 
sample size calculations to mimic an expert elicitation exercise. Though related, the meta-
epidemiological method used in this chapter is distinct from this approach.  
14 In order to combine results across RCTs, primary outcomes in Djulbegovic et al., (2012) were 




of new versus established treatments centred near ‘no effect’, but that the results of 
individual RCTs are unpredictable and tend to fall within an approximate 95% 
interval from 0.19 to 4.3915. The study also reports that trial results have not changed 
significantly over time, and are not significantly affected by choice of comparator 
(e.g., active treatment versus placebo). 
In the absence of other information, the meta-epidemiological approach based on 
historical trials represents a reasonable starting point to inform the magnitude of 
effect and uncertainty for the relative effectiveness of early PTP compared with late 
PTP following TBI. This suggests an odds ratio of 1.09 in favour of early PTP 
improving functional recovery compared with late PTP (i.e., reciprocal of 0.91 for 
harmful outcome) and a 95% CI of 0.23 to 5.24. This effect estimate and CI describe 
the distribution of possible values for the relative effectiveness of early PTP 
compared with late PTP.   
 
 
 RAPID ESTIMATION OF THE HEALTH BENEFITS OF THE PROPOSED TRIAL 
On the balance of existing evidence, early PTP is judged to be the most effective 
option. However, due to uncertainty in the evidence base, there is a 46% chance that 
early PTP is less effective than the baseline treatment of late PTP. The health 
consequences of this uncertainty, at a population level, are estimated by combining 
the range of plausible values for the relative effect of early PTP with the baseline 
probability of functional recovery following TBI, which is also estimated with 
uncertainty, and the annual incidence of TBI.  
The distribution of the health consequences of uncertainty for early PTP following 
TBI is illustrated in Figure 2.4. The balance of evidence favours early PTP with a 
54% chance that it results in more functional recoveries than late PTP. However, this 
means that there is a 46% chance that late PTP could result in additional functional 
recoveries gained per year. The health consequences of uncertainty are not uniform; 
there is a greater chance of more limited consequences (e.g., 9% chance of between 
zero and 250 functional recoveries lost per year) and a smaller chance of greater 
consequences (e.g., 5% chance of more than 2,250 functional recoveries lost per 
                                               
15 This is based on an estimated standard error of 0.8 on the log scale.  
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year). The average over this range of potential outcomes provides an estimate of the 
expected health benefits that could potentially be gained each year if the uncertainty 
in the decision were resolved.  This corresponds to an expected upper bound on the 
value of further research of 577 functional recoveries per year16.  
 
Figure 2.4: Expected consequences of uncertainty in terms of number of 
functional recoveries lost per annum due to uncertainty. 
 
These expected benefits increase with the size of the patient population whose 
treatment choice can be informed by additional evidence and the time over which 
evidence about the effectiveness of the interventions is expected to be useful. It is 
expected that the information from research will be valuable for approximately 15 
years.  This means that the consequences of uncertainty surrounding the decision 
increases greatly by the fact that, in the absence of better evidence, the health system 
is likely to utilise the suboptimal treatment option every year for the next 15 years. 
Extending the yearly consequences of uncertainty over the 15 year time horizon, 
means that the expected maximum health benefits of research is estimated to be 
6,732 functional recoveries gained over the full time horizon (after discounting 
appropriately). This is illustrated in Figure 2.5. 
 
                                               
16 This is calculated by multiplying the consequences by the probability of those consequences: 0 x 
54.7% + 250 x 11% + 750 x 9.9% +1250 x 8.3% + 1750 x 6.5% + 2250 x 4.6% + 2750 x 2.9% + 
3250 x 1.5% + 3750 x 0.5% + 4250 x 0.1% = 574 functional recoveries per year. This is marginally 




Figure 2.5: Expected maximum health benefits of research to inform the 
optimal timing of PTP following TBI over a time horizon of 15 years. 
 
For P1, the proposed RCT is expected to take 5 years to complete and report, and so 
the expected upper bound on the health benefits of research will fall from 6,732 to 
4,086 functional recoveries gained. This is illustrated in Figure 2.6. 
 
 
Figure 2.6: Expected maximum health benefits of research to inform the 
optimal timing of PTP following TBI over a time horizon of 15 years, with 
research reporting in 5 years. 
 
As the research funding budget is limited, the same analysis should be undertaken 
for all competing proposals in order to compare the value of research across 
proposals. However, before doing this, the costs of the research should to be taken 
account of. The proposed RCT is expected to cost the research funder £2,854,000, 
which means that the maximum expected value of the proposed research is estimated 
to be (£2,854,000/4,086 =) £699 per functional recovery gained. Whether this 
represents good value to NETSCC depends on the health benefits of the other 
competing research proposals, which may or may not be funded due to the resources 
required to fund P1. 
Taking account of other aspects of outcome 
The proposed trial is designed with functional recovery as its primary outcome so the 
benefits of implementation and the proposed research are expressed as functional 
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recoveries gained. Although functional recovery may be the most appropriate 
primary outcome, it is not necessarily the only relevant outcome for assessing the 
value of the proposed treatments.  For example, relative to current practice, early 
PTP incurs additional treatment costs of £124,000 per year. Specifying a MCD 
required to change clinical practice is one way to incorporate concerns about 
increased costs and/or potential adverse events that are not captured in the primary 
outcome. For example, since early PTP is more costly than late PTP it might be 
required to demonstrate a 1% increase in the number of functional recoveries, in 
addition to those expected when everything else is considered equal.  Requiring a 1% 
increase implies that the additional costs are equivalent to 88 additional functional 
recoveries per year17.   
Taking the 1% increase into account using the method described in Section 2.3.4, the 
consequences of uncertainty are now estimated to be 618 additional functional 
recoveries per year. This is higher than the previous estimate of 577 additional 
recoveries per year because taking account of the MCD penalises early PTP, which 
is expected to be slightly superior given current evidence, this making the decision 
between treatments more uncertain and so increases the value of additional evidence. 
The expected value of the additional evidence is 4,377 functional recoveries gained 
over the 15 year period (taking account of the 5 years required for research to 
report).  This translates to an expected maximum value of the trial of 
(£2,854,000/4,377 =) £652 per functional recovery gained.  
  
                                               
17 The trade-off implied by requiring a percentage change in a binary outcome is calculated by 




 PRIORITISING ACROSS RESEARCH PROPOSALS 
The previous section shows how to estimate the expected benefit of proposed 
research in terms of the primary outcome (e.g., cost per functional recovery after 
TBI). Research funders with a fixed research budget (like NETSCC) need to make 
research prioritisation decisions across a diverse range of research proposals with 
different primary outcomes. To explore the implications of this, Table 2.3 reports the 
expected value of the proposed research for each 6 NETSCC proposals in terms of 
cost per primary outcome (i.e., expected benefits of proposed research net the 
research costs). It also reports the scale of the additional research costs imposed on 
the NHS outside of the NETSCC budget (i.e., NHS Support and Treatment costs). 
The method to estimate the benefit of P1 has been illustrated in the preceding 
sections of this chapter. Rapid VOI approaches have also been used to estimate the 
value of funding P2-P6. The methods used are an extension of those illustrated in 













Table 2.3: Expected value of proposed research study expressed in terms of the 
primary outcome for each of the six NETSCC proposals  
Proposal 
Upper bound for 










P1: Brain injury 4,377 additional 
functional 
recoveries 
£2,854,000 £652 per additional 
functional recovery 
£490,000 




£2,522,710 £4,641 per additional 




P3: Rare disease 1 composite 
endpoint** 
prevented 





P4: Alzheimer’s 2,390 additional 
MMSE* points 
£3,310,883 £1,385 per additional 
MMSE point  
£1,297,789 
P5: Psychosis 245  relapses 
avoided 








£882,177 £7,869 per additional 
death in preferred 
place 
£4,104 
Total costs   £11,026,654     
*MMSE: mini mental state examination. Questionnaire used to assess severity of Alzheimer’s disease. Maximum 
score is 30. Scores in the MMSE are often classified into different categories: 26–30 (normal ageing), 21–25 
(mild dementia), 15–20 (moderate dementia), 10–14 (moderately severe dementia) and 0–9 (severe dementia) 
** Composite endpoint: death, meningococcal infection or irreversible organ injury 
 
The expected value of the proposed research across the 6 proposals is expressed in 
terms of a broad range of outcomes. There are substantial differences in the number 
of primary outcomes expected gained/avoided across the different proposals (column 
2). The main factors which account for these differences are:  
Incident population  
Proposals which affect a large number of patients each year such as P4 
(100,000/year) and P1 (8,800/year) result in a large number of primary outcomes 
gain/avoided, 2,390 additional MMSE points and 4,377 additional functional recoveries 
respectively. This is compared to research proposals which affect fewer people per 
year; P5 (1,563/year), P2 (1,137/year) and P3 (26.3/year) which are expected to 
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result in 245 relapses avoided, 544 additional months of progression free survival 
and 1 composite endpoint prevented respectively.  
Degree of uncertainty in relative effects  
P6 is an important exception to the rule that a larger incident population results in a 
larger health impact (in terms of primary outcomes gained/avoided). P6 has a large 
incident population (259,150/year) but only results in 112 additional deaths in preferred 
place. This is because P6 investigates the effect of an information booklet on the 
ability of terminal patients to die in their preferred place (e.g. at home). As it is 
highly unlikely that providing the booklet will reduce the number of terminal 
patients dying in their preferred place there is not much uncertainty in the direction 
of the relative treatment effect. As the booklet is cheap and is likely to improve the 
primary outcome, there is not much uncertainty for P6 to address and so it is likely to 
have a relatively small health impact, despite its large incident population.  
In addition to health outcomes per NETSCC spend, the proposals differ in the 
additional costs of research imposed on the NHS. The health foregone due to these 
additional research costs should also be considered when choosing among the 
competing research proposals. For example, P2 and P3 claim substantial NHS cost 
savings associated with funding these research projects. In both cases, current 
practice is associated with large treatment costs and, therefore, the cost savings are 
assumed to follow by allocating patients to less costly treatment options as part of 
the planned research projects. However, whether these cost savings can be expected 





VOI methods can potentially improve the transparency and accountability of 
research prioritisation decisions, however a number of barriers to their use in policy 
remain. This chapter investigated the feasibility of the rapid VOI methods developed 
by Claxton et al., (2015a) for applied research prioritisation using a set of 
retrospective research funding applications received by NETSCC. This method can 
potentially improve the transparency and accountability of research prioritisation by 
highlighting the trade-offs in primary outcomes required when choosing between 
research proposals while taking account of the size of the population affected by the 
decision and the costs of research. The approach does not require a large number of 
inputs and so should be feasible to incorporate into the research prioritisation 
process.  
In order to rank the priority of a set of research proposals decision makers should 
take account of which projects represent the “best buys” to the research funder 
(Culyer, 2016). Table 2.3 shows the value of each project expressed in terms of its 
cost per primary outcome (e.g. £652 per additional function recovery). This 
information helps decision makers to compare value across proposals by making the 
trade-offs between the different outcomes clearer. By providing a starting point for 
deliberation, this analysis represents a clear improvement relative to implicit forms 
of decision making. However, significant implicit scientific judgements are still 
required to make decisions. First, some primary outcomes may be more severe than 
others (e.g., death versus short periods of immobility). Second, some outcomes 
represent concrete clinical events (e.g., overall survival) while others represent 
surrogates (e.g. changes in blood pressure), which may or may not be good 
predictors of relevant outcomes (Kemp and Prasad, 2017). Finally, research will 
result in additional costs that fall directly on the general health system budget (e.g. 
NHS) and the differential health opportunity costs associated with these resources 
must also be accounted for. This means that although the analysis presented in Table 
2.3 can greatly improve the transparency and accountability of research 
prioritisation, the task can be supported further by expressing all primary outcomes 
in terms of a generic outcome which can be compared across disease areas (such as 





As in most applied VOI analysis (e.g. Bennette et al., (2016) and Carlson et al., 
(2018)), the methods illustrated here makes two simplifying assumptions about 
decision making. First, it is assumed that there are no irrecoverable costs associated 
with the treatments considered. Irrecoverable costs are those costs that, once 
committed, cannot be recovered if guidance is changed at a later date (McKenna et 
al., 2015). For example, if large capital investments are required for a treatment to be 
delivered in a health system then this is associated with irrecoverable costs if the 
health system cannot easily sell the capital when guidance changes. The second 
assumption is that decisions to recommend an intervention for widespread use and 
decisions to carry out additional research on that same intervention are independent. 
However, there are cases in which research cannot be carried out at the same time as 
the treatment is available for widespread use. Chapter 6 explores the consequences 
of relaxing these assumptions. 
In applying VOI methods to a retrospective set of real-world proposals received by 
NETSCC, this chapter has highlighted the importance of methods to explicitly 
quantify uncertainty in situations in which suitable pre-existing studies do not exist. 
This is fundamental issue in the use of VOI to aid research prioritisation and has also 
been highlighted by Bennette et al., (2016) and Carlson et al., (2018). Despite its 
importance this issue has received very little attention in the VOI literature. To 
address this, we outlined three available options for decision makers; expert 
elicitation, statistical modelling and the use of meta-epidemiological studies. In this 
chapter we demonstrated the use of a meta-epidemiological approach related to that 
used by Bennette and Carlson. Though providing a useful starting point for 
deliberation, this method could be greatly improved with further research. The 
primary limitation of the approach used here is that applying a generic meta-
epidemiological estimate to inform uncertainty across all research proposals does not 
take account of contextual differences between proposals. There may be good 
scientific reasons to treat proposals differently. This contextual information could be 
incorporated by (i) integrating expert elicitation and meta-epidemiological methods, 
(ii) utilising more sophisticated statistical methods to reflect the fact that different 
disease areas and types of outcome are associated with different distributions of 
effect sizes (iii) combining approaches i and ii. Developing these methods with the 
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aim of supporting research prioritisation is potentially an important and fruitful area 
of further research. 
Relatedly, rapid methods of expert elicitation may be useful to develop and integrate 
into the research prioritisation process. As judgements about uncertainty must be 
made either implicitly or explicitly, expert elicitation may be especially useful in 
cases in which previous randomised trials have not been carried out and the use of 
meta-epidemiological evidence is deemed inappropriate. The importance of expert 
elicitation in decision making has been increasingly recognised in recent years and 
number of user friendly tools have been developed to facilitate its integration into 




Chapter 3  
Prioritising across research proposals by linking 
primary outcomes to a comprehensive measure of 
health outcome 
 INTRODUCTION 
The previous chapter demonstrated that it is possible to rapidly estimate the value of 
research in terms of cost per primary outcome e.g. £652 per additional function 
recovery. This provides a useful starting point for prioritisation however it was also 
shown that choosing between proposals requires a number of implicit scientific 
judgements. These are required as some primary outcomes are more severe than 
others and some primary outcomes are surrogates rather than outcomes of value in 
themselves. Additionally, because the primary outcomes are not comparable across 
disease areas the analysis presented in Table 2.3 cannot help address other questions 
which may be of interest to decision makers such as whether sufficient resources 
being devoted to research. 
The aim of this chapter is to show how these limitations can be addressed and the 
scope of the analysis expanded by using external evidence to link each primary 
outcome to a more comprehensive measure of health outcome. This more 
comprehensive measure must be generic enough to compare benefits across disease 
areas and should capture both quality and quantity of life. QALYs are used 
throughout this thesis but the methods apply to any other comprehensive measure of 
health (e.g. disability adjusted life years (DALYs)). In this chapter we illustrate how 
to link binary primary outcomes to QALYs to calculate the health impact of the 
research in QALYs. This extension has been demonstrated in (McKenna et al., 2016) 
and is illustrated by continuing to use the P1 case study from Chapter 2.  
After this we explore the implications of prioritising across a set of research 
proposals when all benefits are quantified in QALYs. There are a number of 
implications which are illustrated using the full set of 6 retrospective research 
proposals received by NETSCC.  
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The budget for funding research is often not the same as the budget that funds 
general healthcare activities such as staff salaries, drug costs, equipment etc. 
Therefore, the benefits of a particular research proposal must be compared to the 
benefits of other research proposals which could have been funded with these 
resources. This means that research bodies such as NETSCC in the UK cannot fund 
every research proposal which offers health gains relative to general health 
expenditure. In order to reflect these trade-offs appropriately, the “bookshelf” 
approach described by Culyer (2016) is used in this chapter. The bookshelf 
framework is used here to rank interventions from highest to lowest health impact to 
identify the “best buys” for decision makers. This framework is also provides a basis 
to understand whether health outcomes could be improved by expanding the research 
budget relative to the budget for general health expenditure. The bookshelf also 
shows the population health implications for charitable and industry contributions to 
research funding.  
As the research budget is limited, funding research as a method to change practice 
will necessarily divert resources away from research projects which could address 
genuine uncertainties in the health system. However, in some scenarios, research 
may be required to change practice. In Section 3.4 we use the framework to show 
that when practice cannot change in absence of research then smaller research 
studies which report results sooner (and thus can change practice more quickly) will 
be more valuable to fund than large time consuming studies. Additionally, Section 
3.3.4 provides an explicit method to inform an appropriate MCD with reference to 







 LINKING PRIMARY OUTCOME TO A COMPREHENSIVE MEASURE OF 
HEALTH OUTCOME 
Health related quality of life and disease related costs 
Continuing the P1 case study from Chapter 2, the benefits of research were estimated 
in terms of functional recoveries gained. Functional recovery was based on the 
GOSE score which captures both mortality and quality of life effects. In this section, 
we show how the analysis can be extended to estimate the QALYs associated with 
functional recovery.  
If a patient functionally recovers there is a chance that they will end up in one of the 
GOSE states from moderate disability to good recovery (GOSE scores of 5 to 8). If a 
patient does not recover, there is a chance that they will either die (score of 1) or end 
up in vegetative or severe disability states (scores of 2 to 4). A previous TBI study 
by Nichol et al., (2015) is used to estimate the relative probabilities of ending up in 
each of the GOSE states conditional on functional recovery status; this is shown in 
column 3 of Table 3.1. 
Table 3.1: Costs and QALYs associated with functional recovery as defined by 
GOSE score 5-8 



















GOSE 5 Moderate 
disability 
42% 16.73 0.7 £27,047 4.92 £11,360 
GOSE 6 24% 16.73 0.81 £27,047 3.25 £6,491 
GOSE 7 Good 
recovery 
20% 19.23 0.96 £19,575 3.69 £3,915 
GOSE 8 14% 19.23 1 £19,575 2.69 £2,741 
  100%       14.55 £24,507 
 
Linking survival (Shavelle et al., 2006), quality of life (Fuller et al., 2017) and 
disease related costs (Nyein et al., 1999; Wood et al., 1999)18 to each of these GOSE 
states allows us to estimate the consequences of functional recovery expressed in 
terms of costs and QALYs. The expected QALYs for each GOSE state are calculated 
                                               
18 See NICE guidance (National Institute for health and care excellence, 2014) Head injury: Methods, 
Evidence & Guidance. Economic evaluation reported in chapter 11: A cost-effectiveness analysis of 




by multiplying the life expectancy in each state by the utility weight and the 
probability of being in that state e.g. for GOSE 5 the expected QALYs are 16.73 x 
0.7 x 42% = 4.92 QALYs. Summing the expected QALYs for each of the states 
classified as functional recovery provides an estimate of the expected QALYs 
associated with functional recovery, which is 14.55 QALYs. The same process is 
carried out to estimate the expected disease related costs of functional recovery 
(£24,507) and the consequences of no functional recovery (shown in Table 3.2). 
Table 3.2: Costs and QALYs if functional recovery does not occur as defined by 
GOSE score 1-4 



















GOSE 1 Dead 29% 0 0 £0 0 £0 
GOSE 2 Vegetative 7% 7.11 0.11 £45,450 0.05 £3,182 
GOSE 3 Severe 
disability 
41% 12.52 0.41 £154,324 2.1 £63,273 
GOSE 4 23% 12.52 0.58 £154,324 1.67 £35,495 
  100%       3.82 £101,950 
 
Each functional recovery is expected to result in (14.55 – 3.82 =) 10.7 QALYs 
gained per person and (£101,950 - £24,507 =) £77,443 in cost savings per person 
over a lifetime.  These costs savings will free up resources in the NHS budget and, 
therefore, the health impact associated with these resources should also be 
considered. In order to reflect the health opportunity costs associated with higher 
costs to the NHS, we use the value of £15,000 per QALY, which has been endorsed 
by the UK Department of Health for use in health impact assessments (Claxton et al., 
2015b; NHS England, 2015). This means that for every £15,000 of NHS resources, 
the health system can expect to produce one additional QALY. This implies that the 
cost savings per functional recovery are expected to be worth (£77,443/£15,000 =) 
5.16 QALYs elsewhere in the health system. Combining the direct health benefits 
(10.7 QALYs) and the indirect health benefits through cost savings (5.16 QALYs) 
means that each additional functional recovery results in a gain of 15.86 QALYs19. 
                                               
19 It should be noted that the method shown here is just one approach to estimating the expected 
incremental net health benefit associated with functional recovery. A more complex approach would 




In addition to disease related costs, treatment costs should be taken into account to 
reflect the differences in the treatment options. For P1, all patients treated with early 
PTP incur additional treatment costs of £14.10 per patient, which implies additional 
costs of (£14.1 x 8,800 =) £124,080 per year. These increased costs are expected to 
displace (£124,080/£15,000 =) 8.3 QALYs per year for early PTP. 
 
Expected upper bound on the value of research 
To understand the benefits of research in terms of a comprehensive measure of 
outcome we follow the same rapid method as shown in Section 2.3.4. The 
uncertainty in the primary outcome is estimated by sampling from the uncertain 
distributions of relative effect and baseline event rate and multiplying by the number 
of patients per annum whose treatment choice is to be informed by the decision. This 
creates a distribution of the health consequences of uncertainty, which is expressed 
in terms of the primary outcome measure. Here we reflect the scale of the health 
benefits of the primary outcome (functional recovery in this case) by multiplying it 
by its NHB (15.86 QALYs for each functional recovery). The additional costs are 
then subtracted to reflect the empirical evidence on health opportunity costs to help 
understand the NHBs associated with uncertainty. The steps in this calculation are 







                                                                                                                                     










  QALYs per annum 
























(=-P if P<0) 
   [K] [L] [M] [N] [O] [P] [Q] 
Sample 1 4,745 1,871 £124,080 75,256 29,666 -45,590 45,590 
Sample 2 4,923 3,499 £124,080 78,079 55,486 -22,593 22,593 
Sample 3 4,569 4,763 £124,080 72,464 75,533 3,069 0 
Sample 4 5,103 7,425 £124,080 80,934 117,752 36,818 0 
Sample 5 4,836 7,609 £124,080 76,699 120,670 43,971 0 
Average 4,835 5,033 £124,080 76,686 79,821 3,135 13,637 
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Table 3.3 shows that early PTP is expected to be superior after explicitly taking 
account of the health impact of the primary outcome and treatment costs. Again, 
there are samples in which early PTP is expected to be less effective than late PTP 
(samples 1 and 2). Taking the average consequences of uncertainty (column 8) we 
can estimate an upper bound for the benefits of research 13,637 QALYs per year. 
Repeating this process for a large number of samples results in an estimate of 9,169 
QALYs per year. Extending the yearly consequences of uncertainty over the 15 year 
time horizon, the maximum value of research is estimated to be 107,000 QALYs 
gained over the full time horizon (after discounting). It is expected that it will take 5 
years for the research to report and so the upper bound on the value of this research 
is expected to fall to 64,942 QALYs gained20. The rapid VOI approach in Chapter 2 
was a decision tree in which the payoffs were quantified in terms of the primary 
outcome. The method presented here is also a decision in which the payoffs are 
linked to QALYs. 
 
Health costs of using sub optimal treatments in research 
As research will often involve allocating patients to each of the alternative 
treatments; this means that some patients will be allocated to the treatments which 
are expected to be sub optimal given current evidence (Briggs et al., 2006; 
Eckermann and Willan, 2008b). The net health loss associated with the suboptimal 
treatment may be subtle at the individual level but should be considered when 
estimating the health impacts of research proposals as they can have important 
consequences. This net health loss may result from allocating participants to 
treatments which are more costly and/or expected to be less effective. According to 
current evidence, early PTP is expected to improve the chance of functional recovery 
with a mean odds ratio of 1.09 and a 95% CI of 0.23 to 5.24. The probability of 
functional recovery with current practice is 55.1%. Combining the odds ratio for 
early PTP with the probability of functional recovery with current practice results in 
an expected probability of functional recovery of 56.5% for early PTP. 
                                               
20 It is worth noting that the value of research can be estimated in terms of QALYs by a method which 
is equivalent to the one demonstrated in this Section. The alternative approach is to calculate the value 
of research in terms of cost per primary outcome (as shown in Chapter 2) and then divide this by the 
NHB associated with the primary outcome. This approach assumes that the MCD is appropriate. 
Methods to determine an appropriate MCD are provided in Section 3.3.4. 
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As functional recovery is expected to be worth 15.86 QALYs the expected benefits 
of late PTP and early PTP are (55.1% x 15.86 =) 8.739 and (56.5% x 15.86 =) 8.961 
QALYs respectively. Taking account of the additional costs of early PTP means the 
expected benefit of allocating a patient to early PTP is (8.961 - £14.1/£15,000 =) 
8.960. This implies that for every additional patients not allocated to the optimal 
treatment (early PTP) the health system loses (8.960 - 8.739 =) 0.221 QALYs. 
Therefore, according to the design of P1, allocating 650 patients to late PTP as part 
of P1 is expected to be associated with net health losses of (0.221 x 650 =) 143.65 
QALYs.  
The “NHS support and treatment costs” are reported for each proposal in column 5 
of Table 2.3. These are the costs of research which are borne by the general health 
system e.g. treatment costs, staff time and health losses associated with allocating 
patients to sub-optimal treatments during research21. From the calculation above the 
health opportunity losses associated with funding the trial are 143.65 QALYs. The 
total benefits of the proposed trial are the direct benefits of the trial minus the losses 
associated with allocating patients to sub-optimal treatments, (64,942 – 143.65 =) 
64,798.35 QALYs. This means that the value of the trial can be expressed as one 
QALY gained per (£2,854,000/64,798.35 =) £44 of NETSCC expenditure. 
The value of the trial is now expressed in a generic measure of health outcome, 
which can be compared to other proposed research competing for funding. 
For every £15,000 spent on NHS service provision, the health system can expect to 
produce one QALY. By funding P1, NETSCC only has to spend £44 to produce one 
QALY. This means that P1 offers excellent value for money to the health system 
compared to general service provision. However, given that the budget for funding 
research is fixed and separate from general health care provision, the decision about 
whether the proposed trial represents good value to NETSCC depends on how it 
compares to other proposals competing for the same NETSCC funding.  
  
                                               
21 From the information available the methods used by applicants to calculate NHS support and 
treatment costs appear to only consider the additional financial costs associated with new treatments. 
A full estimate of the cost the NHS support and treatment costs is 143.65 x £15,000 = £2,154,750 in 
monetary terms, which is substantially greater than the £490,000 NHS support and treatment costs 
reported in the proposal documentation. 
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 INFORMING KEY QUESTIONS IN RESEARCH PRIORITISATION 
Table 3.4 presents the expected value of research for each of the six NETSCC 
proposals. The value of each proposal is expressed in terms of NETSCC cost per 
QALY gained (column 4) and as QALYs per £15,000 of NETSCC expenditure 
(column 5). The latter is a simple manipulation the former which can potentially 
make health impact more explicit. For example funding P1 is expected to be 
equivalent to paying £44/QALY, this is equivalent to generating (£15,000/£44 =) 
341 QALYs per £15,000 of expenditure. The proposals are ordered from top to 
bottom by their total expected impact on population health. 
The method to estimate the benefit of P1 in terms of QALYs has been illustrated in 
this chapter. Rapid VOI approaches have also been used to estimate the value of 
funding P2-P6 in terms of QALYs. The methods used are an extension of those 
illustrated previously. See Chapter 4 for analysis of P2-P5. See Chapter 5 for 
analysis of P6. Results are presented here primarily to illustrate how a QALY 





Table 3.4: Expected value of proposed research study expressed in terms of 
QALYs for each of the six NETSCC proposals.  
Proposal 
Upper bound for 









P1: Brain injury 64,798 QALYs  £2,854,000 £44 341 QALYs 
P4: Alzheimer’s 967 QALYs £3,310,883 £3,422 4.4 QALYs 
P5: Psychosis 38 QALYs £601,481 £14,806 1 QALY 
P6: Information 
booklet 
10 QALYs  £882,177 £86,836 0.2 QALYs 
P3: Rare disease 707 QALYs lost £855,403 NA  12.4 QALYs lost  
P2: Melanoma 4,160 QALYs lost  £2,523,000 NA 24.7 QALYs lost 






Variation in expected value of research proposals 
There is wide variation in the expected maximum value of research across the six 
proposals (column 2 in Table 3.4) with a range from 64,798 QALYs gained (P1) to 
4,160 QALYs lost (P2). This means that different research proposals are expected to 
have very different contributions to population health (as measured in QALYs). The 
variation between proposals can be explained by a number of factors which combine 
to result in the ordering shown in Table 3.4 and Figure 3.1: 
Incident population  
As in Section 2.5 proposals which affect a large number of patients each year such as 
P4 (100,000/year) and P1 (8,800/year) tend to be associated with a large health 
impact. These proposals rank highly compared to P5 (1,563/year), P2 (1,137/year) 
and P3 (26.3/year). The exception to this is P6 which has a large incident population 
(259,150/year) but ranks below P5 which affects far fewer people. This is explained 
by the low levels of uncertainty in P6 which will be discussed next. 
Degree of uncertainty in relative effects 
P6 affects a large number of people (259,150/year) but has a low health impact, 
ranking below P1, P4 and P5. As discussed in Section 2.5 this is because the new 
intervention that P6 investigates is cheap and is expected to be beneficial, therefore 
there is little uncertainty to address. There is also little uncertainty in the clinical 
decisions investigated by P2 and P3 resulting in low value of research. In these cases 
the lack of uncertainty is due to large differences in relative treatment costs. 
Relative treatment costs  
P3 and P2 both investigate the use of reduced doses of highly expensive treatments. 
The substantial costs savings associated with these reduced doses regimens means 
that according to current evidence the cheaper alternative interventions are highly 
cost effective relative to current practice. Therefore, there is very little uncertainty 
about the optimal choice. Funding P3 and P2 is associated with negative QALYs as 
there is very little uncertainty and commissioning this research will prolong the use 
of the highly expensive current practice. Prolonging the use of expensive treatments 
results in QALYs lost from the opportunity costs of this additional health 
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expenditure22. In practice, there may be barriers to switching to more cost effective 
alternatives in the absence of commissioning new research. This is discussed in 
Section 3.4. 
Net health impact of primary outcome  
The magnitude of the net health consequences of the primary outcome is also 
significant as it reflects the relative importance of uncertainty in different disease 
areas. For example, the estimated net health impact of functional recovery in P1 is 
15.86 QALYs compared to 1.06 QALYs per relapse avoided in P5. This means that 
achieving an additional functional recovery has a similar health impact as preventing 
approximately (15.86/1.06 =) 15 relapses. The estimated value of each research 





                                               
22 Table 2.3 reports “NHS support and treatment costs” to be cost savings of £62,410,967 and 
£10,608,500 for P2 and P3 respectively. These alleged savings arise from allocating patients to new 
interventions which are substantially cheaper than current practice. For both P2 and P3 the new 
interventions are expected to be cost effective given current evidence, therefore these estimated cost 
savings are better thought of as cost increases as patients should be immediately switched to the more 
cost effective alternatives and so commissioning the research involves prolonging the use of the more 




Informing key questions in research prioritisation 
The results in Table 3.4 can be used to support explicit and evidence based 
discussion on a broad range of policy questions faced by research funders such as:23  
 Which proposals represent “best buys” within the research funding budget? 
 Are sufficient resources being devoted to research? 
 How can charity or industry contributions towards research be considered? 
 What change in the primary endpoint is required before practice should 
change? 
 
 WHICH PROPOSALS REPRESENT “BEST BUYS” WITHIN THE RESEARCH 
FUNDING BUDGET? 
In order to rank the priority of a set of research proposals we apply the “bookshelf” 
approach described by Culyer (2016) and Remme et al., (2017) to the research 
prioritisation task. This allows us to rank research proposals from highest to lowest 
health impact and so decision makers can take account of which projects represent 
“best buys” within the research funding budget. Proposals in Table 3.4 are ranked by 
the QALYs gained per £15,000 of research expenditure (column 5), or equivalently, 
ranked by lowest NETSCC cost per QALY (column 4). Proposals with a higher 
QALY impact per £15,000 expenditure (e.g., P1) have the potential to increase 
population health more than those with a lower impact per £15,000 expenditure (e.g., 
P5) and, therefore, should be prioritised first.  
The order of funding priority is P1 followed by P4, P5, and then P6. P2 and P3 are 
expected to result in negative population health per NETSCC expenditure; therefore, 
these proposals should not be funded at any level of the budget24. The set of research 
proposals that can be funded depends on the size of the budget available for research 
funding. The relevance of the available budget is illustrated in Figure 3.1. Each of 
the six proposals is represented by a column, where the height represents the number 
                                               
23 Prioritising a set of research proposals using a finite budget is similar to the task of constructing a 
package of interventions to fund in a health system. Therefore, the analysis here is similar to that 
described in Ochalek et al., (2018b). 




of QALYs per £15,000 of NETSCC expenditure, the width represents the cost of the 
proposal to NETSCC (also labelled within brackets) and the area of the column 
reflects the net health impact (i.e. the total payoff). 
  
Figure 3.1: The net health impact and budget impact of each of the six 
NETSCC proposals 
 
The horizontal axis shows the cumulative NETSCC budget. A budget of just under 
£3 million is required to fund P1, a budget of £6.1 million is required to fund P1 and 






How robust is this ordering? 
A number of scientific and social value judgements are required in order to estimate 
the expected health benefits of research. These judgements are unavoidable and 
subject to uncertainty. Sensitivity analysis is used to assess the impact of changing 
the value of inputs on the expected value of research.  It provides a quick and 
intuitive method to understand the impact that different judgements may have on the 
value of research and whether these are worth exploring further. A scenario analysis 
is presented here which constructs a high value and low value scenario for the 
expected value of research. This shows the effect of changing a group of inputs 
simultaneously, where each input is increased or decreased by 10%. Table 3.5 shows 
the inputs used in the scenario analysis and corresponding results for P1.  
Table 3.5: The maximum expected value of research for P1 under high value, 




Base case Low value 
scenario 
Baseline Probability of 
functional recovery 
146 out of 265 
at risk 
162 out of 294 at 
risk 
178 out of 323 at 
risk 
95% CI for odds ratio for 
functional recovery 
0.21 to 5.76 0.23 to 5.24 0.25 to 4.72 
Cost of early PTP per 
year 
£136,488 £124,080 £111,672 
Incidence 9,680 8,800 7,920 
Time horizon for 
information 
16.5 years 15 years 13.5 years 
Duration of research 4.5 years 5 years 5.5 years 
Research cost to NHS £441,000 £490,000 £539,000 
Cost per QALY £32 £44 £63 
QALYs per £15,000 
NETSCC spend 
469 341 238 
 
Between the low value and high value scenarios, the cost per QALY varies between 
£32 and £63 per indicating that the results are relatively stable for P1. From Table 
3.4 the nearest alternative to P1 is P4 with a cost per QALY of £3,422, therefore the 
P1 remains the top priority for funding in this sensitivity analysis. A similar exercise 
could be carried out for each of the remaining proposals. Because the estimated 
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value of proposals P5 and P6 are closer in value (1 and 0.2 QALYs per £15,000 
NETSCC expenditure respectively) it is possible that their ordering in priority could 
change under some scenarios. Such uncertainty is unavoidable in decision making 
and is an important component of a deliberative approach to research prioritisation. 
It is important to emphasise that the results of sensitivity analysis should be 
interpreted in the context of a given a set of research proposals and a given budget 
constraint. As in the case of P1 sensitivity analysis may result in large variations in 
health impact but no change in the overall funding priority. In other cases it may be 
that small variations in health impact under sensitivity analysis result a substantial 
reordering. This is more likely in cases in which there are a number of research 
proposals with base case estimates of value which are in close proximity. 
 
 ARE SUFFICIENT RESOURCES BEING DEVOTED TO RESEARCH? 
Empirical work estimates that approximately £15,000 of general NHS expenditure is 
required to generate one QALY in the UK (Claxton et al., 2015b; Lomas et al., 
2018). Therefore, research projects which generate more than one QALY per 
£15,000 (such as P1 and P4) compare favourably to direct NHS health care 
provision. If there are research projects which are expected to result in more than one 
QALY per £15,000 expenditure that cannot be funded within the current research 
budget constraints, this indicates that research may be insufficiently funded relative 
to general health care expenditure. The value of expanding the research budget could 
be estimated by calculating the value of research of proposals which just missed out 
on funding due to resource constraints25 (Culyer, 2016). These are the marginal 
projects which would have been funded if the research budget was larger. This could 
form an empirical basis for helping to understand the “marginal productivity” of the 
research budget i.e. how much research funding is required to produce one QALY. 
By comparing this to the marginal productivity of the general health care budget 
(approximately £15,000/QALY) this can inform discussions about the overall size of 
the research budget relative to general health care expenditure. If more health can be 
                                               
25 The methods described in this thesis provide an expected upper bound on the value of research 
when all uncertainty is resolved. As research projects have a finite sample size, they will only 
partially resolve the uncertainty. Methods to adjust research value for sample size and other aspects of 
research design are well developed (A. Briggs et al., 2006; Strong et al., 2015). Without this 
adjustment, the value of research would be overestimated relative to direct service provision. 
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gained by expanding the research budget than would be lost by shrinking the general 
health care budget, then population health may be improved by shifting resources 
towards research26. 
 
 HOW CAN CHARITY OR INDUSTRY CONTRIBUTIONS TOWARDS RESEARCH 
BE CONSIDERED? 
Publicly funded research projects may receive financial contributions from charities 
and/or industry. In this thesis we characterise research costs as falling on two types 
of budget; the research prioritisation body’s budget (e.g. NETSCC in the UK) and 
the general health care budget (e.g. the NHS in the UK). The effect of savings from 
contributions to research funding will depend on which budget these savings accrue 
to. To illustrate, the Alzheimer’s society has offered to contribute to the costs of 
funding P4. If £1 million was granted directly to NETSCC to help fund P4, then the 
cost to NETSCC falls from £3,310,883 to £2,310,883 and, therefore, the NETSCC 
cost per QALY falls to (£2,310,883/967 =) £2,390 per QALY. It is interesting to 
note that though the contribution from the Alzheimer’s society does improve the 
relative value of P4 it does not change its overall priority, it remains the second best 
value for money after P1, but it does free up NETSCC resources to fund other 
potentially worthwhile research.  
If the cost savings were allocated to the NHS to help cover the additional support 
and treatment costs associated with the research (for example by directly 
contributing to the costs of drug acquisition), then NHS support and treatment costs 
fall by £1M. This improves the health benefits of research by (£1M/£15,000 =) 66.7 
QALYs due to cost savings which results in total net benefits of research of (967 + 
66.7 =) 1,034 QALYs and therefore a NETSCC cost per QALY of 
(£3,310,883/1,034 =) £3,202 per QALY. In this case contributing to cover NETSCC 
costs improves the relative value of P4 more than contributing to cover the NHS 
support and treatment costs.  
 
                                               
26 For large changes in the research budget and/or the general health budget the effect of non-marginal 
changes must be accounted for (Lomas et al., 2018).   
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 DETERMINING MCD: TREATMENT PRICE AND THE CHANGE IN PRIMARY 
ENDPOINT REQUIRED BEFORE PRACTICE SHOULD CHANGE 
Chapter 2 illustrated how the value of research will depend on the MCD required for 
practice to change. Informing the appropriate MCD requires an implicit trade-off 
between the health benefits of the primary outcome and the other outcomes of 
interest which are not captured by the primary endpoint (the secondary outcomes). In 
this section we provide a method to help inform an appropriate MCD which uses the 
explicit linkage of the primary outcome to QALYs.  
Consider the comparison of a new intervention to a baseline comparator. In addition 
to differences in the relative effect of each treatment on the primary outcome there 
may be a number (n) of relevant secondary outcomes to consider (i = 1,…n). The 
appropriate overall MCD for the new treatment reflects the improvement in the 
primary outcome required to make up for net losses (if any) associated with the 
secondary outcomes relative to the baseline comparator. These secondary outcomes 
may have countervailing effects, for example the new intervention may be more 
expensive but have a better side effect profile relative to current practice. Here we 
provide a heuristic for informing overall MCD for a treatment. This heuristic applies 
in health systems which are concerned with impacts on total population health27.  
When considering effects on population health, the MCD reflects the additional 
number of primary outcomes which are required to make up for the health losses (if 
any) associated with secondary outcomes28 e.g. side effects. The number of 
additional primary outcomes required to make up for the health loss associated with 
a secondary outcome will depend on the incremental NHB (INHB) associated with 
the primary outcome. A larger MCD is required if secondary outcome i is associated 
with a large net health loss (NHLi). QALYs can be used to facilitate the required 
trade-off.  
                                               
27 Other approaches to resource allocation which attempt to prove a basis for resource allocation in 
insurance based systems through utility maximisation using welfare economics (Basu and Sullivan, 
2017) also involve trade-offs between primary and secondary outcomes. Therefore heuristics to define 
the required MCD for a new treatment to enter the insurance program can also be developed for these 
cases. This should reflect the consumption losses of increased premiums and/or the losses from 
disinvestment in another treatment. Currently the methods outlined here assume linearity in the trade-
off between primary and secondary outcomes which may need to be relaxed in a utility maximisation 
framework. 
28 The primary outcome may be harmful, e.g. heart attacks, in which case the MCD is defined as the 
additional number of primary outcomes which must be avoided to make up for the health losses 
associated with the secondary outcomes. 
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For an individual patient the change in the probability of the primary outcome 
required to make up for secondary outcome i is represented by MCDi. The required 
MCDi is such that the health gains in the primary outcome cancel out the health 
losses from the secondary outcome29: 
MCD𝑖 . INHB −  NHL𝑖 = 0 
Rearranging gives MCDi. = NHLi/INHB. For example, early PTP is associated with 
additional treatment costs (ΔC) of £14.1 per person and this is the only relevant 
secondary outcome (n = 1). Given the marginal productivity of the NHS (k) of 
£15,000/QALY, these additional treatment costs are associated with a NHL of (ΔC/k 
= £14.1/£15,000 =) 0.00094 QALYs per person. From Section 3.2, each additional 
functional recovery is associated with an additional 15.86 QALYs, therefore only 
(0.00094/15.86 =) 0.00006 additional functional recoveries are required to make up 
for the additional costs. This translates to a required MCD of 0.006%, the effect size 
of the new treatment must be greater than this to make up for the additional costs. 
The MCD is approximately zero as the additional costs of the new treatment are 
small relative to the health gains from the primary endpoint. The relationship 





 =  
ΔC
𝑘.INHB
                        (3.1) 
The MCD formula shows that higher relative costs (ΔC) require a larger MCD. 
Larger relative costs may be due to higher prices or increased dosage. A larger MCD 
is required in these cases because costs will result in health opportunity costs and 
larger improvements in the primary endpoint are required to compensate for this 
foregone health. A larger k implies that health care costs do not displace as much 
health and so a larger k will reduce the required MCD. If the primary endpoint is 
associated with large NHBs then this will also reduce the required MCD as small 
changes in the primary outcome have large health consequences. If a new treatment 
has a lower price/dose than current practice (and has a similar side effect profile) 
then ΔC will be negative reflecting the fact that the secondary outcomes associated 
                                               
29 It should be noted that this formulation imposes a structural relationship between the MCD the 
primary outcome and the secondary outcomes. This simple relationship may not be appropriate in all 
cases but is a necessary simplifying assumption to keep the complexity of the analysis down. 
96 
 
with the new treatment are favorable on net. From Equation 3.1 this implies a 
negative MCD which will make the adoption of the new treatment more likely (see 
Chapter 6 for more details). Any decision, requiring minimum changes in primary 
endpoints makes implicit judgements about ΔC, k and INHB, each of which can be 
usefully informed with reference to external evidence. 
The above analysis only considers price as a relevant difference between the 
treatments, however the MCD implicitly proxies the health effects of all other 
differences between treatments. The appropriate overall MCD is the sum of each of 




+ ⋯ +  
𝑁𝐻𝐿𝑛
𝐼𝑁𝐻𝐸




 FUNDING RESEARCH TO CHANGE CLINICAL PRACTICE 
There are two distinct ways to improve health outcomes. The first is to implement 
the findings of existing evidence (implementation value), while the second is to fund 
research to reduce uncertainty about the health impact of alternative treatments 
(information value). For some clinical decisions, the methods described here may 
indicate that current practice is not the most cost-effective and there is very little or 
no uncertainty about this judgement. As there is no uncertainty there is no value in 
further research. However, in special circumstances research may be necessary to 
change current practice. This scenario can occur in situations in which key inputs 
such as relative treatment effects have been informed using indirect sources of 
evidence such as meta-epidemiological evidence or expert elicitation. In these 
situations clinicians, legal and/or professional bodies may demand a minimum 
amount of direct empirical evidence from RCTs or well conducted observational 
research before a change in practice is warranted. If practice cannot change in 
absence of research then the value of the research is the implementation value plus 
the information value. If the information value is zero the effect of the trial will be 
dominated by its effects on practice. As gathering information is no longer the 
objective smaller trials will have larger health impacts as they will report quicker and 
so can change practice quicker. 
For example P2 describes research to investigate the effect of reducing the use of 
expensive immunomodulating anti-programmed death receptor 1 (PD1) antibodies in 
patients with advanced (unresectable stage III, IV) melanoma who are due to start 
anti PD1 as first line treatment. The primary outcome in the trial is the effect on 
progression free survival (PFS), with a non-inferiority margin defined for reduced 
doses of PD1 antibodies. The proposed trial was designed to compare continuous 
treatment until disease progression (TTP) to treatment for 12 months (TF12) and 
treatment for 6 months (TF6). Both of the new interventions TF12 and TF6 come 
with substantial expected cost savings. No relevant empirical evidence (RCTs or 
observations studies) was reported which investigated the use of TF12 or TF6 in this 
population. In absence of direct evidence, meta-epidemiological evidence was used 
as a starting point to understand the range of outcomes that may be plausible with 
TF12 or TF6. Due to the significant health opportunity costs resulting from the high 
prices of PDI antibodies, the TF6 dose reduction is expected to be superior to current 
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practice and there is no uncertainty in this decision. Due to prolonging the use of 
TTP during the research and the absence of any uncertainty in the decision, funding 
P2 is expected to reduce population health (as reported in Table 3.4 and Figure 3.1). 
Though TF6 appears to be the most cost effective option, there is no direct evidence 
on the use of TF6 in this population and the current (high cost) practice is mandated 
by NICE. Therefore practice may be difficult to change in absence of direct 
evidence. As TF6 is more cost-effective than current practice, health is foregone by 
delaying the switch to this treatment. Table 3.6 shows that the value of changing 
practice declines over time as the number of patients who can potentially be 
provided the cost effective alternative gets smaller30. After 10 years it is assumed 
that the treatment will no longer be relevant due to innovation and the value of 
changing practice falls to zero. 
Table 3.6: Benefits of changing practice over time for P2 in terms of QALYs. 
Year 
Discounted vale of 
changing practice per 
year (QALYs) 
Total value of changing 
practice over time 
(QALYs) 
1 11,463 98,423 
2 11,069 86,960 
3 10,688 75,891 
4 10,321 65,203 
5 9,966 54,882 
6 9,623 44,917 
7 9,292 35,294 
8 8,972 26,002 
9 8,664 17,029 
10 8,366 8,366 
11 0 0 
 
As the value of changing practice declines over time, any trial which is 
commissioned with the express purpose of providing a minimum standard of direct 
empirical evidence should be as small as possible so as to minimise this delay and 
report quickly31.  
                                               
30 This table is calculated by (continuously) discounting the implementation value per year (11,665) 
over the 10 year time horizon (column 2) and calculating the cumulative sum from year 10 back to 
year 1 (column 3). 
31 Unbalanced research designs which preferentially enrol individuals to the expected optimal 
treatment will also be favoured. 
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The research design as described in the proposal requires a large number of patients 
(n = 2,025) and so will facilitate changing practice only after it reports in 6 years. 
From Table 3.6, this change in practice from TTP to TF6 after 6 years is expected to 
result in an additional 44,917 QALYs through cost savings. Considering the health 
losses associated with delaying the switch to TF6, a smaller research design (say, n = 
300) which would report within approximately 2 years may be more appropriate32. In 
addition to being cheaper for NETSCC to fund, by facilitating changing practice at 2 
years the small trial is worth approximately 86,960 QALYs meaning it dominates the 
original design. The policy implication is that if practice cannot change in absence of 
research then a smaller design than P2 would result in greater health impact.  
The requirement of minimum levels of empirical evidence (i.e. the unwillingness to 
change practice based on indirect methods such as meta-epidemiological evidence or 
expert elicitation), such that it exists, may be due to professional discomfort and/or 
ethical obligations to patients to not expose them to untested interventions. As the 
research budget is limited, using the research budget as a method to change practice 
will necessarily divert resources away from research projects which could address 
genuine uncertainties in the health system. Therefore, in addition to the ethical 
concerns, the health losses associated useful research foregone must also be 
considered.  
In many cases the other mechanisms and policies such as incentives and sanctions 
will be more appropriate to affect implementation of treatments which are expected 
to be cost effective. Indeed, the analysis of P2 strongly suggests that 
immunomodulating anti PD1 antibodies should not have been approved for use with 
a TTP dosing schedule at the current price. A more appropriate action from the 
reimbursement agency would have been to reject the treatment at the offered price 
and treatment schedule. This action would have maintained the incentive for the 
manufacturer to either reduce the price, carry out research on the less intensive 
treatment regimes, or both carry out research and reduce the price (Claxton et al., 
2012; Griffin et al., 2011; Rothery et al., 2017).  
                                               
32 This smaller trial must enrol only 300 individuals. This is approximately (300/2,025 =) 15% the 
size of the original design. Therefore the cost to NETSCC is assumed to be (£2,522,710 x 15% =) 
£378,407, it is expected to take approximately (6 x 15% =) 10.8 months to report. This assumes a 





This chapter has shown that quantification of health benefits in terms of QALYs is a 
feasible extension to the methods introduced in Chapter 2. The P1 case study was 
used to illustrate how to link binary primary outcomes to costs and QALYs using the 
method described in (McKenna et al., 2016). A limitation of this method is that it 
can only be used for binary primary outcomes and so is insufficient to address all of 
the NETSCC proposals, Chapter 4 extends these methods to link continuous and 
survival outcomes to costs and QALYs. 
This chapter also demonstrated how quantifying the benefits of research in terms of a 
generic measure of health outcome (e.g. QALYs) can facilitate the consideration of a 
number of questions of relevance to research prioritisation bodies. A central 
contribution of this thesis is to address research prioritisation questions through a 
novel application of the “bookshelf” approach. This captures the resource constraints 
faced by research prioritisation bodies and provides a framework to inform the key 
questions in research prioritisation. 
The bookshelf approach allows for identification of “best buys” by explicit ranking 
the available research projects by a comparable health outcome. Decision makers 
may have a range of considerations other than health maximisation such as reducing 
health inequalities, or maintaining equity in funding across disease areas. However, 
quantitative estimates of research benefit can help policy makers understand whether 
the trade-offs involved are worth making and provides a framework to communicate 
their decisions to stakeholders (Ochalek et al., 2018b). 
The bookshelf also facilitates calculation of the marginal productivity of the research 
budget. The marginal productivity of the research budget is the amount of additional 
research funding which is required to produce one QALY (or some other measure of 
benefit). Recent years have seen a flowering of marginal productivity research which 
aims to empirically estimate the health effect of direct service provision in health 
care (e.g. general NHS activity). This has been carried out in the UK (Claxton et al., 
2015b; Lomas et al., 2018), Spain (Vallejo-Torres et al., 2018), Australia (Edney et 
al., 2018) and estimates have been produced for 98 low-income and middle-countries 
(Ochalek et al., 2018a). Estimates of the marginal productivity of the general health 
budget can be used make decisions about which treatments to fund as it facilitates 
101 
 
judgements about whether gains in health from the treatment are expected to be 
greater than health gains that would have been possible if the additional resources 
required for the treatment had, been used in other healthcare services. As the budget 
for direct service provision (e.g. NHS) and the health research budget (e.g. 
NETSCC), in principal, compete for funding, estimates of their respective marginal 
productivities can also be used to decide whether more resources should be devoted 
to research rather than to direct patient care (Claxton et al., 2007; Remme et al., 
2017).  
The consequences of charity or industry contributions towards research have also 
been explored in this chapter. A framework is provided for taking account of these 
contributions when prioritising research. From the perspective of a research 
prioritisation body, these contributions should be subtracted from the original costs 
of the research as they do not fall on the research budget. From a the perspective of a 
charitable organisation such as the Alzheimer’s society, any contribution towards 
research in will come with opportunity costs i.e. the money given to research could 
have been used in another charitable Alzheimer’s related activity such as in 
providing psychological support to families. This resource allocation decision faced 
by charities requires a comparison of “information value” and “implementation 
value” as discussed in Chapter 2. Therefore VOI methods can also be used by 
charitable bodies to aid decision making. 
Section 3.3.4 provides a method to help inform an appropriate MCD which uses the 
explicit linkage of the primary outcome to QALYs. This represents an important 
development of the MCD concept from the work of Claxton et al., (2015a) and 
McKenna et al., (2016) as it provides a consistent link between MCD, the 
opportunity costs of health expenditure, price and the net health benefits associated 
with the primary outcome. 
In addition to providing quantitative estimates of the value of research, applying VOI 
methods to the research prioritisation task also provides a consistent framework for 
decision making. In Section 3.4 this framework is used to conceptualise the 
implications of using research to change practice. The approach assumes that 
funding a trial will have an effect on the use of treatments in the health system 
meaning the value of the research is entirely “implementation value” (Fenwick et al., 
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2008). This provides an upper bound for the value of funding this research to change 
practice as it represents the value of practice immediately changing to the most cost 
effective treatment option after the trial reports. In reality, it takes time for practice to 
respond to research. Grimm et al., (2017) extending Willan and Eckermann, (2009) 
provide an extended framework which explicitly models the effect of study results 
on the diffusion of adoption decisions through the health system. This takes account 
of the counterfactual case in which the study was not carried out. This approach 
provides a more realistic characterisation of the decision however the additional 
modelling requirements for each proposal may be prohibitive for resource 
constrained decision makers. Future research should investigate the effects of 
considering diffusion and, should they prove significant, develop rapid methods 
which could incorporate these concerns without a large analytical burden. 
The methods described in this thesis to understand the value of research primarily 
focus on the value of research in reducing uncertainty in relative treatment effects 
e.g. the odds ratio33. However, there are a number of other inputs into decision 
making which may be uncertain. For example, when linking primary outcomes to 
costs and QALYs there may be uncertainty about the magnitude of health gains and 
cost savings associated with a primary outcome. The sensitivity analysis such as that 
carried out in Section 3.3 partially addresses this issue. Sensitivity analysis can 
demonstrate how the value of research changes with different assumptions about 
how the primary outcome relates to costs and QALYs, however, it does not provide 
estimates of the value of reducing uncertainty about this relationship. This is 
important as understanding the value of reducing different aspects of decision 
uncertainty can be used to guide the prioritisation of research which is appropriate to 
resolve the most relevant uncertainties.  
  
                                               




Chapter 4  
Generalising methods for rapid assessment of need 
for evidence 
 INTRODUCTION 
Chapters 2 and 3 have illustrated how to rapidly estimate the value of comparative 
effectiveness research for a binary primary outcomes using the methods introduced 
by Claxton et al., (2015a) and McKenna et al., (2016). These methods can be used to 
rapidly estimate the value of research in terms of cost per primary outcome or cost 
per generic health outcome (e.g. QALY). It has also been shown how these methods 
can assist decision makers in addressing the key tasks of research prioritisation. 
However, these methods are directly applicable to only two of the six research 
proposals provided by NETSCC (P1 and P6). The remaining four proposals have 
features which are outside of the scope of the methods in their existing form. The 
current methods are limited in two respects; first, they address only comparative 
effectiveness research i.e. research which identifies which interventions work best 
for improving health. Second, the methods can only be applied to binary primary 
outcomes. The aim of this chapter is to extend these methods of Claxton et al., 
(2015a) and McKenna et al., (2016) to provide decision makers with toolbox of 
methods which can be rapidly applied to feasibility/pilot studies and a wider range of 
primary outcomes types. 
P5 is for a feasibility study which cannot be analysed as comparative effectiveness 
research. Though there are subtle differences in the definitions of “feasibility 
studies” and “pilot studies”34, both involve carrying out a small initial study to 
determine whether a larger comparative effectiveness research project (a “full trial”) 
is possible. These study types are an important component of modern health research 
and so methods are required to understand their value and avoid waste (Chalmers et 
                                               
34 From the NIHR website (2017): ‘Feasibility Studies are pieces of research done before a main study 
in order to answer the question "Can this study be done?" They are used to estimate important 
parameters that are needed to design the main study. For instance: standard deviation of the outcome 
measure, willingness of participants to be randomised etc. Pilot studies are a smaller version of the 
main study used to test whether the components of the main study can all work together. It is focused 
on the processes of the main study, for example to ensure that recruitment, randomisation, treatment, 
and follow-up assessments all run smoothly. It resembles the main study in many respects, including 
an assessment of the primary outcome.’ 
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al., 2014; Morgan et al., 2018). If funding for feasibility/pilot studies and full trials 
come from the same research budget then quantitative estimates of the health 
benefits of feasibility/pilot studies are required in order to understand their value 
relative to full trial proposals. P4 utilises a continuous primary outcome, P2 utilises a 
survival (time to event) primary outcome and P3 utilises a binary primary outcome 
for which the costs of treatment depend on whether the outcome occurs or not.  
In this chapter we first outline a rapid method to link a binary primary outcome to 
costs and QALYs when the costs of treatment depend on whether the outcome 
occurs or not. This is an extension of the methods demonstrated in Chapter 3 and is 
illustrated using the P3 case study. Second, we outline a rapid method to calculate 
the value of research in terms of both cost per primary outcome and cost per QALY 
for continuous primary outcomes using P4 as a case study. Third, we do the same for 
survival primary outcomes using P2 as a case study. Fourth, we demonstrate a rapid 
method to estimate the value of a given feasibility study using P5 as a case study 
throughout.  
The analysis for each case study was carried out using the RANE tool (formally 
introduced in Chapter 5). The full set of inputs required to reproduce the analysis for 









 RESEARCH PRIORITISATION WITH DIVERSE PRIMARY OUTCOMES 
 RESEARCH PRIORITISATION WHEN TREATMENT COSTS DEPEND ON THE 
BINARY OUTCOME 
The methods from Chapter 3 show how to rapidly calculate the benefits of research 
for binary primary outcomes in terms of QALYs. The method used assumed that 
treatment costs were independent of the primary outcome. For example, in the P1 
case study, the additional costs associated with early treatment (£14.1 per person) are 
not affected by whether functional recovery occurs or not i.e., they are independent 
of the primary outcome. However, for P3, this assumption is not appropriate. This is 
because treatment with the baseline therapy is continuous unless the primary 
outcome occurs, at which point the treatment may be discontinued.  Therefore, if the 
primary outcome occurs the treatment costs may no longer be incurred. Rapid 
methods to address this more complex case are described and demonstrated here 
using P3 as a case study.  
 
4.2.1.1 Overview of P3 
This proposal is for a non-randomised, open label study to examine the safety of 
withdrawing Eculizumab (Soliris) in patients with atypical haemolytic uraemic 
syndrome (aHUS). aHUS is a disease typically causing acute kidney injury, but also 
damage to other organs. It is a rare disease (0.4 cases/million/year in the UK) but it 
has a profound impact on patients, with 50% of patients dying or developing renal 
failure within 1 year of diagnosis (Fremeaux-Bacchi et al., 2013), and associated 
with a high risk of recurrence after transplantation (Noris and Remuzzi, 2010). 
Eculizumab has been shown to be effective in the treatment of aHUS, both for the 
induction and maintenance of remission. Lifelong treatment with Eculizumab is 
currently recommended because of risk of relapse. However, there is limited safety 
data on long-term use and Eculizumab is associated with significant treatment costs 
(£340,000/patient/year). The proposed trial aims to answer whether individuals with 
aHUS receiving Eculizumab treatment can safely withdraw from treatment following 
supervised withdrawal.   
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Summary of proposal 3 
Research question: Can individuals with Atypical haemolytic uraemic syndrome 
(aHUS) receiving Eculizumab treatment safely withdraw from treatment? 
Intervention: Supervised withdrawal of Eculizumab infusions every 2 weeks (high 
cost) replacing it with weekly blood tests (month 1), fortnightly blood tests (months 
2-6) then monthly thereafter and home urinalysis monitoring (low cost). 
Reintroduction of Eculizumab if relapse occurs. 
Control: Continuous treatment with Eculizumab. 
Primary outcome: Number of serious withdrawal attributable adverse events (SAE) 
during a 2 year follow up (death, meningococcal infection or irreversible organ 
injury).  
Proposed study: Non-randomised, open label study (withdrawal, n= 30; continuous 
treatment, n =20) 
Duration of proposed study: 4 years. 
Costs of proposed study to NETSCC:  £855,403 
NHS support and treatment costs:  £10,608,500 cost savings 






4.2.1.2 Health benefits of further research in terms of primary outcome 
The primary outcome in P3 is a composite of serious adverse events (SAE) 
composed of; death, meningococcal infection or irreversible organ injury. The 
benefits of research can be quantified in terms of SAE avoided using the same 
methods as described in Chapter 2.  From the proposal the probability of SAE with 
continuous treatment is between 5% and 6%. As shown in Chapter 2, the probability 
of SAE with the new treatment is determined by the baseline probability combined 
with an estimate of the relative effect. There currently exists no evidence to inform 
this and so in the absence of direct evidence meta-epidemiological data is used as a 
starting point to understand uncertainty. As the primary outcome (SAE) is harmful it 
is expected that the odds ratio is likely to be between (95% CI) 4.39 and 0.19 (see 
Section 2.4.4 for further details).  
The health consequences of uncertainty can be understood in terms of SAEs in the 
same manner as described in Chapter 2: by drawing random samples from the 
distribution of the relative effect (CI around the odds ratio) and combining these 
samples with the baseline event rate. This is combined with; incidence (26.3 
individuals per year), the time the information is expected to be valuable for (10 
years), the time it will take the research to report (4 years) and the cost of the 
research (£855,403). All inputs used are provided in Appendix A6. With these 
inputs, the upper bound for the health benefit of the proposed research is estimated to 
be 1 SAE avoided over the full time horizon. The proposed research is expected to 
cost the research funder £855,403 meaning the maximum value of the proposed 
research is estimated to be (£855,403/1 =) £570,510 per SAE avoided. 
 
4.2.1.3 Linking the primary outcome to a comprehensive measure of health 
outcome 
In order to translate this outcome into costs and QALYs to aid research prioritisation, 
the substantial cost differences between withdrawal and continuous treatment must 
be reflected. As the SAE includes death, treatment costs will no longer be incurred 
for those individuals. Therefore, treatment costs will depend on the primary 
outcome. The methods developed previously have assumed that treatment costs do 
not depend on the primary outcome and so an extension is required. This extension is 
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very similar to the approach described in Chapter 3 and is illustrated here in three 
steps. In step 1, the primary outcome (SAE) is linked to costs and QALYs. In step 2, 
expected treatment costs are linked to the primary outcome. In step 3, these are 
combined to link uncertainty in relative effects to costs and QALYs. The only 
difference between this method and the one outlined in Chapter 3 is that the 
treatment costs depend on whether the primary outcome occurs or not. 
4.2.1.4 Step 1: Link primary outcome to costs and QALYs 
If the primary outcome occurs (i.e. a patient has a SAE), there is a chance of the 
individual entering one of three different health states; death, meningococcal 
infection or irreversible organ injury. Using the same approach as in Chapter 3, in 
this step we estimate the health consequences of the primary outcome by attaching 
the clinical states to cost and quality of life outcomes. 
Each of the three health states (death, meningococcal infection and irreversible organ 
injury) have different disease related costs and health consequences. For illustrative 
purposes, we assume that there is an equal chance (33.3%) of each of the events 
occurring conditional on the individual experiencing a SAE35. If the individual dies, 
we assume that this happens near the start of the trial and there are no additional 
disease related costs associated with this. If meningococcal infection occurs, we 
assume that individuals will live for the full additional life expectancy of 35.47 years 
(National Institute for Health and Care Excellence, 2015) but will have the lower 
health state utility of 0.2 from Christensen et al., (2013). According to the same 
source they will also incur disease related costs associated with time spent in hospital 
(£2936.2) and a follow up appointment (£279.98). If irreversible organ injury occurs 
we assume this will require kidney transplant costing £17,000 in the first year and 
£5,000 in subsequent years (NHS England, 2013). Individuals are assumed to 
survive for their remaining 35.47 years of life, resulting in a total cost of £115,503 
after discounting.  We assume that utility in this health state will be 0.59, which is 
the average UK utility in diseases of kidney and ureters (Sullivan et al., 2011). Table 
4.1 illustrates how these values are combined to help understand the health impact of 
the primary outcome in terms of costs and QALYs. 
                                               
35 This is an assumption made to quickly illustrate the P3 case study. This judgement could be 
informed with reference to published studies which report the proportion of patients who experience 
death, meningococcal infection and irreversible organ injury. 
109 
 
Table 4.1: Expected costs and QALYs associated with the primary outcome; 
serious adverse event. This is a composite outcome of death, meningococcal 
infection and irreversible organ injury. 
Primary outcome occurs (serious adverse event) 
Possible states 
Probability 














Death 33.3% 0 0 £0 0 £0 
Meningococcal 
infection  




33.3% 35.5 0.59 £115,503 6.97 
£38,462 
  100%       9.33 £39,533 
 
If the primary outcome does not occur we assume that individuals will live for the 
full additional life expectancy of 35.47 years. We also assume again that utility in 
this health state will be 0.59 which is the average UK utility in diseases of kidney 
and ureters (Sullivan et al., 2011). Other than the treatment costs, we assume no 
other disease related costs. This is illustrated in Table 4.2. 
Table 4.2: Expected costs and QALYs when the primary outcome does not 
occur and the patient’s illness proceeds naturally. 
Primary outcome does not occur (no serious adverse event) 
Possible states 
Probability 














Normal illness 100% 35.47 0.59 £0 20.93 £0 
  100%       20.93 £0 
 
Comparing these two possibilities, each additional SAE is expected to result in 
(20.93 – 9.33 =) 11.6 QALYs lost per person and £39,533 in additional costs. Taking 
account of the opportunity costs of health expenditure implies that the cost increases 
per SAE are expected to be worth (£39,533 /£15,000 =) 2.64 elsewhere in the health 
system (Claxton et al., 2015b). Combining the direct health loses (11.6 QALYs) and 
the indirect health loses through cost increases (2.64 QALYs) means that each 




4.2.1.5 Step 2: Link treatment costs to primary outcome 
The therapies considered in this trial are: continuous treatment (baseline) and 
withdrawal. In contrast to the method described in Chapter 3, for each option we 
require the treatment costs when the primary outcome occurs and the treatment costs 
when it does not. For the continuous treatment, we assume that if the primary 
outcome does not occur, individuals will continue receiving Eculizumab for the 
expected additional lifetime (35.47 years). With yearly costs of £340,000 this results 
in total expected costs of £7,316,623 per person after discounting36. As discussed 
above, if the primary outcome occurs, there is a chance of the individual entering one 
of three health states; death, meningococcal infection or irreversible organ injury. 
These health states are associated with different treatment costs and these should be 
reflected in the analysis. For continuous treatment, if the primary outcome occurs we 
assume treatment will cease for those who die but will continue for all those who 
survive. The relationship between continuous treatment costs and the primary 
outcome is illustrated in Table 4.3. 
Table 4.3: Expected treatment costs associated with continuous treatment. 
Treatment costs depend on whether the primary outcome (SAE) occurs or not. 












No SAE Normal illness   £340,000 £7,316,623 
SAE occurs  Death 33.3% £0 £0 
 
Meningococcal infection  33.3% £340,000 £7,316,623 
 
Irreversible organ injury 33.3% £340,000 £7,316,623 
  
Expected costs if SAE 
occurs     
£4,877,749 
SAE: serious adverse event.  
If the primary outcome occurs, continuous treatment with Eculizumab is expected to 
cost (£0 + £7,316,623 + £7,316,623)/3 = £4,877,749 per individual. If SAE does not 
occur then the expected treatment costs are £7,316,623. This means that for 
                                               
36 It should be noted that this assumes that this treatment will continue to be used for the remainder of 
the patient’s lifetime. However, new treatments may enter which increase competition or change best 
practice. There are a number of uncertainties involved in long term forecasts and so it is difficult to 
know in advance how these factors would affect treatment costs. 
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continuous treatment, treatment costs are lower when the primary outcome occurs 
due to the fact that treatment costs will not be incurred if the patient dies. 
For the withdrawal treatment option, if the primary outcome does not occur, we 
assume that each individual will receive the equivalent of one year of Eculizumab 
during the tapering off period37. Furthermore, the proposal states that after 
withdrawal approximately 50% will successfully withdraw from treatment for the 
remainder of their lifetime with the remaining 50% returning to treatment38.  
With yearly costs of £340,000 this results in total expected costs of £340,000 + 0.5 x 
(35.47 x £340,000) = £6,369,900 per individual and £3,965,432 per individual after 
discounting. Again, if the primary outcome occurs treatment will cease for those who 
die. Continuous treatment will be reinstated in those who experience meningococcal 
infection or organ injury (£7,316,623). The relationship between continuous 
treatment costs and the primary outcome is illustrated in Table 4.4. 
 
Table 4.4: Expected treatment costs associated with withdrawing treatment. 
Treatment costs depend on whether a serious adverse event (SAE) occurs or 
not. 





of being in 
state 
Treatment 




No SAE Normal illness   £340,000 £3,965,432 
SAE 
occurs  
Death 33.3% £0 £0 
 
Meningococcal infection  33.3% £340,000 £7,316,623 
 
Irreversible organ injury 33.3% £340,000 £7,316,623 
  
Expected costs if SAE 
occurs     
£4,877,749 
SAE: serious adverse event.  
 
                                               
37 To inform decision making this should be justified with reference to empirical evidence and/or 
expert opinion. 
38 Though not discussed in the proposal this judgement is likely to be uncertain. A more complex 
analysis would take account of the uncertainty in the number of patients who can successfully 
withdraw. Including this uncertainty would increase the overall decision uncertainty and increase the 
value of research. 
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If the primary outcome occurs, the withdrawal of Eculizumab is expected to cost (£0 
+ £7,316,623 + £7,316,623)/3 = £4,877,749 per individual.  
In summary, if the primary outcome occurs both continuous treatment and 
withdrawal are expected to cost £4,877,749 per individual. If the primary outcome 
does not occur continuous treatment is expected to cost £7,316,623 per individual 
and withdrawal is expected to cost £3,965,432. From this it is clear that there are 
substantial cost savings associated with withdrawal. 
4.2.1.6 Step 3: Linking uncertainty in relative effects to costs and QALYs 
The uncertainty in the expected number of primary outcomes per year can be 
characterised in the same manner as described in Chapter 2: by drawing random 
samples from the distribution of the relative effect (CI around the odds ratio) and 
combining these samples with the baseline event rate. To get an indication of the 
health consequences of uncertainty in terms of a more comprehensive measure of 
outcome, the health consequences of the primary outcome and the treatment costs 
must be linked to the probability of SAE. A simplified example is shown for 
illustrative purposes. Table 4.5 displays five samples for the probability of SAE with 
each treatment. 
Table 4.5: Probability of primary outcome with continuous treatment and 
withdrawal of treatment 
  







  [A]  [B]  
Sample 1 5.0% 1.0% 
Sample 2 5.1% 2.7% 
Sample 3 5.5% 5.0% 
Sample 4 5.6% 18.8% 
Sample 5 5.6% 20.7% 
Average 5.4% 9.6% 
 
Taking the continuous treatment as an example, treatment costs are calculated by 
multiplying the probability of SAE by the treatment costs when SAE occurs 
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(£4,877,749) and the probability of SAE not occurring by the treatment costs when 
SAE does not occur (£7,316,623). This is illustrated in Table 4.6. 
 
Table 4.6: Expected treatment costs for continuous treatment. Treatment costs 
depend on the probability of the primary outcome occurring. 
  
Probability of serious 
adverse event (SAE) 
Treatment costs for continuous 
treatment 
  
 Continuous treatment SAE occurs 
(=A*£4.9M) 
SAE does not occur            
(=(1-A)*£7.3M) 
  [A]  [C] [D] 
Sample 1 5.0% £243,887 £6,950,792 
Sample 2 5.1% £248,765 £6,943,475 
Sample 3 5.5% £268,276 £6,914,209 
Sample 4 5.6% £273,154 £6,906,892 
Sample 5 5.6% £273,154 £6,906,892 
Average 5.4% £261,447 £6,924,452 
 
There are health opportunity costs associated with the increased treatment costs and 
these can be calculated for each sample by dividing by the opportunity cost of health 
expenditure (£15,000) (see Table 4.7, column E). From step 1, each additional SAE 
results in a loss of 14.24 QALYs. The expected NHBs for each sample can be 
calculated by multiplying the probability of SAE by -14.24 and then subtracting the 




Table 4.7: QALY effects of continuous treatment, taking account of the 
opportunity cost of health expenditure 
    












SAE does not 
occur              
(=(1-A)*£7.3M) 
Opportunity 
costs of treatment             
(=(C+D)/15000) 
QALYs per 
person             
(=A*-14.24-E) 
  [A]   [C] [D] [E]  [F] 
Sample 1 5.0% £243,887 £6,950,792 479.6 -480.4 
Sample 2 5.1% £248,765 £6,943,475 479.5 -480.2 
Sample 3 5.5% £268,276 £6,914,209 478.8 -479.6 
Sample 4 5.6% £273,154 £6,906,892 478.7 -479.5 
Sample 5 5.6% £273,154 £6,906,892 478.7 -479.5 
Average 5.4% £261,447 £6,924,452 479.1 -479.8 
 
The same process can be carried out for withdrawal and the expected QALYs per 
person calculated for each sample. The results of this are shown in Table 4.8. 
 
Table 4.8: Net QALY effects of withdrawal treatment, taking account of the 
opportunity cost of health expenditure 
    











SAE does not 
occur              
(=(1-B)*£3.9M) 
Opportunity costs 
of treatment             
(=(G+H)/15000) 
QALYs per 
person           
(=A*-14.24 - I) 
  [B]   [G] [H] [I]  [J] 
Sample 1 1.0% £48,295 £3,926,170 265.0 -265.1 
Sample 2 2.7% £132,604 £3,857,630 266.0 -266.4 
Sample 3 5.0% £245,346 £3,765,975 267.4 -268.1 
Sample 4 18.8% £918,374 £3,218,828 275.8 -278.5 
Sample 5 20.7% £1,007,821 £3,146,110 276.9 -279.9 
Average 9.6% £470,488 £3,582,943 270.2 -271.6 
 
As we now have samples for the NHB of continuous treatment (Table 4.7 column F) 
and withdrawal (Table 4.8 column J) the expected health consequences of 
uncertainty can be calculated in the same manner as described in Table 3.3. 
Comparing column F and J of Table 4.7 and Table 4.8 respectively shows that for 
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each sample treatment withdrawal is superior to continuous treatment. Therefore 
there is no uncertainty about the superior treatment meaning that the value of 
research is zero. This is driven by the large differences in costs between the 
treatment options. The treatment savings from withdrawal primarily arise from the 
assumption that for 50% of patients the high costs of Eculizumab over a lifetime are 
avoided. These savings are expected to result in benefits across the health system and 
so the analysis suggests that accepting the uncertainty and switching treatment to 
withdrawal results in the largest population health benefits39.  
However, just as for any other, this analysis does not proscribe social choice. There 
may be ethical arguments to distribute research resources in a manner which is not 
health maximising. The aim of this analysis is to help inform these discussions by 
estimating the health consequences of decisions and showing the health foregone 
which is inevitable in decision making. Decision makers may still choose to fund 
this study over other research proposals with larger expected health impacts. By 
making the ethical trade-offs clear this analysis can add to the transparency and 
accountability of this process. 
 
  
                                               
39 Furthermore, funding the trial may delay the recommended change in practice and this is also 
associated with health opportunity costs. From the proposal the health costs are £10.6M which 
translates to (£10.6M / £15,000 =) 707 QALYs in health opportunity costs. As the value of research is 
zero, the overall impact of the project is a loss of 707 QALYs. 
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 RESEARCH PRIORITISATION FOR CONTINUOUS PRIMARY OUTCOMES 
Rapid methods to address continuous outcomes are described and demonstrated here 
in using P4 as a case study.  
4.2.2.1 Overview of P4 
This proposal is for a four arm complex adaptive RCT to examine whether 
Exenatide, Telmisartan or their combination can slow neurodegeneration in 
Alzheimer’s disease (AD). The only drugs approved for the management of AD 
(cholinesterase inhibitors and memantine) are for symptomatic relief and show 
limited clinical effects. At least 200 new drugs have advanced to phase 2 trials in the 
past 30 years but none have demonstrated disease modification (Schneider et al., 
2014). Exenatide is a glucagon like peptide-1 (GLP-1) agonist that crosses the blood 
brain barrier and facilitates insulin signalling. Its use is based on the hypothesis that 
AD is linked to glucose and insulin signalling, and animal models provide empirical 
evidence to support the hypothesis. Telmisartan is an angiotensin II receptor blocker 
(ARB) which has been associated with delayed disease progression and preserved 
cognitive function in cognitive disorders. The NHS has effective mechanisms for 
diagnosing AD, but current drug therapies offer only modest improvement in 
symptoms and do not affect decline. Though P4 is a complex adaptive trial, a partial 
analysis is carried out in which the trial is assumed to be a regular 4 arm RCT (i.e., 
without accounting for the adaptive nature of the complex trial), which is expected to 
complete and report in 6 years.   
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Summary of proposal 4 
Research question: Can Exenatide, Telmisartan or their combination slow 
neurodegeneration in Alzheimer’s disease (AD)? 
Interventions: Exenatide prolonged release 2mg once weekly, Telmisartan 40mg 
once daily and combination of Exenatide 2mg once weekly and Telmisartan 40mg 
once daily 
Control: Placebo 
Primary outcome: Slowed 2 year decline in Mini Mental State Examination 
(MMSE) of 3.1 points (vs 4.5 points expected for placebo) 
Proposed study: Four arm complex adaptive RCT, n = 920 randomised 1:1:1:1 
Duration of proposed study: 6 years for first stage with option to extend trial to add 
treatments 
Costs of proposed study to NETSCC:  £3,310,883 
NHS support and treatment costs:  £1,297,789 





4.2.2.2 Informing uncertainty for mean difference 
In order to estimate the value of additional research for continuous outcomes an 
explicit summary of current uncertainty about the expected mean difference in 
MMSE score for the new interventions (Exenatide, Telmisartan and their 
combination) is required. However, meta-epidemiological evidence currently exists 
only for binary and survival outcomes40. To inform uncertainty in the primary 
outcome for P4 we apply an approach similar to Bennette et al., (2016). This 
approach calibrates current uncertainty in mean difference using a judgement about 
the probability of treatment success (alternative hypothesis) and the probability of 
treatment failure (null hypothesis). For P4, treatment success is defined in the 
proposal as an increase on the MMSE scale of 1.4 points. Treatment failure is 
defined as a relative decrease on the MMSE scale. Combining judgements about the 
probability of treatment success and the probability of treatment failure implies a 
distribution of expected mean difference in MMSE score for the new interventions. 
First we demonstrate how a judgement about the probability of treatment success can 
be formed based on current evidence; we then show how this can be used to inform a 
judgement about the uncertainty in mean difference. 
  
                                               
40 Meta-epidemiological analysis to help inform continuous outcomes may be feasible. This could be 
carried out by converting the results of historical continuous outcome trials to standardised mean 
differences (SMDs). The global mean and heterogeneity for the set of SMDs could then be calculated 
and the predictive distribution could then be used in trials that are exchangeable by converting the 
SMD to the natural outcome (this requires the standard deviation of the natural outcome). 
119 
 
Probability of treatment success (the alternative hypothesis) 
The proposal states that a change of 1.4 MMSE points constitutes disease 
modification and that this has not been achieved in the 200 previous phase 2 trials 
carried out over the previous decade (Schneider et al., 2014). Using this information 
it is possible to statistically inform the probability of success (i.e., a change of 1.4 
MMSE points) in a new trial. This judgement can be informed using Laplace’s rule 
of succession (Laplace, 1829). This is a method used in quality control to calculate 
the probability of an event occurring given that the event has not occurred after a 
large number of trials. The probability of the event is given by: 
Probability of event = (Observed events +1) / (Number of trials +2) 
In P4, zero events (treatment successes) have been observed from 200 previous 
trials. This implies that the probability of success in the two hundred and first trial is 
approximately (0 + 1) / (200 +2) = 0.5%. This approach assumes that that each 
previous trial investigated a different drug and the trials were sufficiently powered to 
detect treatment success41.  
 
Characterising uncertainty in mean difference 
The probability that the new treatment is less effective than the current treatment is 
assumed to be 50%, i.e., there is equipoise and we are equally uncertain about the 
effectiveness of the alternative treatments. This represents the probability that the 
null hypothesis is true. From the calculation above, there is a 0.5% chance that a new 
treatment will result in an increase of more than 1.4 MMSE points over no treatment. 
Using these values we assume the outcome is approximately normally distributed 
and find the distribution which fits these values. A normal distribution which has a 
50% chance of negative values and a 0.5% chance of values greater than 1.4 has a 
mean of zero and a standard deviation of 0.54 (see Box 4.3 for fitting method). This 
                                               
41 There are a number of assumptions made in the approach taken here. First, the method assumes that 
each of the drugs tested are independent. If groups of drugs are from a similar class (e.g. similar 
structure and/or biological pathway) then the independence assumption will not hold. Second, the 
approach assumes that the previous studies had 100% statistical power, which is unlikely in any 
research study. The impact of both of these assumptions is to underestimate the probability of success 
in future trials. In principal, it is possible to extend this method to take account of these limitations but 
this is beyond the scope of this thesis. 
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distribution reflects current uncertainty about the expected mean difference in 




Fitting a normal distribution to reflect uncertainty in mean difference 
Here we show how to find the mean (𝜇) and standard deviation (𝜎) of a normal 
distribution which is consistent with the null (treatment failure) and alternative 
hypothesis (treatment success). 
From equipoise, we assume that the probability that the new treatment is worse than 
the current treatment is 50%. This implies that the difference in MMSE score for the 
new treatment has a 50% chance of being below zero. This is the null hypothesis. As 
the normal distribution is symmetrical this means that the mean of the required 
normal distribution (𝜇) must be zero.  
From the fact that there have been zero treatment successes in 200 previous trials we 
calculated that there is a 0.5% chance that a new treatment will result in an increase 
of more than 1.4 MMSE points over no treatment. This implies that the difference in 
MMSE score for the new treatment (∆MMSE) has a 0.5% chance of being greater 
than 1.4. This is the alternative hypothesis and is represented by the formula: 
𝑃(∆𝑀𝑀𝑆𝐸 > 1.4) = 0.005 
From the rules of standard normal distributions, this implies: 
1.4 − 𝜇
𝜎
= 𝛷−1(1 − 0.005) = 2.576 








This same logic can be used more generally to fit normal distributions if plausible 
estimates of the probability of null and alternative hypotheses can be made. 





4.2.2.3 Health benefits of further research in terms of primary outcome 
For continuous outcomes, uncertainty about the benefits of a new treatment is 
represented by the standard deviation or CI around the mean difference in effect. 
This represents the plausible change in the outcome compared to the baseline 
treatment, where zero represents no difference. In a similar manner as for binary 
outcomes, the consequences of uncertainty for continuous outcomes are derived by 
taking random samples from the distribution of mean difference. A simplified 
version of the P4 analysis is used to illustrate how we can get from mean difference 
with uncertainty to an estimate of the value of changing practice and the health 
consequences of uncertainty42. Assuming a normal distribution, consider a random 
sample of five possible values for the mean difference in MMSE for Exenatide 
(treatment) compared with no treatment (-1.08, -0.52, 0, 0.54, 1.08) which is the 
control. By definition, the baseline change in MMSE with no treatment is zero. The 
five random samples from the range of relative treatment effect and baseline change 
are shown in Table 4.9. 
 
Table 4.9: Mean difference in primary outcome (MMSE) with Exenatide and no 
treatment 
  
Relative treatment effect Change in MMSE with 
no treatment 
  
Mean difference in MMSE 
(Exenatide vs no treatment) 
  
  [A]  [B] 
Sample 1 -1.41 0 
Sample 2 -0.54 0 
Sample 3 0 0 
Sample 4 0.54 0 
Sample 5 1.41 0 




                                               
42 Only two treatment options are considered here: no treatment and Exenatide. In P4 there is also 
Telmisartan and a combination of Exenatide and Telmisartan. 
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The health impact of additional research  
From Table 4.9, the average mean difference in MMSE for Exenatide is zero and so 
there is no additional health to be gained by changing practice from no treatment to 
Exenatide. The expected health consequences of the uncertainty depend on the 
chance that Exenatide is more effective, in addition to the size of this effect and the 
number of patients eligible for treatment. Given the information in Table 4.9, we can 
estimate the chance that Exenatide is more effective than no treatment. This is the 
probability of observing a mean difference of greater than 0, which is 2 out of 5 
samples, i.e. 40%. To understand the scale of health that would be lost if no 
treatment were used instead of Exenatide in these samples, we calculate the number 
of additional MMSE points that would be observed with no treatment and compare it 
to the number that would be expected with Exenatide given an incident population of 
100,000. The steps in this calculation are shown in Table 4.10. 
 
Table 4.10: Rapid estimation of the health benefits of additional evidence for a 
continuous primary outcome, Mini-Mental State Exam (MMSE) 
      
Additional MMSE points per 
100,000 eligible patients 

























(=F if A>0) 
  [A] [B] [C] [D] [F]  [G] 
Sample 1 -1.41 0 -141,000 0 -141,000 0 
Sample 2 -0.54 0 -54,000 0 -54,000 0 
Sample 3 0 0 0 0 0 0 
Sample 4 0.54 0 54,000 0 54,000 54,000 
Sample 5 1.41 0 141,000 0 141,000 141,000 
Average 0 0 0 0 0 39,000 
 
Combining the probability of error with the loss of health we can estimate the 
expected health consequences of uncertainty, 0.2 x 54,000 + 0.2 x 141,000 = 39,000 
MMSE points per year. The above is a highly stylized example involving only two 
treatments and 5 samples. The analysis of P4 (using RANE) considers all 4 treatment 
options and is based on 50,000 samples (see Appendix A2 for full list of inputs). 
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This results in an estimate of the health consequences of uncertainty of 47,609 
MMSE points per year. This provides an estimate of the value of research but does 
not yet account for the differences in costs across the treatments; this is addressed in 
the next section. 
 
Other aspects of outcome to consider 
Although change in MMSE score may be the most appropriate primary outcome, it 
is not necessarily the only relevant outcome for assessing the value of the proposed 
treatments. As for binary outcomes, specifying a minimum clinical difference 
(MCD) required to change clinical practice is one way to incorporate concerns about 
increased costs and/or potential adverse events.  Since each of the active 
interventions in P4 (Exenatide and Telmisartan) are associated with increased 
treatment costs, there may be a need to demonstrate an improvement in average 
MMSE before practice should change. The research proposal specifies a required 
average change of 1.4 MMSE points per person for each of the active treatments. A 
single MCD for every treatment is hard to justify as the treatments differ 
substantially in price. A MCD of 1.4 is used here for illustrative purposes but this 
assumption is explored in the next Section (4.2.2.4). This MCD implies that if any of 
the treatments demonstrate a 1.4 point increase in MMSE at 2 years relative to 
placebo then that treatment would be considered superior to placebo and should be 
implemented. Requiring a 1.4 point increase implies that the additional costs are 
equivalent to 140,000 additional MMSE points per year43. Table 4.11 illustrates how 
the MCD is used to calculate the net MMSE points provided by Exenatide under 
different realisations of uncertainty. 
 
                                               
43 The trade-off implied by requiring an absolute change in a continuous outcome is calculated by 
multiplying the required absolute change (e.g. 1.4 points) by the incident population (e.g. 100,000) = 
100,000 x 1.4 = 140,000 points. 
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Table 4.11: Rapid estimation of the health benefits of additional evidence for a 
primary outcome of Mini-Mental State Exam (MMSE) taking account of MCD 
= 140,000 MMSE points per annum 
Gross MMSE points per annum for 
an incidence  
of 100,000 eligible patients 
  






Net MMSE points 
per annum for 
Exenatide             
(=C-140,000) 
Absolute net effect 
for Exenatide in 




of uncertainty  
(=I if I>0) 
[C] [D] [H] [I] [J] 
-141,000 0 -281,000 -281,000 0 
-54,000 0 -194,000 -194,000 0 
0 0 -140,000 -140,000 0 
54,000 0 -86,000 -86,000 0 
141,000 0 1,000 1,000 1000 
0 0 -140,000 -140,000 200 
 
Only in sample 5 does Exenatide provide a sufficiently large increase in MMSE to 
provide net health gains. Combining the probability of error with the loss of health 
we can estimate the expected health consequences of uncertainty, 0.2 x 1,000 = 200 
MMSE points per year. As before, the above is a highly stylized example using 5 
samples to compare only Exenatide and no treatment. The full analysis of P4 
reported in Table 2.3 is based on 50,000 samples and considers four treatment 
options: no treatment, Telmisartan, Exenatide and the combination of Telmisartan 
and Exenatide44. An MCD of 1.4 for all active treatments results in an estimate of the 
health consequences of uncertainty of 266 MMSE points lost per year. When this is 
extended over the full time horizon (20 years) and the trial duration is taken account 





                                               
44 This analysis is carried out using RANE with full inputs in the Appendix A2. 
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4.2.2.4 Informing an appropriate MCD: what change in the primary endpoint is 
required before practice should change? 
A MCD of 1.4 was used above for all active treatments however as Exenatide is 
more expensive than Telmisartan, Exenatide might be required to demonstrate a 
larger improvement in MMSE than Telmisartan before it can be considered superior.  
As discussed in Section 3.3.4 the MCD for each intervention should represent the 
change in the primary outcome that is required to make up for relevant secondary 
outcomes associated with each intervention. The appropriate MCD is determined by 
the same logic for continuous outcomes as for binary outcomes. Equation 3.2 applies 
to continuous outcomes but in this case 𝐼𝑁𝐻𝐵 is understood as the net health effect 
of a unit change in the continuous primary outcome measure. Treatment specific 
MCDs can be estimated for P4 by calculating the improvement in MMSE required to 
compensate for the additional costs associated with each of the active treatments. 
As will be shown in Section 4.2.2.6 a one unit increase in MMSE is approximately 
associated with an additional 0.01242 QALYs and a (£14 x 12 =) £168 reduction in 
costs. The opportunity cost of health expenditure (£15,000/QALY) can be used to 
express the benefit of a unit change in MMSE score in net health terms. This is 
calculated by adding the QALY gain per additional MMSE point and adding the 
expected health benefits of any cost savings. In the present case this is 0.01242 + 
£168/£15,000 = 0.0236 QALYs per additional MMSE point. 
Assuming that additional costs are the only relevant secondary outcome, the 
appropriate MCD is that which offsets the treatment costs for each new intervention. 
Assuming a 1 year treatment duration, these treatment costs are; (£73.36 x 12 =) 
£880.32 for Exenatide, (£14.83 x 12 =) £177.96 for Telmisartan and (£88.19 x 12 =) 
£1,058.28 for the combination treatment.  
From Equation 3.1 the appropriate MCDs for each of the treatments are therefore 
(£880.32/(0.0236 x £15,000) =) 2.5 for Exenatide, (£177.96/(0.0236 x £15,000) =) 
0.5 for Telmisartan and (£1,058.28/(0.0236 x £15,000) =) 3 for the combination 
treatment. Repeating the full analysis using these MCD values means the upper 
bound for the value of research is estimated to be 45,764 MMSE points. This is 
much larger than the previous estimate of 2,390 MMSE points because the cheapest 
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treatment, Telmisartan, is no longer being penalised by the same amount as the other, 
more expensive, treatments. Because it is no longer being penalised the analysis 
suggests there is a 17% chance that Telmisartan provides positive NHB and so there 
is more value in carrying out research to investigate this. This result illustrates how 
sensitive results can be with different values of MCD and the importance of 
considering the MCD for each treatment carefully.  
 
4.2.2.5 Linking the primary outcome to a comprehensive measure of health 
outcome 
Here we demonstrate a method to link continuous outcomes to costs and QALY, 
again using P4 as a worked example. In step 1, changes in the primary outcome are 
translated to QALYs; in step 2, the primary outcome is linked to disease related 
costs; in step 3, these are combined along with treatment costs to link uncertainty in 
relative effects to costs and QALYs. 
 
4.2.2.6 Step 1: Link changes in primary outcome to quality of life 
One method to understand the health impact of changes in the primary outcome is to 
link these changes to QALYs. QALYs are calculated by multiplying a measure of 
health related quality of life for a health state by the time spent in that health state. 
One questionnaire used to measure health related quality of life and calculate 
QALYs is called the EQ-5D (Briggs et al., 2006; Dolan, 1997). The resulting EQ-5D 
score is often referred to as health state utility. The relationship between changes in 
the primary outcome and changes in utility will depend on the severity of the disease 
and the units and range of the primary outcome measure. “Mapping” studies which 
use statistical methods to estimate the effect of a unit change in a clinical outcome on 
utility provide this link. These are commonly used in economic modelling and a 
database of mapping studies is available from Dakin et al., (2018). For P4, evidence 
on the relationship between MMSE and health utility is based on a study by Jönsson 
et al., (2006). This study was used in a NICE appraisal of drugs for Alzheimer’s 
disease (Bond et al., 2012). Jönsson et al., (2006) measured both MMSE and EQ-5D 
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for Alzheimer’s patients across a range of disease severity. The results are 
reproduced below in Table 4.12. 
Table 4.12: Relationship between Mini-Mental State Exam (MMSE) and health 








Taking the midpoint of the MMSE score and estimating the relationship between 
MMSE and utility using simple linear regression implies that a one unit increase in 
MMSE results in a 0.01242 increase in utility45. Using this result, the additional 
health utility associated with changes from baseline can be converted to incremental 
QALYs by multiplying it by a judgement about the treatment effect duration. 
Estimates of treatment effect duration exist for few outcomes in the literature so in 
practice this will require expert opinion to inform this.  Sensitivity analysis should 
also be carried out to investigate the impact of different values on results. For the 
purposes of the analysis it was assumed that the treatment effect will last for 1 year 
and that patients stay on treatment for the duration of treatment effect. This implies 
that a one unit increase in MMSE will result in an additional (0.01242 x 1 =) 
0.01242 QALYs.  
 
4.2.2.7 Step 2: Link changes in primary outcome to disease related costs  
Changes in the primary outcome may also be expected to result in changes in disease 
related costs. Therefore, in the same manner as for health utility, changes in the 
continuous outcome must be approximately linked to changes in disease related 
costs. From the NICE appraisal of drugs for Alzheimer’s disease (Bond et al., 2012), 
a study by Wolstenholme et al., (2002) was identified which estimates that a one 
point increase in MMSE is associated with a £56 decrease in 4 monthly costs. 
                                               
45 A more flexible model relating changes in MMSE to changes in utility (e.g. a spline) would fit the 
data better. However, incorporating any non-linearities into the model relating MMSE and utility 
would substantially increase the complexity of the model. 
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Assuming linearity, this implies a one unit increase in MMSE is associated with a 
(£56/4 =) £14 decrease in monthly costs. 
 
4.2.2.8 Step 3: Link uncertainty in relative effects to costs and QALYs 
In addition to disease related costs, treatment costs must also be taken into account to 
reflect the differences in treatment options. Here it is assumed that individuals are 
treated for the duration of treatment benefit and so treatment costs per person are 
calculated by multiplying monthly cost by treatment effect duration (in months). For 
P4, there are substantial costs associated with each of the active treatments; 
Exenatide costs £73.36 and Telmisartan costs £14.83 per month respectively 
(Medicines Complete, 2018). The combination treatment therefore costs (£73.36 + 
£14.83 =) £88.19 per month. As the incident population is 100,000 one month of 
treatment for Exenatide, Telmisartan and their combination is expected to cost £7.3 
million, £1.4 million and £8.8 million respectively. 
To understand the impact of each treatment on costs and QALYs, each sample for 
mean difference is translated to QALYs, linked to cost savings/increases in disease 
related costs and the treatment costs are recorded. The opportunity costs of health 
expenditure can then be used to translate the increased costs into health foregone to 


















costs per annum          
(=A*-£14*100,000) 
Total health 
opportunity costs per 





  [A] [K] [L] [M] [N] [O]  
Sample 1 -1.41 12 £88,032,000 £1,974,000 6,000 -6000 
Sample 2 -0.54 12 £88,032,000 £756,000 5,919 -5919 
Sample 3 0 12 £88,032,000 £0 5,869 -5869 
Sample 4 0.54 12 £88,032,000 -£756,000 5,818 -5818 
Sample 5 1.41 12 £88,032,000 -£1,974,000 5,737 -5737 
Average 0 12 £88,032,000 £0 5,869 -5,869 
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By definition the baseline change in MMSE with no treatment is zero and the 
additional treatment costs are also zero. Therefore the baseline option will be 
associated with zero additional QALYs per year for every sample. We now have 
samples for the NHB of no treatment (zero) and Exenatide (column O) so the 
expected health consequences of uncertainty can be calculated as shown in Section 
3.2 in Chapter 3. As column O does not contain any samples in which the NHB of 
Exenatide is positive there is no uncertainty about the superior treatment meaning 
there is no value in further research. This is due to the high treatment costs (£88M 
per year) of Exenatide, with gains in MMSE insufficient to make up for the health 
opportunity costs of these additional treatment costs.  
The full analysis of P4 reported in Table 3.4 is based on 50,000 samples and 
considers all four treatment options: no treatment, Telmisartan, Exenatide and the 
combination of Telmisartan and Exenatide. The full analysis with RANE (full inputs 
in Appendix A2) results in an estimate of the health consequences of uncertainty of 
117 QALYs per year and 967 QALYs over full time horizon. The value of research 
is positive in this case as Telmisartan monotherapy is considerably cheaper than 
Exenatide and there is a non-zero probability that Telmisartan is superior to no 
treatment in some simulations. The analysis suggest that it is very unlikely that 
Exenatide will provide sufficient benefit to compensate for its additional costs. This 
means that the expected value of the research could be increased by replacing the 
Exenatide arms with other promising therapies which are cheaper than Exenatide. 
These conclusions will be sensitive to the assumptions made in the analysis. An 
important assumption is the duration of treatment effect. The above analysis is based 
on assuming a one year treatment effect duration. Extending this to two years 
increases the value of research from 967 to 1,985 QALYs. The value of research 
increases as each additional MMSE point is associated with a larger impact on 
population health.   
132 
 
 RESEARCH PRIORITISATION FOR SURVIVAL PRIMARY OUTCOMES 
Rapid methods to address survival primary outcomes are described and demonstrated 
here using P2 as a case study.  
4.2.3.1 Overview of P2 
P2 describes a three arm RCT investigating treatment with immunomodulating anti-
programmed death receptor 1 (PD1) antibodies for patients with advanced 
(unresectable stage III, IV) melanoma who are due to start anti PD1 as first line 
treatment. The proposed trial will compare continuous treatment until disease 
progression (TTP) to treatment for 12 months only (TF12) and treatment for 6 
months only (TF6). The anti PD1 antibodies are nivolumab and pembrolizumab 
which have been recently approved for use by NICE. The treatments are licensed for 
continuous use until disease progression (TTP) and so this is the UK standard of 
care. Prior to this guidance, the standard of care was dabrafenib, ipilimumab and 
vemurafenib. The proposal states that two years of treatment with nivolumab costs 
£140,000 for one patient which imposes significant costs on the NHS (we assume 
the same costs for pembrolizumab). There is no biological evidence that justifies the 
intensive treatment schedule and there are reports that patients who have 
discontinued treatment due to toxicity have maintained good disease response. The 
trial investigates whether acceptable rates of 2 year progression free survival (PFS) 
can be maintained with more conservative treatment schedules. The primary analysis 
of 2 year PFS is planned to report after 6 years. There is also an additional long term 






Summary of proposal 2 
Research question: Can individuals with advanced melanoma receiving 1st line 
anti-programmed death receptor 1 (PD1) antibody therapy (nivolumab or 
pembrolizumab) achieve and maintain as good an outcome if they receive 6 or 12 
months total treatment duration compared with standard treatment duration of until 
disease progression? 
Interventions: 6 months of anti-PD1 therapy; 12 months of anti-PD1 therapy (or 
until disease progression if sooner) 
Control: Anti-PD1 therapy until disease progression 
Primary outcome: 2-year PFS 
Proposed study: Three-arm non-inferiority RCT in 1,068 participants (6-month 
intervention arm, n = 361; 12-month intervention arm, n = 361; control arm, n = 361) 
Duration of proposed study: Primary analysis at 6 years (recruitment period of 5 
years, followed by 12 months follow-up); long-term follow-up for 4 years taking the 
duration of the study to 10.3 years 
Costs of proposed study to NETSCC:  £2,522,710 
NHS support and treatment costs:  Saving of £62,410,967  






4.2.3.2 Health benefits of further research in terms of primary outcome 
Survival outcomes describe the length of time spent in a particular health state. The 
health state in question may be beneficial such as remission in which case longer 
durations spent in the state are desirable. Or the state may be harmful, such as time in 
a state of relapse. For each health state there is a probability of leaving the state in 
each time period (e.g. each month). Consider the stylized example in Figure 4.1, 
each month there is assumed to be a 99% chance that patients will remain in the 
origin state (e.g. remission) and a 1% chance they will move to some post origin 
state (e.g. relapse or death).  
 
Figure 4.1: Example illustrating the transition between different health states in 
which hypothetical patients transition from the origin state to the health state at 
a rate of 1% per month 
 
If the post origin states are not desirable (e.g. disease progression, death) then it is 
beneficial to remain in the origin state (e.g. remission) for longer periods. The 
chance of moving out of the origin state is governed by a hazard. This determines the 
probability of leaving the state each month. A smaller hazard is associated with a 
lower probability of leaving the state and vice versa. The relative effect of new 
interventions on the baseline hazard is represented using hazard ratios. A hazard 
ratio below 1 implies that individuals are less likely to move out of the origin state 
with the new intervention. Uncertainty about the effect of a new intervention is 
represented by the CI surrounding the hazard ratio. Similar to binary and continuous 
outcomes, the consequences of uncertainty for survival outcomes are derived by 
taking random samples from the distribution of the hazard ratio. This is combined 
with the baseline hazard and this is used to calculate the expected number of months 
spent in the origin state for each sample. 
135 
 
A simplified version of the P2 analysis is used to illustrate how we can use a hazard 
ratio with uncertainty to rapidly estimate the value of changing practice and the 
health consequences of uncertainty. In the case of P2 the origin state is pre-
progression melanoma and the post origin states are disease progression and death. 
As the post origin states are not desirable, it is beneficial to remain pre-progression 
for longer periods. Time spent in the origin state is the PFS time and this is the 
primary outcome in P2. Therefore, in this section the benefits of research will be 
quantified in terms of months of PFS. P2 aims to compare TTP, TF12 and TF6; 
however, for simplicity we illustrate the methods comparing only TTP and TF6.  
Baseline hazard 
The first step is to define the baseline hazard for current practice. From the sample 
size calculation it is expected that 51% of individuals receiving the baseline 
treatment will not have exited the pre-progression state by two years. Assuming 
constant hazards this implies a baseline hazard of 0.03 for TTP (see Box 4.5)46.  
Estimating the baseline hazard i.e. baseline rate 
The sample size calculation for P2 states that PFS at two years (24 months) is 
expected to be 51% for the baseline treatment (TTP). If a constant hazard is 
assumed; then this implies a (1 – 0.51 =) 0.49 probability of having left the 
progression free state by 24 months. To calculate the hazard over one month we use 
the formula from (Briggs et al., 2006): 
𝑟 =  − log(1 − 𝑃)/𝑡 
Where P represents the probability of leaving the state (0.49) and t represents the 
time period (24 months). This results in a baseline monthly hazard of: 
𝑟 =  − log(1 − 0.49)/24  ≈ 0.03 
Box 4.5: Estimating the baseline hazard for P2 
 
                                               
46 The constant baseline hazard assumption can be relaxed by modelling the baseline hazard using a 
using a more flexible model such as a Weibull. This requires two inputs; a lambda and a gamma 
parameter. The lambda parameter determines the initial hazard and the gamma parameter describes 
how this hazard changes over time. These inputs may come from a published survival analysis or 
expert elicitation exercise. It is also assumed that there is no uncertainty in the baseline hazard. 
136 
 
Relative effect; hazard ratio 
Section 2.4.4 described a meta-epidemiological approach to characterizing 
uncertainty in relative effects in the absence of existing data. This was based on an 
empirical analysis by  Djulbegovic et al., (2012) who analyzed the results of 743 
publically funded RCTs pooling log odds ratios and log hazard ratios. The results of 
individual RCTs are unpredictable and tend to fall within an approximate 95% 
interval from 0.19 to 4.39. In the absence of other information, this approach 
represents a reasonable starting point to inform the magnitude of effect and 
uncertainty for the relative effectiveness of TF6 relative to TTP. However, the meta-
epidemiological analysis currently does not take account of the fact that TF6 is 
effectively a reduced dose of TTP. Therefore there are good reasons to expect that 
TF6 will be less effective than current treatment and so will be associated with a 
higher hazard of transitioning out of pre-progression state to either progression or 
death; this implies a hazard ratio > 1. As it is very unlikely that treatment for 6 
months will be superior to standard care we assume a range for the hazard ratio from 
1.1 to 4.39. Further meta-epidemiological research and/or expert elicitation is 
required to better characterize uncertainty in this case. 
Value of additional research 
Let us now consider a random sample of five possible values for the hazard ratio for 
progression with the new intervention (0.9, 1.9, 2.2, 3.5 and 4.3). These five random 
samples are shown in Table 4.14.  
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Table 4.14: Samples of hazard ratio and baseline hazard for treatment and 
control 





TF6 hazard ratio for leaving 
pre-progression state 
Hazard of leaving 
pre-progression state 
with TTP 
  [A]  [B] 
Sample 1 0.9 0.03 
Sample 2 1.9 0.03 
Sample 3 2.2 0.03 
Sample 4 3.5 0.03 
Sample 5 4.3 0.03 
Average 2.56 0.03 
 
As the average hazard ratio for TF6 is greater than 1 this implies that on average 
individuals will leave the pre-progression state faster with the new treatment. 
Therefore the current evidence does not support changing practice as patients benefit 
when they remain in the pre-progression state longer. The expected health 
consequences of the uncertainty depend on the probability that TF6 is more 
effective, in addition to the size of this effect and the number of patients eligible for 
treatment. Given the information in Table 4.14 we can estimate the chance that 
current treatment (TTP) is less effective than TF6. This is the probability of 
observing a hazard ratio less than 1, which is 1 out of 5 samples, i.e. 10%. To 
understand the scale of health that would be lost if practice remains as TTP, we 
calculate the number of months of PFS that would be observed with TTP and 
compare it to the number that would be expected with TF6. Assuming constant 
hazards the expected number of months spent in the pre-progression state is 
1/(hazard of leaving the state). For TTP is simply 1/(column B). For TF6 the hazard 
of leaving the state is calculated by multiplying the baseline hazard (column B) by 
the hazard ratio (column A). The NICE budget impact statement for the appraisal of 
nivolumab and pembrolizumab estimates that approximately 1,137 individuals per 
year will meet the criteria required for use of these drugs and so the number of 
months spent in the pre-progression state must be multiplied by 1,137 to calculate 
the population impact. The steps in this calculation are shown in Table 4.15. 
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Table 4.15: Rapid estimation of the health benefits of additional evidence for a survival primary outcome, months in pre-
progression state. TTP, treatment to progression. TF6, treat for six months. 
      
Months in pre progression state 
per annum 















 TTP                                
(=1/B*1,137) 








TTP                    
(=F if A<0) 
  [A] [B] [C] [D] [F] [G] 
Sample 1 0.9 0.03 37,900 42,111 4,211 4,211 
Sample 2 1.9 0.03 37,900 19,947 -17,953 0 
Sample 3 2.2 0.03 37,900 17,227 -20,673 0 
Sample 4 3.5 0.03 37,900 10,829 -27,071 0 
Sample 5 4.3 0.03 37,900 8,814 -29,086 0 
Average 2.56 0.03 37,900 19,786 -18,114 842 
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Combining the probability of error with the loss of health we can estimate the 
expected health consequences of uncertainty in the same manner as described for 
other outcomes, 0.2 x 4,211 = 842 months in the pre-progression state per year. 
 
Other aspects of outcome to consider 
In the sample size calculation in the research proposal a hazard ratio of 1.25 is 
considered acceptable for the new interventions (TF6 and TF12). This implies that if 
any of the treatments demonstrate a hazard ratio below 1.25 then that treatment 
would be considered superior to current practice. To state this MCD in absolute 
health terms, assuming a constant baseline hazard of 0.03 this hazard ratio implies 
that a reduction in 6.7 months of PFS per individual is acceptable for the new 
interventions47. At a population level this implies that the additional costs are 
equivalent to 7,618 months of PFS each year48.  
As discussed in Box 4.5 this baseline hazard estimate is based on two year expected 
PFS of 51% in the control arm (TTP). The MCD in absolute health terms will 
depend on this value of baseline hazard and so sensitivity analysis is useful to 
understand how this can change with different values. A two year PFS of 40% and 
60% implies baseline hazards of 0.04 and 0.02 respectively. In this case, the hazard 
ratio of 1.25 implies that a reduction of 5.2 months and 9.4 months PFS per 
individual is acceptable for the new treatment. Alternative formulations for the 
baseline hazard will also affect these results. 
As in P4 a single MCD for both treatments (TF6 and TF12) is hard to justify as the 
treatments differ substantially in costs, however this MCD is used here for 
illustrative purposes. The steps involved in taking account of the MCD to calculate 
net PFS from gross PFS are the same used in Section 2.3.4.1; the gross benefits of 
each treatment are calculated in terms of the primary outcome then the absolute 
                                               
47 The relationship between months of an outcome (e.g. months of PFS) and a hazard ratio (e.g. 1.25) 
given a baseline hazard (e.g. 0.03) is given by: 1/(hazard x hazard ratio) – 1/hazard = 1/(0.03 x 1.25) – 
1/(0.03) = -6.7 months. 
48 The trade-off implied by requiring an absolute change in a survival outcome is calculated by 
multiplying the acceptable absolute change (e.g. -6.7 months) by the incident population (e.g. 1,137) 
= 1,137 x -6.7 = 7,818 months. 
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MCD is added to the new treatment to calculate the net benefits of the new 
treatment. This is illustrated in Table 4.16. 
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Table 4.16: Rapid estimation of the health benefits of additional evidence for a primary outcome of progression free survival 
(PFS) taking account of MCD = 6.7 months per person. TTP, treatment to progression. TF6, treat for six months. 
Gross PFS per annum (in months) MCD: acceptable 
decrease of 6.7 
months per 
person for TF6          
(=1,137*6.7) 
 
Net health benefits of additional 
evidence 




Net PFS per 
annum for 
TF6           
(=C+H) 
Net absolute 




(=J if J>0) 
[C]  [D]  [H]  [I] [J] [K] 
37,900 42,111 7,618 49,729 11,829 11,829 
37,900 19,947 7,618 27,565 -10,335 0 
37,900 17,227 7,618 24,845 -13,055 0 
37,900 10,829 7,618 18,447 -19,453 0 
37,900 8,814 7,618 16,432 -21,468 0 




As the expected net PFS for the new treatment is negative (bottom row, column 5), 
current evidence suggest that TTP should be chosen above TF6. Only in sample 1 
does TF6 provide a sufficiently large increase in months of PFS to provide net health 
gains. Combining the probability of error with the loss of health we can estimate the 
expected health consequences of uncertainty, 0.2 x 11,829 = 2,366 months of PFS 
per year.  
The full analysis of P2 reported in Table 2.3 is based on 50,000 samples and 
considers three treatment options: TTP, TF6 and TF1249. Given an absolute MCD of 
6.7 for all active treatments the upper bound for the value of research is estimated to 
be 544 net months of PFS. This is much lower than the one year estimate from Table 
4.16; this is due to the small sample size used. 
4.2.3.3 Informing an appropriate MCD: what change in the primary endpoint is 
required before practice should change? 
The MCD in this case should represent the change in the primary outcome (PFS) that 
is acceptable given the total per person cost savings associated with TF12 and TF6. 
The appropriate MCD is determined by the same logic for survival outcomes as for 
binary and continuous outcomes. Equation 3.2 applies to survival outcomes but in 
this case 𝐼𝑁𝐻𝐵 is understood as the net health effect of a unit change in the survival 
primary outcome. 
As will be shown in Section 4.2.3.4 an additional month of PFS is associated with 
approximately (0.79/12 =) 0.0658 QALYs and £100 in additional costs. The net 
health effect of an additional month of PFS (𝐼𝑁𝐻𝐵) is calculated by adding the 
QALY gain and subtracting the health opportunity costs of any additional costs. In 
the present case this is 0.0658 - £100/£15,000 = 0.059 QALYs per additional month 
of PFS. 
Assuming that additional costs are the only relevant secondary outcome, the 
appropriate MCD is that which offsets the treatment costs for each new intervention. 
Given that per person costs associated with current treatment are estimated to be 
£215,760 the cost savings of TF12 and TF6 are expected to be (£215,760 - £72,504 
=) £143,256 and (£215,760 - £36,252 =) £179,508 for TF12 and TF6 respectively. 
                                               
49 This analysis is carried out using RANE with full inputs in Appendix A3. 
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The MCD should represent the reduction in the primary outcome which is acceptable 
given the cost savings.  
From Equation 3.1 the appropriate per person MCDs for each of the treatments are 
therefore (£143,256/(0.059 x £15,000) =) 162 months of PFS for TF12 and 
(£179,508/(0.059 x £15,000) =)  203 months of PFS for TF6. This implies that given 
the cost savings, reductions in PFS of 162 months and 203 months for PF12 and PF6 
are acceptable. As discussed previously, the research proposal specifies a MCD of 
6.7 month reduction in PFS for both of the interventions. The analysis here suggests 
that this MCD is too small to reflect the large cost savings associated with the 
interventions. 
As such large reductions in PFS are impossible at the individual level this suggests 
that the new treatments will dominate current practice due to the large cost savings. 
Therefore there is a zero probability that current practice will be shown to be the 
optimal treatment in a trial and so there is no value in including TTP in research. It 
also suggests that current practice should immediately switch to one of either TF6 or 
TF12 whether or not the trial is carried out50. 
There may be reasons to dispute these treatment specific MCD values. For example 
if the correct estimate of k was £30,000 rather than £15,000 the appropriate per 
person MCDs for each of the treatments would be (£143,256/(0.059 x £30,000) =) 
81 months of PFS for TF12 and (£179,508/(0.059 x £30,000) =)  101 months of PFS 
for TF6. Treatment costs may also differ from those included in the formula 
(£143,256 for TF12 and £179,508 for TF6). Finally, the net health benefits of 
additional months of survival may be greater or less than 0.059 QALYs. Sensitivity 
analysis should be conducted to investigate the impact of changing these 
assumptions. 
4.2.3.4 Linking the primary outcome to a comprehensive measure of health 
outcome 
Decision making can be supported by translating months of PFS into generic health 
outcomes along with the relevant costs and cost savings. Here we demonstrate this 
method to link survival outcomes to costs and QALYs using P2 as a worked 
                                               
50 There may be reasons that it is not desirable and/or feasible to change practice in absence of new 
research. This was discussed in Section 3.4. 
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example. In step 1, changes in the primary outcome are translated to QALYs; in step 
2, the primary outcome is linked to disease related costs; in step 3, treatment costs 
are incorporated51.  
4.2.3.5 Step 1: Link changes in primary outcome to quality of life 
To understand the magnitude of health consequences associated with spending 
additional months in the origin state, a health state utility is required. For P2 the 
utility for the pre progression health state is estimated to be 0.79 from the 
CHECKMATE-006 trial (Robert et al., 2015). To illustrate, this implies that if a 
treatment is associated with a 30 months PFS this will result in ((0.79 x 30)/12 =) 
1.98 QALYs. 
4.2.3.6 Step 2: Link changes in primary outcome to disease related costs  
In the same manner as for health utility, to understand the magnitude of disease 
related costs associated with spending additional months in the origin state, monthly 
disease related costs are required. From the NICE appraisal of pembrolizumab 
(National Institute for Health and Care Excellence, 2015), a study by Johnston et al., 
(2012) was identified which estimates that monthly costs in the pre-progression state 
(not including treatment costs) are £100. For example, this implies that if a treatment 
is associated with a 30 months PFS this will result in (£100 x 30) =) £3,000 in 
disease related costs. 
4.2.3.7 Step 3: Link uncertainty in relative effects to costs and QALYs 
In addition to disease related costs, treatment costs must also be taken into account to 
reflect the differences in treatment options. Treatment may continue (with the 
attendant costs) until the individual leaves the origin state or it may halt after a set 
period of time. In this approach, treatment is always assumed to stop after leaving 
the origin state. 
Monthly costs for each treatment in P2 are expected to be £6,042. The expected PFS 
for the baseline treatment is (1/rate = 1/0.03 =) 35.7 months. At £6,042 per month 
this implies expected cost per patient of (35.7 x £6,042 =) £215,760. The maximum 
                                               
51 Continuous discounting can be implemented to take account of the fact that treatment costs and 




duration of treatment for the new interventions (TF12 and TF6) are capped at 12 and 
6 months, resulting in maximum per patient costs of (12 x £6,042 =) £72,504 and (6 
x £6,042 =) £36,252 for TF12 and TF6 respectively. These are the maximum per 
patient treatment costs as treatment is assumed to stop if the patient leaves the pre-
progression state.  
Calculating NHBs 
To understand the impact of uncertainty on costs and QALYs, each sample for PFS 
in Table 4.15 is translated to QALYs, linked to cost savings/increases in disease 
related costs and the treatment costs are recorded. The opportunity costs of health 
expenditure can then be used to translate the increased costs into health foregone to 
calculate NHBs.  
For example, if TF6 is expected to be associated with 15 months PFS in a given 
sample this would translate to ((0.79 x 15)/12 =) 11.85 QALYs. This duration of PFS 
is also associated with (£100 x 15 =) £1,500 in disease related costs. Additional 
treatment costs are expected to be (6 x £6,042 =) £36,252 meaning net costs 
associated with 6 months treatment this simulation are (£36,252 + £1,500 =) 
£37,752. Combining costs and QALYs using the opportunity cost of health 
expenditure of £15,000/QALY, NHBs are estimated to be (11.85 - £37,752/£15,000 
= 11.85 – 2.52 =) 9.33 QALYs. In the same manner as shown in Section 3.2 this is 
repeated and combined with the incident population to describe the distribution of 
health consequences of uncertainty for each of the treatments and thus the value of 
additional research.  
Section 4.2.3.3 illustrated that due to the large treatment costs associated with TTP it 
is very unlikely to provide greater net health than TF6. This is because the health 
opportunity costs of using TTP relative to TF6 far outweigh any health gains from 
additional PFS. This means that the value of research comparing TF6 to TTP is zero. 
The full analysis includes three treatments; TTP, TF6 and TF12. This analysis also 
shows that the value of research is zero52 as TF6 dominates both TTP and TF12 due 
to cost savings. As discussed in Section 4.2.1.6, this analysis does not proscribe 
                                               
52 Funding the trial may delay the recommended change in practice and this is also associated with 
health opportunity costs. This is discussed in detail in Section 3.4. 
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social choice; rather it provides a framework for thinking about research 






 HOW CAN THE HEALTH IMPACT OF FEASIBILITY/PILOT STUDIES 
BE CONSIDERED? 
The methods from Chapter 2 and 3 show how to rapidly calculate the benefits of 
research for comparative effectiveness research. However, P5 is for a feasibility 
study which can be understood as a preliminary step before full comparative 
effectiveness research is commissioned. The health benefit of feasibility/pilot studies 
primarily derives from the full trials they potentially lead to. Therefore to understand 
the value of a feasibility/pilot study, some judgement must be made about (i) the 
value of the full trial it will potentially facilitate and (ii) the probability that the full 
trial is actually feasible. An implication of this is that proposals for feasibility/pilot 
studies must include judgements about future research. Here we demonstrate a rapid 
method to estimate the value of a given feasibility/pilot study53. We describe the 
information required to carry out the analysis and how to compare the health impact 
of this type of study to other research competing for funding. P5 is used as a case 
study throughout. 
Understanding the value of a feasibility/pilot study requires two steps. First, the 
value of the potential full trial must be estimated, using either the rapid methods 
described in this thesis or a full economic model. Second, this “potential VOI” must 
be adjusted for the fact that the full trial will not take place if the feasibility/pilot 
study shows that it is not possible. The final section will discuss the relevant 





                                               
53 The methods described here provide a method to understand the value of a given feasibility/pilot 
study proposal, they do not provide a framework for understanding whether a feasibility/pilot study or 
a full trial should be carried out as this would require additional inputs and complexity. This is 
expanded upon in the discussion. 
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 OVERVIEW OF P5 
The proposal states that there is mounting evidence that antipsychotics (APs) are 
poorly tolerated by adolescents, causing significant safety concerns. There is also 
evidence that talking therapies (such as cognitive behavioural therapy or family 
intervention) can help reduce symptoms and prevent relapse.  The NICE guideline 
for treatment of psychosis and schizophrenia in adolescents (National Institute for 
Health and Care Excellence, 2014) suggests that treatment options should include 
the possibility of choice between talking therapies, APs or both.  However, there is 
uncertainty around the effectiveness and safety of these interventions, with no clear 
evidence base for adolescents. There are challenges and uncertainties associated with 
running a full RCT. To address this, the applicants propose a feasibility study to 






Summary of proposal 5 
Research question: Is it possible to carry out a full RCT to assess whether 
psychological interventions (PI) for first episode psychosis (FEP) in children and 
young people (CYP) is non-inferior to APs in managing psychiatric symptoms. Also, 
to assess whether combination therapy of PI and AP is superior to monotherapies in 
managing psychiatric symptoms. 
Intervention: PI (up to 30 sessions of cognitive behavior therapy delivered to CYP 
at home over 6 months + 6 sessions of family intervention with parents / carers); 
Combined treatment of PI + APs. 
Control: APs for 6 months. APs will be chosen based on NICE guidance. 
Primary outcome: Feasibility of conducting a full RCT.  For subsequent RCT. 
Proposed study: 3-arm pilot feasibility RCT (n = 90) to inform whether a future 
full, clinical and cost-effectiveness trial is possible.  
Duration of proposed (feasibility) study: 2 years 
Costs of proposed (feasibility) study to NETSCC:  £601,481 
NHS support and treatment costs for feasibility study:  £150,000 






 ESTIMATING THE HEALTH BENEFITS OF FEASIBILITY RESEARCH 
4.3.2.1 Step 1: Estimate potential VOI for full trial 
Health consequences of the current uncertainty 
P5 aims to compare three treatments for use in FEP, the current treatment (APs) and 
two new interventions PI and AP + PI. As the primary outcome (relapse) is binary 
the upper bound for the consequences of uncertainty can be estimated using the rapid 
methods illustrated in Chapters 2 and 3. The analysis was carried out using the 
RANE tool with full details on evidence used and judgements made in the Appendix 
A1. 
There currently exists no evidence to inform the relative effect for the new 
interventions and so in the absence of direct evidence meta-epidemiological data is 
used as a starting point to understand uncertainty. As the primary outcome (relapse) 
is harmful it is expected that the odds ratio for PI and AP + PI is likely to be between 
(95% CI) 4.39 and 0.19 (see Section 2.4.4 for further details)54.  
From this judgement about the current evidence there is considerable uncertainty 
about the optimal treatment. Using the methods illustrated in Chapter 2 this 
uncertainty in relative effects is combined with an estimate of baseline probability of 
relapse (Craig et al., 2004) and incidence (Kirkbride et al., 2013) to understand the 
consequences of uncertainty in absolute health terms. From this the health 
consequences of this uncertainty are estimated to be 181 relapses per year.  
Health impact of the full trial 
Extending the yearly consequences of uncertainty over the 15 year time horizon, the 
maximum value of research is estimated to be 2,114 relapses avoided over the full 
time horizon. This is illustrated in Figure 4.2 and represents the maximum value of 
research.  
                                               
54 Applying the same prior distribution to the odds ratio for both PI and PI in combination with APs 
may not be justifiable on scientific grounds as there may be substantive evidence and/or clinical 
rationale to suggest that the combination of treatments will work noticeably better than any of the 




Figure 4.2: Consequences of uncertainty for P5 over the full 15 year time 
horizon 
 
This must be adjusted for the fact that the longer research takes to report the lower 
will be its value. This is because as time moves forward medical knowledge and 
technology moves with it. Therefore the longer research takes to report the greater is 
the chance that the information gained will be irrelevant. This is important to 
consider when estimating the value of feasibility studies as it will take time for both 
the feasibility study to report and for the full trial to report (should the full trial be 
deemed feasible). From the proposal, the feasibility study is expected to take two 
years to report. An estimate of the time required for the potential full trial to be 
commissioned and report is also required but was not provided in the research 
proposal. Morgan and colleagues (2018) carried out a survey and analysed the trials 
funded by the NIHR Research for patient benefit (RfPB) programme to understand 
the costs and benefits associated with feasibility studies. They found that the average 
time from the reporting of a feasibility study to the reporting of the associated full 
trial report is approximately six years. This provides an empirically based starting 
point for analysis. 
If the full research is deemed possible by the feasibility trial, the earliest it will report 
is the sum of the time taken for both the feasibility study and the full trial to report. 
In the case study this is (2 + 6 =) 8 years, and so the upper bound on the value of the 




Figure 4.3: Upper bound for value of research given that the feasibility study is 
expected to report in two years and the full research is expected to take an 
additional 6 years 
 
In some cases the value of research may fall to zero after the time to report has been 
taken account of. In these cases there is zero value in the feasibility study. In this 
scenario shorter full trials may be still provide research value and research funding 
applicants should take this into account. 
 
4.3.2.2 Step 2: Value of feasibility research 
The above value of research (850 relapses avoided) represents an upper bound on the 
value of the feasibility study assuming it leads to a full study. However the 
motivation for the feasibility study is that there is uncertainty about whether the full 
trial is possible. If the feasibility study shows that the full trial is not possible, the 
research budget spent on the feasibility study will have no impact on health 
outcomes. For this reason, the likelihood of a feasibility study leading to the full trial 
is an important determinant of its value. The value of the feasibility study is 
calculated by multiplying the value of the proposed full research by the probability 
of this research occurring. Morgan and colleagues (2018) estimate that there is a 
64% chance that a feasibility study will lead to a full trial. Taking account of this, the 
upper bound on the value of this project falls to (850 x 64% =) 544 relapses avoided. 
In the same manner as the expected health impact of the project must be adjusted for 
the fact that the full trial may not occur, the expected costs of the project must also 
be adjusted for. The feasibility study costs (of £601,481) will be incurred regardless 
of whether the full trial is commissioned. However, the full trial costs will only be 
incurred if the full trial is commissioned. Again, from Morgan and colleagues (2018) 
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full trials funded by the NIHR RfPB programme cost £1,163,996 on average and if 
the full trial is feasible, it is expected to take place 10 months after the feasibility 
trial reports i.e. (24 + 10)/12 = 2.8 years. Discounting to present value the expected 
cost of the full trial is approximately £1 million55. The total expected NETSCC 
research costs are therefore (£601,481 + £1,000,000 x 64% =) £1,241,48156. The 
expected cost per outcome of the research project is the expected cost to the research 
funder divided by the expected health benefit, (£1,241,481/544 =) £2,282 per relapse 
avoided in this case. 
If the primary outcome is linked to costs and QALYs, the research costs imposed on 
the NHS can also be taken account of.  As before, the NHS costs associated with the 
feasibility trial are always incurred but the NHS costs for the full trial are 
conditional. Prior to taking account of the costs imposed in the NHS, P5 is estimated 
to be worth a maximum of 115 QALYs in total (inputs listed in Appendix). 
Assuming the NHS costs associated with the full trial are £490,000 (after 
discounting) in the case study, the expected costs of research imposed on the NHS 
are estimated to be (£150,000 + £490,000 x 64% =) £463,600. The health 
opportunity costs associated with the above health system resources can then be 
subtracted from the maximum value of the research. The opportunity costs are 
estimated to be (£463,600/£15,000 =) -31 QALYs. After these costs have been 
subtracted the maximum value of this research falls from 115 to 84 QALYs. 
Therefore, the expected upper bound on the value of funding the feasibility trial is 





4.3.2.3 How to value pilot/feasibility studies relative to other research proposals? 
                                               
55 £1,163,996/(1.035)^2.8 = £1,057,106 
56 This assumes that if it is possible, the costs of funding the full research will fall on NETSCC (or a 
similar UK body). 
57 Table 3.4 reports that the value of P1 is £14,806/QALY rather than £14,780 per QALY this slight 
discrepancy is due to rounding. 
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In understanding value (£14,780 per QALY) of a feasibility58 study, the costs and 
health benefits of the feasibility study cannot be separated from the costs and health 
benefits of the potential full trial. This is because the health benefits of a feasibility 
study depend on the health benefits of the full trial, as shown above. 
Though the value of the project is determined by the total expected research costs 
(£1,241,481) only the up-front feasibility study costs (£601,481) are borne at the 
time of feasibility study commissioning. This means that in applying the bookshelf 
approach to research funding, commissioning a feasibility study will consume 
£601,481 of the research budget and so this is the appropriate width of the “book” 
representing P5 in Figure 3.1. The height of the P5 book is determined by the 
expected value of the project (£14,780 per QALY). 
If the feasibility study is “successful” and the full research is found to be feasible, 
then the value of this full research should be assessed on its own merits relative to 





                                               
58 This reasoning also applies to pilot studies. 
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 DISCUSSION  
This chapter has extended the models outlined in Chapters 2 and 3 to provide a set of 
methods which can be applied to a wide set of research proposals. The extensions 
were motivated by the set of six historical proposals that were considered as part of 
the NETSCC programme (introduced in Chapter 2). Methods were developed in two 
directions: first, to address trials with primary outcomes other than simple binary 
outcomes; second, to extend the types of research design to include feasibility/pilot 
studies. Limitations and possible extensions of these methods are discussed in turn 
below. 
4.3.3.1 Research prioritisation with diverse primary outcomes 
This chapter extended the methods of Claxton et al., (2015a) and McKenna et al., 
(2016) to rapidly estimate the value of research for binary, continuous and survival 
primary outcomes. The “rapid approach” to VOI analysis is to provide decision 
makers with models which are practical, built around primary outcomes and are 
quick to implement. Therefore in developing rapid models for each of these primary 
outcomes the aim was; to keep the models general enough to apply to a number of 
disease areas, require a minimum number of inputs and be capable of reflecting the 
salient difference between treatments (see Chapter 7 for further discussion). There 
are a number of limitations and possible extensions to the methods described in this 
chapter. These are discussed individually for each type of primary outcome; binary, 
continuous and survival. 
Binary, multinomial and composite primary outcomes 
The most important limitations in linking primary outcomes to QALYs arise when 
the binary primary outcome is a result of an inappropriate dichotomisation i.e. when 
a multifaceted outcome has been inappropriately forced into two categories. 
Applying models which link binary primary outcomes to QALYs assumes that the 
dichotomisation of outcomes is appropriate. This means that it is possible and 
appropriate to analyse patient outcomes in terms of an event which either occurs or 
does not occur. For example in the P1 case study described in Chapters 2 and 3, the 
primary outcome was a binary concept called “functional recovery” which was 
deemed to have occurred if the patient had a GOSE score of 4 or above and was 
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deemed to not have occurred if the GOSE score was 3 or below. Splitting the GOSE 
scale into two parts in this way follows recent clinical literature in this field (Nichol 
et al., (2015) which reports the probability of functional recovery as its primary 
outcome. Linking this primary outcome to QALYs as shown in Chapter 3 is one 
means to understand the health impact of the primary outcome. However, as the 
GOSE scale has eight categories dichotomisation may not sufficiently reflect the 
different health consequences of these states. McKenna et al., (2016) use the GOSE 
score as a primary outcome but do not split it into a binary outcome. Rather 
McKenna and colleagues analyse the GOSE score as a multinomial (multi category) 
outcome. In this case prior studies are used to estimate the individual probability of 
entering each of the GOSE states considered and how this probability differs 
between treatment and control. This is more realistic than the binary approach but 
correspondingly increases the number of required inputs and hence the complexity of 
the analysis. Another important barrier to using a multinomial outcome (as opposed 
to dichotomisation) in research prioritisation is the difficulty in explicitly quantifying 
the uncertainty for the relative effect of new treatments in absence of previous 
studies. Meta-epidemiological methods are available as a starting point for binary 
outcomes (as discussed in Section 2.4.4) but further research is required to provide 
useful methods for multinomial outcomes. 
Composite outcomes in the medical literature result from creating a binary outcome 
from a group of outcomes. In this case the composite outcome usually consists of a 
group of harmful outcomes (e.g. heart attack, death and stroke). A rationale for using 
composite endpoints is that they can increase the number of events in a trial and so 
will increase the overall statistical power, however the interpretability of results 
reported in terms of composite outcomes have been challenged (Montori et al., 
2005). The P3 case study described in Section 4.2.1 is an example of a composite 
primary outcome in which the binary primary outcome is a composite of three 
serious adverse events; death, meningococcal infection and irreversible organ injury. 
In order to understand the health impact of the outcome (in terms of QALYs) an 
assumption was required about the relative frequency of the serious adverse events 
conditional on the composite event occurring. Informing this judgement is difficult 
and depending on the context this dichotomisation may or may not be appropriate to 
capture the effects of different treatments on health outcomes. This process 
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illustrates the implicit assumptions required to understand the health impact of 
composite endpoints and so can be used more generally to aid their interpretation. 
Continuous outcomes model 
The methods for analysis of continuous outcomes outlined in Section 4.2.2 are based 
around changes in mean difference. They assume that the average mean difference 
for a treatment (the relative effect) is constant over time and ceases after the 
treatment effect duration has elapsed. It also assumes that the treatment effect 
duration is the same for each of the treatments considered. In specific cases, subject 
matter knowledge may indicate that these assumptions are unrealistic. For example, 
the effects of a pharmacological intervention in chronic diseases may be expected to 
build up slowly over time, plateau for an extended period and then taper off 
gradually. This means that the models provided in this thesis can provide only an 
approximation to the disease process, though the practical implications of this are 
unlikely to be dramatic. 
A potentially more important assumption is that the analysis is currently 
unconstrained by the minimum and maximum range of the primary outcome scale. 
This is likely to be important in situations in which the baseline outcome is close to 
the maximum or minimum value of the scale and large changes in mean difference 
are plausible. In this case theoretically impossible scale values may influence results. 
For the P4 case study the primary outcome (the MMSE scale) ranges from 0 to 30 
(Folstein et al., 1975), the patients in the proposed trial have mild to moderate AD 
and so the baseline MMSE will range from 10 – 26. It is unlikely that changes in 
mean difference sufficient to result in theoretically impossible MMSE scores (below 
0 and above 30) will occur. This is because the standard errors for the relative 
treatment effects are estimated to be 0.54 meaning that changes greater than +/- 1.08 
MMSE points are unlikely. A model which takes account of the maximum and 
minimum range of continuous outcomes is possible but would require users to 
specify the expected baseline score on the primary outcome scale (including 
uncertainty) in addition to the scale’s theoretical minimum and maximum. 
Another potentially worthwhile extension to the rapid model used for continuous 
outcomes is to allow for a relationship between the continuous outcome and 
expected survival. This would be important in scenarios in which changes in the 
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continuous outcome are predictive of survival. To implement this extension, users 
would be required to specify the change in survival associated with a unit change on 
the primary outcome in addition to the expected baseline score on the scale 
(including uncertainty) (Ibrahim et al., 2010). 
Survival outcomes model 
The most important simplification made when linking survival outcomes to QALYs 
(outlined in Section 4.2.3) is that only the costs and health gains associated with time 
spent in the origin state are considered. This approach assumes that all relevant 
differences between treatment effects are captured by the time spent in the origin 
state. More technically it assumes that the outcomes which occur after leaving the 
origin state are fixed, in that they do not depend on (i) the particular treatment used 
or (ii) the time spent in the origin state. For example, in the P2 case study it is 
assumed that post-progression survival, quality of life and costs are not affected by 
the time spent in the pre-progression state. Post progression outcomes are also not 
affected by any side-effects of the treatment choices. To relax this assumption would 
require the user to explicitly specify the costs and health outcomes in the post origin 
state in addition to the relationship between time spent in the origin state and time 
spent in the post origin state. This is the approach taken by Bennette et al., (2016) 
and Carlson et al., (2018). These authors constructed a customised Markov decision 
model for each research proposal submitted to a US based oncology research 
prioritisation body. Compared to the simple survival model outlined in this chapter, 
the fully customised approach can create a more realistic model of the disease 
process but is more complex and time consuming. In particular, the customised 
approach presents challenges to the development of software which can rapidly 
construct a decision model and calculate VOI outputs (see Chapter 5). It is important 
to recognise, however, that the more intensive methods described by Bennette and 
Carlson are not competing alternatives to those described in this chapter, rather, 
these methods form a continuum of options from which analysts and decision 





4.3.3.2 Feasibility/pilot studies 
The method described in this chapter can be used to compare the value of 
feasibility/pilot studies to more directly informative comparative effectiveness 
research such as RCTs when both types of research compete for scarce funding. In 
order to apply this method, information on the potential definitive trial is required 
(such as trial duration, cost etc.). This information was absent from the P5 
application received by NETSCC. Only information on the feasibility study itself 
was included, with no information provided about the potential full research that the 
feasibility study may lead to. Though information on the definitive trial may be 
limited, resources exist to empirically inform the necessary judgements (Morgan et 
al., 2018). Though it provides a useful starting point for analysis, the method 
described in this section contains a number of simplifying assumptions. As 
elsewhere in this thesis, the methods proposed aim to balance both complexity and 
realism with demands on analyst resources.  
It is possible to model feasibility studies with varying degrees of complexity. For 
example, a feasibility study may be conceptualised as a diagnostic test which is used 
to determine whether the full research is feasible or not. The method for assessing 
the value of feasibility studies described in the previous section assumes that the full 
research is either feasible, in which case it reports in full (true positive), or it is not 
feasible, in which case this is discovered with certainty by the feasibility study (true 
negative). It is assumed (for simplicity) that the feasibility study is perfectly 
predictive of whether the full research will successfully report or not, but in reality 
there is always the possibility that the feasibility study will incorrectly declare the 
full research impossible (false negative) or incorrectly declare the full research 
possible (false positive).  
A more sophisticated approach still would be to explicitly link the recruitment rate, 
the feasibility of randomisation and effect sizes observed in a feasibility trial to the 
decision to carry out the full research. This could be extended to inform decisions 
about whether it is better to fund a feasibility study, conduct an internal pilot phase 
within the trial or to attempt to run the full research and accept the possibility that it 
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may fail59. The additional inputs, complexity and computational burden of these 
methods mean they are outside the scope of the present thesis, though they are 




                                               
59 This more complex approach would nest uncertainties about recruitment rate, randomisation etc. 
into the overall research design space (Conti and Claxton, 2009). 
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Chapter 5  
Rapid Assessment of Need for Evidence (RANE) tool 
 INTRODUCTION 
The methods described in Chapters 2 to 4 provide a means to rapidly estimate the 
value of research for a range of primary outcomes for both comparative effectiveness 
research and feasibility/pilot studies. In order to reduce the demands on analyst 
resources these methods were designed to capture the most important aspects of the 
decision without requiring a large number of inputs. In addition to searching for 
appropriate inputs, constructing decision models and performing VOI analysis 
demands a large amount of analyst resources and expertise (Myers et al., 2012).  
The rapid approach to VOI analysis is to provide decision makers with models which 
are practical, built around primary outcomes and are quick to implement. The aim of 
this chapter is to introduce and test a tool which has been designed to reduce the 
technical barriers to implementation of VOI methods. This tool is called Rapid 
Assessment of Need for Evidence (RANE) and has been developed as part of this 
PhD. RANE is open source, hosted by the University of York and is freely available 
for use by anyone at https://shiny.york.ac.uk/rane/ (Full code available at 
https://github.com/david-glynn). This website embeds the methods described in 
Chapters 2 to 4 and so allows users to quickly carry out VOI calculations to help 
inform research prioritisation. This is important as reducing the technical barriers to 
VOI analysis can facilitate its use more widely in the health system thus improving 
the transparency and accountability of research decision making. 
In this chapter we first informally review the software currently available for 
research prioritisation using VOI. Second, we provide an overview of the RANE tool 
and its capabilities. Third, we use a case study (P6) in a step by step illustration of 
how to use the RANE tool. Finally we assess the generalisability of the tool by 






 CURRENT SOFTWARE FOR RESEARCH PRIORITISATION USING VOI 
Chapters 2 to 4 demonstrated methods which can be used to aid research 
prioritisation. For this approach to be practical for resource constrained applicants 
and decision makers these methods must not present a large technical barrier. Online 
tools have begun to emerge to facilitate VOI analysis for the purposes of research 
prioritisation. A prominent example is Sheffield Accelerated Value of Information 
(SAVI) available at http://savi.shef.ac.uk/SAVI/ which takes the results of a full 
economic model and uses these to calculate the value of further research (Strong et 
al., 2014). The limitation of this approach is that a full economic model is required 
before this the value of research prioritisation can be estimated. As discussed, these 
models require time, technical skill and large amounts of information to construct. A 
web tool which aims to address this limitation is Value of Information for 
Cardiovascular Trials and Other Comparative Research (VICTOR) available at 
https://uwchoice.shinyapps.io/victor/ which provides a simple user interface to build 
a disease model for cardiovascular outcomes. This model draws on survival models 
based on US, English and Danish data (Basu et al., 2018a)60. VOI calculations are 
then carried out given the user inputs and the background disease models. This 
approach addresses both the time and technical barriers posed by full economic 
modelling; however it is limited as it is currently only applicable to cardiovascular 
outcomes and currently only quantifies the benefits of research in terms of life 
expectancy (i.e. VOI cannot be calculated in terms of a generic outcome such as 
QALYs). 
To overcome the limitations of the existing tools we have developed the RANE tool. 
Unlike SAVI, this tool is based on the method described in Chapters 2 to 4 and so 
does not require a full economic model. Unlike VICTOR, it is based on a primary 
outcome so it is not limited to only cardiovascular research and can be linked to 
QALYs to facilitate decision making across disease areas.  
                                               
60 VICTOR implements a Markov model with six states: no events, non-cardiovascular death, 
cardiovascular death, myocardial infarction, stroke and bleeding. The latter three states are attached to 




In the next section we illustrate the how to use RANE by applying it to the P6 case 
study (this is one of the six research applications received by NETSCC, as discussed 





 OVERVIEW OF RANE TOOL 
RANE is written in Shiny (Chang et al., 2017) which provides user friendly interface 
for the R statistical programming language (R Core Team, 2017). RANE currently 
supports binary, continuous and survival primary outcomes. The tool can be used to 
estimate the potential value of full research (i.e. RCTs or well conducted 
observational studies) and feasibility/pilot studies. After entering the required 
information and clicking the “run analysis” button, the tool automatically calculates, 
presents and interprets a VOI analysis (based on 50,000 simulations) in 
approximately 2 seconds. After becoming familiar with the tool, the analysis of new 
proposals is expected to take approximately between one and four days per research 
proposal where the majority of this time is spent searching the literature for relevant 
inputs. This is an approximation, thorough piloting is required to establish time 
required in practice. 
 STEP BY STEP APPLICATION OF THE RANE TOOL TO A RESEARCH 
APPLICATION 
 OVERVIEW OF P6 
This proposal is for a two arm RCT to examine the benefits of an education booklet 
containing practical information on the management of common problems during 
end of life care for family carers of advanced cancer patients with estimated 
prognosis of 8-24 weeks. Most cancer patients want to die at home (Higginson and 
Sen-Gupta, 2000) and a 201 Macmillan survey of 1,019 UK adults living with cancer 
cited in the proposal found 73% would prefer to die at home if concerns e.g. access 
to pain relief, support for family carers were addressed, however currently 
approximately 30% achieve their wish (Office for National Statistics, 2014). The 
educational booklet was designed to provide carers with knowledge and to facilitate 
patients’ wishes to die at home. It was co-compiled with family carers, assessed by 






Summary of proposal 6 
Research question: Does an educational booklet facilitate family carers in 
supporting end of life care for patients with advanced cancer and allowing them to 
die at home (if this is their preferred place)? 
Intervention: Practical booklet with standardised structured advice from a health 
professional on its use (with usual care) 
Control: Usual care 
Primary outcome: Death at home (if this is their preferred place), assessed and 
documented at recruitment and post-death 
Proposed study: Two arm RCT in 679 patients (intervention arm, n = 453; control 
arm, n = 227) 
Duration of proposed study: Primary outcome at 3 years 
Costs of proposed study to NETSCC:  £882,177 
NHS support and treatment costs:  £4,104 







 APPLYING THE RANE TOOL TO A RESEARCH FUNDING APPLICATION 
There are three steps involved in applying RANE to a new application. In this 
section we illustrate the inputs and judgements required for each step to inform the 
value of research in terms of costs and quality adjusted life years (QALYs) using P6 
as a case study. Depending on the type of analysis (e.g. type of primary outcome, 
type of research, QALY outcomes etc.) the required inputs will differ slightly.  
Step 1: Primary outcome 
After clicking the link to RANE (https://shiny.york.ac.uk/rane/) the user is taken to 
the “Welcome” tab. For information on VOI methods and the methods underlying 
the tool the user can choose the “How to estimate research value” tab. To begin the 
analysis the user should choose the “Inputs” tab and will be taken to “Step 1: 





The first choices are to select the type of primary outcome (binary, continuous or 
survival) and whether the results are to be presented in terms of natural outcomes 
(i.e. in clinical units such as number of additional functional recoveries) or in 
QALYs. As calculating results in terms of QALYs involves additional steps we 









Choosing the type of primary outcome 
As in any analysis judgements are required about the appropriate analysis given 
time, expertise and resource constraints (Brennan et al., 2006). For P6, the primary 
outcome is death at home (when this is the preferred place). This is a binary outcome 
i.e. there are only two possible outcomes; either the patient dies at home or they are 
assumed to die in hospital. The inputs into RANE required for a QALY analysis of a 





Linking primary outcome to costs and QALYs 
If QALY analysis is chosen a set of judgements is required to link the primary 
outcome to this generic measure of health outcome. As the costs of the treatment (the 
booklet) are not expected to depend on the primary outcome (whether the patient 
dies at home) in P6, “No” should be left selected. 
 
As death at home is not a composite endpoint and there is no scale of severity, we 
only consider the costs and health effects when the endpoint occurs and when it does 
not. This is contrasted with P1 in Section 3.2 in which those experiencing the 
primary outcome (functional recovery) may enter one of four possible health states. 
As there is only one possible state when the patient dies in their preferred place and 
one possible state when the patient dies elsewhere, the inputs into RANE are shown 
below61. 
 
To understand the costs and health consequences for patients who die at home 
compared to those who do not; judgments are required for the patient time horizon, 
health state utility and disease related costs associated with both states. From 
proposal, those included in the trial have a prognosis for survival of 8-24 weeks. The 
                                               
61 In this analysis, patients are assumed to either die at home or in hospital. If death in a hospice is 
considered and there are differences in the expected costs and health outcomes associated with dying 
in a hospice compared to dying in hospital then this could be reflected by choosing 2 possible states 




midpoint in this range is 16 weeks which is equivalent to (16/52 =) 0.3 years. It is 
assumed that dying at home or at hospital does not affect survival or health related 
quality of life and so the patient time horizon for both states is 0.3 years. It is also 
assumed that the health state utility is not affected by whether the patient dies at 
home or at hospital. As the patients requiring care will be heterogeneous we use a 
review of health state utilities at the end of life to estimate an average utility of 0.76 
(Dixon et al., 2009). To understand the costs associated with the primary outcome 
we assume that if patients do not die at home they will die at hospital. From a review 
carried out by the End of Life Care Programme (2012), the average cost of a hospital 
stay ending in death is estimated to be approximately £3,000. This same report 
provided a range of £1,415 to £2,800 for the cost of dying in the community. Taking 
the midpoint of this range, a death a home is expected to cost £2,108. These 
judgements are entered as shown below, completing step 1. The user now must click 






Step 2: Interventions 
In this section the user must select the number of treatments and provide an explicit 
quantification of the current evidence for these treatments. In order to estimate the 
value of implementing the results of current evidence, the user can also input the 
current utilisation of the interventions, though this is optional. The first step is to 
select the number of treatments considered. For P6 there are two treatments; usual 
care which is the baseline treatment and the information booklet which is the new 
intervention. No information was provided on the cost of the booklet, it is assumed 
that additional copies cost £1 to produce. It is also assumed that the booklet is not 
currently in use so utilisation of the new treatment is 0%. These judgements are 






Baseline event rate 
A judgement about the probability of dying at home with the baseline treatment is 
required to understand the value of research. From proposal, of those who wish to 
die at home approximately 30% achieve their wish (Office for National Statistics, 
2014). No more information is provided about this study and so we assume +/- 10% 
uncertainty for this estimate resulting in a 95% CI from 20% to 40%. This is entered 








Relative treatment effect 
Using the meta-epidemiological approach described in Section 2.4.4 as a starting 
point to inform the uncertainty about dying at home reflects the fact that before 
carrying out the research we don’t know what the odds ratio for the effect of the new 
treatment will be relative to usual care. Current evidence suggests that because death 
in home (when it is preferred) is a binary beneficial outcome the odds ratio for the 
effect is likely to fall between 0.23 and 5.24. However, it is reasonable to expect that 
providing the information booklet will be unlikely to reduce the chance of dying in 
home, which implies that odds ratios < 1 are very unlikely. Therefore we assume a 
95% range for the odds ratio from 1.3 to 5.24. Further meta-epidemiological research 
and/or expert elicitation is required to formally characterize uncertainty in cases such 
as this. These judgements are entered as shown below, completing step 2. The user 







Step 3: Proposed research 
In this step the user selects the inputs describing the type, duration and costs of the 
research in addition to the time the information is expected to be valuable, the 
incidence and the opportunity cost of health expenditure. The research proposed is a 
3 year RCT which aims to address the research question directly i.e. it is for a full 
research study, not a feasibility/pilot study. The cost to the research funder 
(NETSCC in this case) is £882,177 and the estimated excess health system costs are 
£4,014. As practice in this area appears to move relatively slowly, it is anticipated 





The discount rate is not reported in the proposal, however guidance from the UK 
Treasury suggests the use of a discount rate of 3.5% per annum (HMT Green Book, 
2013). To calculate the incident population the Palliative Care Funding Review (T. 
Hughes-Hallett et al., 2011) estimates that 355,000 patients need palliative care each 
year and a 2010 Macmillan survey cited in the report estimates 73% of these patients 
would prefer to die at home. Therefore the population of interest is approximately 
(355,000 x 0.73 =) 259,150 patients per annum. As in previous sections the 
opportunity cost of health care expenditure for the NHS is £15,000/QALY (Claxton 








After these values have been entered, the user must click “Run analysis” and proceed to the “Results” tab where the results will be 
presented (in approximately 2 seconds). The headline results summarise the value of further research with a more detailed breakdown of 




These results indicate that there is a lot of value in implementing information 
booklet, 5,007 QALYs per year and very little in carrying out research, 10 QALYs 
over 15 years. The cost per QALY from funding this research is £86,836/QALY 
which compares poorly to the other proposals in Section 2.5 i.e. it provides a 
relatively low number of QALYs for its funding costs. However, there may be other 
reasons to consider funding this proposal over the other proposals considered for 
funding. The first reason is that there may be aspects of benefit which have not been 
captured. In the analysis the benefits of dying at home are captured only by cost 
savings associated with not dying in hospital. There are likely to be patient and 
family relevant benefits from dying at home and the analysis here does not reflect 
this. Taking this into account would increase the impact of the primary outcome and 
so would increase the value of the research. A second reason is that it may be 
difficult to distribute the booklet in absence of a trial demonstrating its effectiveness. 
As discussed in detail in Section 3.4 using the research budget as a method to change 
practice will necessarily divert resources away from research projects which could 
address genuine uncertainties in the health system. Because the research booklet is 
not costly and is unlikely to result in additional patients dying in hospital other 
mechanisms to change implementation are likely to be more appropriate. Such 







 IS THE RANE TOOL GENERALIZABLE? 
In addition to avoiding a large technical or resource barrier, another requirement of 
rapid methods for research prioritisation is that they are generally applicable to the 
diverse range of research proposals received by a research funding agency such as 
NETSCC. The rapid methods (and RANE tool) were designed to address an initial 
set of six proposals provided by NETSCC (P1-P6). To test their generalisability; we 
investigate whether their scope is sufficient to address an additional set of NETSCC 
proposals. 
 ADDITIONAL SET OF NETSCC PROPOSALS 
Six additional retrospective proposals were received from NETSCC, however 
permission from the authors was only granted for three of the six new proposals. 
These three are listed below and Table 5.1 summarises the research design, 
comparisons and primary outcome for each. 
 Proposal 7 (P7): Trial of treatments for high risk non muscle invasive bladder 
cancer. 
 Proposal 8 (P8): Trial investigating the timing of labor inducement in order to 
limit risk in hypertensive pregnancy.  
 Proposal 9 (P9): Trial of a diagnostic test to indicate the use of adjuvant 





Table 5.1 Summary of new proposals received from NETSCC P7-P9 
Proposal Research 
design 
Comparisons Primary outcome 
P7: Bladder cancer 2 arm RCT · BCG treatment Survival: time free 
from recurrence, 
progression or death 
at 2 years. 




2 arm RCT · Planned delivery at 38 to 41 
weeks  
(Mother) Binary: 
composite of poor 
maternal outcomes.  
 
· Monitoring to 40 weeks 
   
(Baby) Binary: 
neonatal care unit 
admission >= 4 hours.       
P9: Test directed 
radiotherapy 




free interval of 
carcinoma or invasive 
breast cancer. 
· Test directed decision 
making based on Oncotype 
DX DCIS score 
 
Each of the three proposals are for RCTs in which the largest number of treatment 
arms is three. The RANE tool can currently analyse a maximum of four arms, 
therefore, the methods are sufficient to address these research designs. The rapid 
methods (and the RANE tool) are currently capable of analysing binary, continuous 
and survival outcomes. The primary outcomes for each of the new proposals are 
either binary (P8) or survival (P7, P9) and the so the rapid methods are applicable to 
all three. P8, however, aims to investigate an intervention in pregnancy and so 
involves two primary outcomes, one for mother and one for baby. The research 
funding decision can be usefully informed by separately presenting the analysis for 
each of the primary outcomes. However, rapid methods do not currently exist to 
simultaneously analyse both primary outcomes jointly.  P9 is designed to investigate 
the value of a clinical test i.e. a diagnostic technology. It is possible to use the RANE 
tool to understand the value of this research by comparing the outcomes in the 
control and treatment arms. However, because the value of diagnostic tests cannot be 
separated from the treatments used in response to their results, methods are currently 
in development to better understand their mechanisms of value (Phelps and Mushlin, 
1988; Soares et al., 2018). Future iterations of the RANE tool should reflect these 




An important barrier to the use of VOI methods is the time and expertise required to 
construct decision models and carry out VOI analysis. This chapter describes freely 
available software which can be used for research prioritisation across disease areas 
and jurisdictions. The tool provides a non-technical interface which rapidly 
calculates and interprets VOI outputs. The reduced time and technical barriers can 
facilitate the wider use of VOI by both research funders (such as NETSCC in the 
UK) and research applicants (such as academic organisations applying for public 
funding for research).  
As the RANE tool is based on the methods described in Chapters 2 to 4, it has the 
same limitations as these methods (discussed in Chapters 2, 3 and 4). These 
limitations reflect trade-offs between complexity and simplicity which are required 
to keep the number of required inputs to a minimum. One route to move beyond this 
trade-off is to build a tool which is more disease specific. This is the approach taken 
by the developers of the VICTOR tool (Basu et al., 2018b). VICTOR implements a 
relatively complex decision model but the user is not required to search for a large 
number of inputs. This is possible as the VICTOR tool is specific to cardiovascular 
outcomes and so a general disease process and a number of the required parameters 
such as life expectancy and all-cause mortality are pre specified within the tool. This 
represents an important and useful direction for research but its use in research 
prioritisation is currently limited by the specificity of the tool to a specific disease 
area (cardiovascular disease) and the potential opacity of the pre specified inputs to 
users.  
Section 5.5.1 tested the generalisability of the RANE tool to a new set of NETSCC 
proposals. It was found that though there are is room for further research the tool is 
sufficient to provide useful analysis for each of the proposals in the new set P7-P9 
supporting its claim to generalisability. However this is based on only three 
proposals, more intensive piloting of the tool is required to understand how 
generalizable the tool is and to guide further development where necessary. 
The methods described in this thesis (and embedded in the RANE tool) provide an 
expected upper bound on the value of research when all uncertainty is resolved. As 
research projects have a finite sample size, they will only ever partially resolve the 
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total uncertainty. Methods to adjust research value for sample size and other aspects 
of research design are well developed (McKenna and Claxton, 2011; Strong et al., 
2015) and further work is required to incorporate this into RANE.  
The RANE tool facilitates calculation of VOI outputs for up to four treatment 
options (inclusive of the baseline treatment). However, it currently forces the 
assumption that the relative effects for each intervention are uncorrelated with each 
other. This is important as there may be good scientific reasons to expect that there 
are relationships between some of the treatment effects which should be captured by 
the analysis. These relationships may be due to (i) combination treatments or (ii) 
correlations between baseline and interventions. There are good reasons to expect 
that there are correlations between combination treatments and their component 
parts. For example in case study P4 (introduced in Section 4.2.2) three interventions 
were compared to placebo; Exenatide 2mg, Telmisartan 40mg and the combination 
of Exenatide 2mg and Telmisartan 40mg. For combinations of treatments, there may 
be substantive evidence and/or clinical rationale to suggest that the combination of 
treatments will work noticeably better than any of the treatments alone. This 
information should be incorporated into the analysis (Mills et al., 2012; Thorlund et 
al., 2017).  
For binary outcomes there may also be correlations between the baseline outcome 
and the relative effects (Riley, 2009). This is relevant in cases where an intervention 
has a greater relative effect in patients who are high or low risk and can be important 
in understanding subgroups. 
Both of these relationships between treatments discussed here can potentially 
influence VOI estimates and therefore will affect the value of research. An extension 
which would allow analysts to address both of these statistical issues (and many 
others) would be to permit users to upload a matrix of simulated results directly into 
the RANE tool. This output matrix can be produced either directly by a statistical 
software or may require additional modelling of results through Cholesky 
decomposition (Briggs et al., 2006). This approach maintains all relevant 
correlations between parameters captured by the analysis and can be carried out for 
data analysis or for an expert elicitation exercise. This would allow the RANE tool to 
182 
 
provide estimates of the value of research for a wide range of statistical models and 








Chapter 6  
Informing early access and research decisions 
without full economic modelling 
 INTRODUCTION 
Chapters 2 to 4 have provided practical methods to facilitate transparent and 
accountable research prioritisation by public bodies such as NETSCC in the UK and 
PCORI in the USA. By addressing binary, continuous and survival primary 
outcomes in addition to RCTs and feasibility/pilot studies, the methods have been 
developed to be generally applicable to a range of research applications. Rapid 
methods to calculate the benefits of research in terms of costs and QALYs have been 
proposed in order to inform research prioritisation across proposals. Chapter 5 
introduced an online tool which can implement each of the models above in order to 
reduce the time and technical barriers to carrying out the analysis. 
However, not all health research is funded by public prioritisation bodies such as 
NETSCC. Approximately 30% of applied biomedical research capital is allocated by 
the public sector with 60% allocated by the private sector (pharmaceutical 
companies and medical device manufacturers) and 10% allocated by private and 
non-profit organisations (Røttingen et al., 2013). Previous chapters have focused on 
methods to improve accountability in public sector research prioritisation. In this 
chapter we include private and charity sector research funding into the framework 
and show how research prioritisation decisions can depend on which sector bears the 
research costs. Price is an important consideration for the private sector and so the 
relationship between price and approval of treatments will be explored. 
Additionally, the previous chapters have implicitly assumed that decisions to 
recommend an intervention for widespread use and decisions to carry out additional 
research on that same intervention are independent. However, there are cases in 
which research cannot be carried out at the same time as the treatment is available 
for widespread use. The implications of this constraint are also explored in this 
chapter. By considering decisions about technology approval in addition to research 
decisions, this chapter moves away from a HTA funding panel setting into a more 
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comprehensive HTA decision making context in which approval and research 
decisions are made simultaneously.  
 EARLY ACCESS AND RESEARCH DECISIONS 
In the current policy environment there is pressure on public payers to grant early 
access to new, high cost treatments of uncertain benefit (Gyawali and Kesselheim, 
2018; McCabe et al., 2016; Prasad, 2017). Some payers have responded by 
developing accelerated access schemes such as the cancer drugs fund and the 
accelerated access collaborative (Grieve et al., 2016; NICE, 2016) in the United 
Kingdom and the food and drug administration (FDA) accelerated approval program 
in the United States (Gyawali and Kesselheim, 2018; Johnson et al., 2011). Industry 
representatives argue that these arrangements facilitate faster access to vital 
medicines (Svensson et al., 2013). However, these policy responses have come under 
criticism and have been subject to intense discussion across social media and 
mainstream media outlets (Barczyk, 2018; Edwards, 2018).  
Deciding which treatments to provide early (market) access to and which treatments 
to research further requires trade-offs. This is true regardless of whether the health 
system is privately or collectively funded and whether the health budget is fixed or 
elastic (Basu and Sullivan, 2017). Treatments which are more clinically effective 
may also come with additional out of pocket costs and/or a higher risk of side effects 
compared to current treatment options. Trade-offs must also be made when funding 
research as research budgets are limited and choosing to fund research in one clinical 
area, means that research funding is not available for another clinical area. Further, 
resources spent on research could have been spent on direct provision of care (see 
Section 3.3.2). Research decisions can also involve trade-offs between current 
patients and future patients in the case of early access decisions. The benefit of 
granting early access to new treatments which appear to be effective based on 
current evidence is that potentially worthwhile treatments can be quickly provided to 
patients without undue delay (Claxton et al., 2016; Eckermann and Willan, 2008a). 
A potential cost of granting early access is that some types of research are not 
possible after widespread access has been granted (discussed further in Section 
6.3.4). This means that even in cases in which the public sector does not bear any 
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research costs, trade-offs must be made; whether to provide immediate access to 
potentially beneficial treatments or to delay access to do additional research. 
VOI methods provide a means to estimate the health benefits of reducing 
uncertainty. This provides an explicit, evidence-based basis to inform trade-offs 
between the value of early approval and the value of further research to future 
patients. To provide a coherent framework for decision making which takes account 
of these benefits and costs, a series of assessments have been outlined to structure 
deliberation (Claxton et al., 2016; Walker et al., 2012). Historically, decision makers 
have usually considered only binary decision options, either approve or reject the 
new treatment. However, decision options exist that facilitate early access to new 
treatments while taking account of the health consequences of using sub-optimal 
treatment options. These include the conditional coverage options such as “Only in 
Research” (OIR) and “Approval with Research” (AWR). The former only allows the 
use of new treatment in a research setting. The latter approves the treatment for 
widespread use on the condition that additional evidence is collected (McKenna et 
al., 2015). The decision about the appropriate guidance is determined through a 
series of seven assessments which are listed below and described in detail in 
(Claxton et al., 2012). 
1. Is the technology worthwhile? 
2. Are there significant irrecoverable costs? 
3. Does more research seem worthwhile? 
4. Is the research possible with approval? 
5. Will other sources of uncertainty resolve over time? 
6. Are the benefits of research greater than the costs? 
7. Are the benefits of approval greater than the costs? 
In previous work, these assessments were informed with reference to a full economic 
model which reported results in terms of costs and QALYs. The barriers to 
developing full models were discussed in Chapter 2. In this chapter, we demonstrate 
how to inform the seven required assessments without a full economic model by 
extending the methods for binary outcomes described in Chapter 2. 
There are two primary aims of this chapter. First, we demonstrate how the 
assessments required for research and early approval decisions can be informed 
186 
 
without a full economic model. Second, we show how early access and research 
decisions depend on whether costs of additional research are borne by the public 
sector or some other entity (e.g. from the private or charity sector). It should be noted 
that this analysis takes a health system perspective in which only (public sector) 
healthcare costs and health care benefits are taken into account62 (NICE, 2013; 
Willan and Eckermann, 2012). The methods are illustrated using the P1 case study 
described in detail in Chapter 2.   
                                               
62 This more narrow perspective is taken here for two reasons: first, this is the perspective 
recommended by NICE; secondly including other sectors, such as the pharmaceutical industry, would 
substantially increase the complexity of the analysis. This is beyond the scope of the current thesis but 
is an important area of further research. 
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 RESEARCH AND APPROVAL CHECKLIST 
 POINT 1 - IS THE TECHNOLOGY EXPECTED TO BE WORTHWHILE? 
As described in Chapter 2, there are two treatments considered for use in P1; current 
practice which is late PTP and a new treatment, early PTP. The first step is to assess 
whether implementing, the new treatment is expected to provide an overall gain or 
loss to population the health system serves. In the approach outlined here, the 
starting point to answer this question is the current evidence on the primary outcome, 
which in the case of P1 is the probability of functional recovery. The relative effect 
of the new treatment (early PTP) on functional recovery is described by an odds ratio 
which is 1.09 with 95% CI from 0.23 to 5.24. To understand the population health 
consequences of implementing the new treatment requires consideration of the 
absolute number of functional recoveries expected with both the new treatment and 
current practice. This requires an estimate of the probability of functional recovery 
with current practice and an estimate of the number of patients which are expected to 
be affected by the decision each year63. As described in Section 2.4 of Chapter 2, the 
probability of functional recovery with current practice is expected to be 55.1% with 
uncertainty, which combined with an annual incidence of 8,800 is expected to result 
in (8,800 x 55.1% =) 4,849 functional recoveries each year with late PTP.  
An estimate of the expected probability of functional recovery with the new 
treatment can be calculated by combining samples from the odds ratio and samples 
from the baseline uncertainty as shown in Chapter 2. This results in an expected 
probability of functional recovery of 56.5% for early PTP. Therefore current 
evidence suggests that the new intervention is expected to result in (8,800 x 56.5% 
=) 4,972 functional recoveries each year. This implies that implementing the new 
treatment is expected to result in a gross increase of (4,972 - 4,849 =) 123 functional 
recoveries per year as shown in Figure 6.1. 
This indicated that there may be health benefits from providing immediate access to 
the new treatment. However there may be important differences between the 
treatments which are not captured by the primary outcome. This may include 
differences in side effect profile, relative price, out of pocket expenditures etc. These 
                                               
63 The treatment of traumatic brain injury considered in P1 is an acute condition and so there is no 
significant prevalent population. The method described here can theoretically be extended to take 
account of a prevalent population. 
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differences which are not captured by the primary outcome will be referred to here as 
secondary outcomes.  
If on balance, the secondary outcomes of the new treatment are unfavourable then 
the new treatment may be expected to improve the primary outcome to such a degree 
that it makes up for the unfavourable secondary outcomes. This is the MCD required 
before practice should change (described in Chapter 2). For binary outcomes the 
MCD can be expressed in terms of a required odds ratio (OR), risk ratio (RR) or risk 
difference (RD). As decision making is concerned with absolute differences in 
outcomes between treatments, MCD is most naturally expressed as a RD i.e. the 
difference in absolute probability of the primary outcome between two treatments. 
For a given baseline probability, a required OR can be converted to RD and vice 
versa. Naturally, as an OR of 1 indicates no difference between treatments, this 
corresponds to a RD of 0%. However, the relationship between changes in OR and 
changes in RD is highly non-linear and so exact closed form solutions are 
challenging. Methods to translate between an MCD expressed in RD and OR are 
provided the Appendix. These functions require simulation methods which are 
provided as R functions. Figure 6.1  illustrates that each value of OR (bottom axis) 
maps onto a RD (top axis). Unless stated otherwise, MCD will be expressed in terms 
of RD in this chapter. 
The function of the MCD is to trade off in the gains (or losses) in the primary 
outcome against the losses (or gains) associated with the secondary outcomes. Using 
the primary endpoint as a unit of account, the gross expected gain from the new 
treatment can be adjusted using the MCD to estimate the net health benefits (NHBs) 
of early access in terms of the primary endpoint. 
For P1, the new treatment (early PTP) is expected to be more effective on the 
primary outcome but also slightly more costly and so a positive MCD may be 
required before it should be implemented. If a MCD of 0.5%  (equivalent to a 
required OR of 1.02) is required to account of the additional costs associated with 
the new intervention this means an expected improvement of at least (8,800 x 0.5% 
=) 44 additional functional recoveries are required each year before the new 
intervention can be considered worthwhile. Taking account of this MCD, the NHB 
of access is therefore equivalent to (123 – 44 =) 79 functional recoveries each year, 
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providing an estimate of the net health benefits of early access each year. This is 
illustrated in Figure 6.1. 
 
Figure 6.1: The current evidence for the effect of early PTP on functional recovery is 
shown on both the OR (bottom) and RD (top) scale. For the OR scale the new 
treatment has a mean of 1.09 and 95% CI from 0.23 to 5.24, for the RD scale the new 
treatment has a mean of 2.1% and 95% CI from -33% to 31.4%. In gross terms early 
PTP is expected to provide 123 additional functional recoveries each year. After 
adjusting for the MCD (which is 1.02 on the OR scale and 0.5% on the RD scale) the 
net functional recoveries associated with approval are 79 each year. CI, 
confidence/credible interval. OR, odds ratio. RD, risk difference. 
As this treatment decision will have consequences beyond one year, this should be 
taken into account to understand the benefits of early access. If the treatments are 
expected to be in use for approximately 15 years with a discount rate of 3.5%, the 
total discounted population over time is therefore 101,353 patients64. The gross gain 
in functional recoveries with the new treatment is (101,353 x 56.5% - 101,353 x 
55.1% =) 1,419 functional recoveries. With a MCD of 0.5% this would be a net gain 
of (1,419 - 101,353 x 0.5% =) 912 functional recoveries. 
As relative price, among other factors, is a component of MCD (see Section 3.3.4), it 
is useful to illustrate how the benefit of approving the new treatment changes over a 
range of MCD values. Figure 6.2 below illustrates the net functional recoveries 
associated with the current treatment (equivalent to a Reject decision) and 
implementing the new treatment (equivalent to an Approve decision).   
                                               




Figure 6.2: Net functional recoveries from approving or rejecting early PTP for 
different possible MCD values. If the appropriate MCD is below 1.4% then there is a 
net gain to early approval, otherwise there is expected to be a net loss and the new 
technology should be rejected. MCD, minimum clinical difference. A, approve. R, 
reject. 
Figure 6.2 illustrates that the number of functional recoveries expected from 
rejecting early PTP is the expected functional recoveries from keeping late PTP 
which is (101,353 x 55.1% =) 55,846 functional recoveries in total. It also illustrates 
that given differences between the treatments if the appropriate MCD is below the 
Approve | Reject threshold of 1.4% then there is a net gain in approving early PTP. 
This threshold is simply the risk difference between the alternative treatments with 
current evidence, in the case of P1 this is 56.5% - 55.1% = 1.4%. If the appropriate 
MCD is above 1.4% (due to the new treatment having a much larger price for 
example) there is expected to be a net health loss and the new technology should be 
rejected. It is not necessary to have perfect knowledge about the exact MCD to 
understand whether a technology expected to be worthwhile or not, what is required 
is a judgement about whether the MCD is likely to be below the Approve | Reject 
threshold. It should be noted that in Figure 6.2 the MCD may be negative, for a 
treatment to justify a negative MCD it must demonstrate substantial improvements 
over the comparator e.g. lower relative price or reduced side effects (see Section 
3.3.4 for a method of informing an appropriate MCD).  
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 POINT 2 - ARE THERE SIGNIFICANT IRRECOVERABLE COSTS? 
An assessment of whether there are irrecoverable costs along with their potential 
significance is also required for decision making. Irrecoverable costs are those costs 
that, once committed, cannot be recovered if guidance is changed at a later date 
(Eckermann and Willan, 2007; McKenna et al., 2015; Thijssen and Bregantini, 
2017).  
Irrecoverable (opportunity) costs are present when initial per-patient losses are 
compensated by later gains and can be captured by the MCD. The additional costs 
associated with early PTP are borne immediately at the time of treatment with the 
benefits of functional recovery accumulating gradually over time. Figure 6.3 
illustrates the “investment profile” of how these net functional recoveries accumulate 
over time for a MCD of 0.5% and 0.1%. From Section 3.2, it takes up to 19 years for 
the full benefits of functional recovery to be realised. It is assumed that the benefit 
from the primary outcome accumulates at a constant rate over time while accounting 
for the discount rate of 3.5%65. For an MCD of 0.5%, the initial losses are in excess 
of the immediate health benefits in the initial period of treatment. These losses are 
gradually offset with a “breakeven” point of 14 years. For a MCD of 0.1% early PTP 
breaks even immediately as the initial MCD penalty is modest. The figure also 
illustrates that for both MCD values, it takes 33 years for the incremental net 
functional recoveries to reach their long run values; 912 and 1,318 functional 
recoveries for MCD 0.5% and 0.1% respectively. 
 
                                               




Figure 6.3: Cumulative incremental net functional recoveries of early PTP for the 
population. The initial costs of early PTP are captured the MCD. For the larger MCD 
of 0.5% (which would imply larger costs) the initial costs are in excess of the immediate 
health benefits. These negative NHBs are gradually offset population gains in health 
after 14 years. For a MCD of 0.1% the initial health benefits immediately compensate 
for the initial costs incurred. MCD, minimal clinical difference. 
The potential significance of the irrecoverable costs illustrated in Figure 6.3, depends 
on whether there is sufficient flexibility in when a patient’s treatment can be initiated 
(McKenna et al., 2015). If the treatment of a patient can be postponed until 
uncertainty is resolved, then the initial per-patient losses can potentially be avoided 
(i.e., they are potentially significant). If the decision to treat cannot be delayed, 
however, these type of irrecoverable costs cannot be avoided; thus, they will have no 
influence on the type of guidance (i.e., irrecoverable costs are present but are not 
potentially significant) (Claxton et al., 2016). Early PTP, is a treatment for acute 
traumatic head injury in which there is insufficient flexibility to delay the initiation 
of treatment for presenting patients until the results of research reports become 
available or other sources of uncertainty resolve. Therefore, any irrecoverable 
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opportunity costs exhibited by early PTP should not be judged to be potentially 
significant because they cannot be avoided by delaying the initiation of treatment for 
particular patients. It should be noted that Figure 6.3 illustrates the investment 
profile assuming that any costs or side effects are borne at the time of treatment. This 
is appropriate in the case of P1, however, in other clinical decisions additional costs 
or side effects may be borne long after initial treatment. In these cases the MCD 
penalty could be apportioned over the patient time horizon and consequently the 
investment profile for these treatments would be differ from Figure 6.3. 
Irrecoverable costs may also exist at the collective level in the form of one off capital 
purchases and can be accounted for in terms of the primary outcome. This requires a 
judgement about the additional number of primary outcomes (ΔP0) which are 
sufficient to offset the health losses associated with the irrecoverable capital cost. 
Similar to Equation 6.1, the judgement required can be usefully informed by explicit 




    
For example if a capital investment of £16,000,000 was required to implement early 
PTP, in terms of primary endpoints this is equivalent to a required increase of 
(£16,000,000/(£15,000 x 15.86) =) 67 additional functional recoveries. From point 1, 
with a MCD of 0.5% early PTP is associated with a net gain of 912 functional 
recoveries, taking account of the one off capital costs above this would reduce to 
(912 – 67 =) 845 functional recoveries. Assuming that capital costs were incurred in 
the initial period, this would change the investment profile in Figure 6.3 by shifting 
the curves down by 67 functional recoveries meaning that the origin point for both 
curves would be -67. These capital costs are allocated proportional to the number of 
individuals that are expected to be treated during the lifetime of the equipment. 
Treating these upfront capital costs as if they are paid per individual will have no 
effect on the expected benefit of the treatments as long as guidance is not changed. If 
the initial approval decision is withdrawn before the end of the lifetime of the 
equipment (due to research reporting or price changes), the expected future patients 
will not receive treatment with the technology and so the total cost of the must be 
allocated to the smaller number of treated individuals which will increase the cost 
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per patient treated (McKenna et al., 2015). For P1 there does not appear to be any 





 POINT 3 - DOES MORE RESEARCH SEEM WORTHWHILE? 
Point 3 requires an assessment of whether the potential benefits of conducting 
additional research are worth the costs of this research. If the public sector does not 
bear the costs of research then more research will always be worthwhile (see Section 
6.3.3.1). However, as trade-offs between the benefits of early access and the benefits 
of additional research may be required for decision making, some assessment of the 
benefit of research is required even in this case. 
This requires judgments about how uncertain a decision to approve or reject the 
treatment might be based on expected NHBs. From the assessment in point 1, the 
new treatment is expected to be worthwhile; however the OR is highly uncertain 
with a 95% CI from 0.23 to 5.24 meaning that there is a chance that a decision to 
approve the new treatment will be incorrect. Some assessment of the consequences 
of uncertainty is required. As illustrated in detail in Chapter 2, this involves drawing 
samples from the distribution of the OR and combining this with the baseline 
probability of the outcome to characterise the distribution of the consequences of 
uncertainty. For each sample, the expected benefits of the new treatment are adjusted 
to take account of the MCD and calculate the net functional recoveries associated 
with the new treatment. For an MCD of 0.5%, this results in an estimate for the 
maximum value of research of 590 functional recoveries per year. Extending the 
yearly consequences of uncertainty over the 15 year time horizon, the maximum 
value of research is estimated to be 6,791 functional recoveries gained over the full 
time horizon. The above estimate of the value of research is for an MCD of 0.5%. As 
discussed under point 1, the appropriate MCD value may be reasonably disputed 
and/or under control by the manufacturer through price; therefore Figure 6.4 shows 




Figure 6.4: Illustration of the upper bound on the value of research, in terms of net 
functional recoveries for a range of MCD values. The value of research reaches a 
maximum at a MCD of 1.4% which is the Approve | Reject threshold. MCD, minimum 
clinical difference. A, approve. R, reject. 
As Figure 6.4 illustrates, the value of research reaches as peak of 7,222 functional 
recoveries at an MCD of 1.4%. This is expected as this is the Approve | Reject 
threshold and so is the point at which the choice between the two treatments is 
maximally uncertain (Briggs et al., 2006; Claxton, 1999).  
6.3.3.1 Who pays for research? 
Figure 6.4 does not yet incorporate the costs of research. The decision about whether 
additional research is worthwhile depends on the opportunity cost of research 
funding resources. This in turn depends on whether research is funded by the public 
or from some other source such as the private sector (health care firms) or the charity 
sector.  
Private companies fund research in an attempt to demonstrate the efficacy of their 
technologies. This incentive for research exists because of the patent system. In the 
present system, patents are awarded to private companies for developing novel 
technologies (e.g. drugs or medical devices). These patents provide these companies 
with monopoly status for the production and sale of novel technologies for a limited 
time period. As the holder of a patent enjoys monopoly profits during the period of 
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protection, private companies stand to gain from widespread use of their products. 
This creates an incentive for the private sector to fund sufficient research to gain 
access to health systems (Rothery et al., 2017). If manufacturers fund the required 
research on their own products then these research costs do not fall directly on the 
health system and so from the perspective of the health system research will always 
be worthwhile if there is any uncertainty in the decision66. This is also the case if 
charities, acting on behalf of their stakeholders, fund research on promising 
technologies67. 
If research is publically funded then there will be health opportunity costs associated 
with funding research. From the proposal, research appropriate to address the 
question is expected to cost £2,854,00068. This allows for an estimate of the upper 
bound for the value of research by dividing the cost of the research by the expected 
upper bound for the value of additional research. For a MCD of 1.4% the upper 
bound for the value of research is (£2,854,000/7,222 =) £395 per functional 
recovery. The value of research is shown for a range of MCD values. 
                                               
66 It is assumed here that treatment price is not renegotiated in response to the results of research. 
However, as will be discussed in Point 5, price may change in response to generic entry. 
67 As both charities and manufacturers have limited budgets, it may be the case that paying for 
research on treatment A will result in less funding available for treatment B. This means that carrying 
out additional research on treatment A can have consequences for the health system even if the health 
system does not bear the financial costs of research. To reduce the complexity of the analysis, this 
channel is assumed not to operate in this case. Further research is required to characterise this 
multisector dynamic. 
68 This approach to calculating the value of additional research is based around the idea of a 
“definitive trial” i.e. it assumes that the size and therefore the cost of a trial which will adequately 
address the uncertainty is given by a power calculation or more sophisticated Bayesian methods 
(O’Hagan et al., 2005; Sutton et al., 2007). This is in contrast to other applications of VOI to decision 
making which can help inform the size and cost of the required trial (Briggs et al., 2006; Eckermann 
and Willan, 2007; McKenna and Claxton, 2011). Further research is required to provide a framework 




Figure 6.5: Cost per functional recovery gained from research for a range of MCD 
values for research which is expected to cost £2,854,000. The cost per functional 
recovery from carrying out research reaches a minimum at a MCD of 1.4% which is 
the Approve | Reject threshold. MCD, minimal clinical difference. 
Figure 6.5 shows that the cost per functional recovery from research declines to a 
minimum at MCD 1.4% which is the Approve | Reject threshold. At this point, £395 
of research expenditure is required to gain an additional functional recovery. As this 
is the point at which the decision is most uncertain, if the research is not good value 
at this point then it will not be good value at any MCD value. Therefore a necessary 
condition for research funding is that research is considered worthwhile at this MCD.  
Public research funds will either come from a dedicated research budget or general 
health expenditure. In the case of a dedicated research budget, the value of research 
must be compared to the value of other research which could be funded with these 
same resources. For P1, the maximum value of research has been estimated to be 
£395 per functional recovery. Whether this represents good value for money depends 
on the value of the alternative research proposals which could be funded with the 
£2,854,000 required for this research. This judgement involves implicitly comparing 
the benefits of primary outcomes across different disease areas as discussed in 
Chapter 2. To aid this process, the value of research can be converted from the 
primary outcome to generic health units (such as QALYs) using an estimate of the 
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INHB associated with the primary outcome. From Chapter 3, the health gain from an 
additional functional recovery is approximately 15.86 QALYs. By arithmetic this 
means that an upper bound for the value of the proposed research is £395/15.86 = 
£25 per QALY. This compares very favourably the alternative research proposals 
discussed in Chapter 3, indicating that more research in this area appears worthwhile. 
If the costs of funding further research fall on the budget for general health care 
expenditure (e.g. the NHS in the UK) then the health benefits of research must be 
compared to the health benefits of general health system activities. Empirical 
research estimates that general NHS expenditure requires approximately £15,000 to 
produce one QALY (Claxton et al., 2015b). Therefore the cost per QALY from 
funding the planned research (£25 per QALY) compares very favourably to the 




 POINT 4 - IS THE RESEARCH POSSIBLE WITH APPROVAL? 
This point entails an assessment of the type of evidence which is required and a 
judgment about whether the research required can be conducted while the 
technology is approved for widespread use. An important consideration is whether 
randomisation is required. If more precise estimates of relative treatment effect are 
required then a RCT may be necessary to avoid selection bias. However, randomised 
research may not be considered ethical once a technology is approved for general use 
(McKenna et al., 2015) which would rule out AWR. 
Understanding which type of research is required requires an assessment of the 
importance of different sources of clinical uncertainty. For binary primary outcomes, 
there are two sources of clinical uncertainty (i.e. parameters) which can be addressed 
by further research; uncertainty in the relative effect estimate (the OR in this case) 
and uncertainty in the baseline probability of the primary outcome. Assessing the 
importance of these parameters entails judgments about i) how important these 
parameters are to the decision; ii) the values these parameters would have to take to 
change the decision; iii) how likely it is that these parameters would take these 
values; and iv) what the health consequences would be if they take these values. This 
analysis can provide an estimate of the health gain if the uncertainty could be 
instantly resolved (McKenna et al., 2015). 
With current evidence (point 1), it appears that early PTP provides greater benefit 
than late PTP. However, if the relative effect and/or baseline probability parameters 
take certain values then the optimal treatment would switch to late PTP. The 
simulated probabilities of functional recovery for each treatment described in point 1 
can be analysed to determine the contribution of each parameter to overall 
uncertainty as measured by the expected value of perfect parameter information 
(EVPPI). Uncertainty in relative treatment effect contributes most to the probability 
of making an incorrect decision. This is because the baseline probability determines 
the absolute health effect of the treatments whereas the relative effect can take values 
which can change the relative benefits of the two treatments. 
An understanding of the expected health consequences of this uncertainty is also 
required. The simulated probabilities of functional recovery for each treatment 
described in point 1 can again inform this assessment through combining the 
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uncertainty in the potential values of the parameters with their importance in 
changing decisions. The health consequences of resolving uncertainty in the relative 
effect parameter are estimated to be 6,936 functional recoveries and are 146 
functional recoveries for the baseline probability69. As better estimates of relative 
treatment effect are most important, randomised research is required to address this 
question. Therefore a judgement is required as to whether randomised research can 
be carried out alongside the approval of early PTP. If it is considered unethical to 
enrol patients into a trial when one comparator is already considered superior and 
approved for use, randomised research may not be possible. In this case, OIR is the 
remaining research option. Under points 6 and 7 we will explore the judgements 
required when AWR is and is not possible. 
 
  
                                               
69 Note the separate contribution of each parameter (6,936 + 146 = 7,082) does not equal the overall 
consequences of uncertainty; 7,222 functional recoveries. This is because the value of resolving 
uncertainty in both parameters simultaneously is greater than the value of resolving the uncertainty in 
each of them individually. 
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 POINT 5 - WILL OTHER SOURCES OF UNCERTAINTY RESOLVE OVER TIME? 
Point 5 requires a judgement about the likelihood of future changes that will 
influence the relative benefits of the alternative technologies and the expected 
benefits of research. These uncertain future changes include: i) price changes of the 
technologies, ii) the appearance of new technologies which make existing 
technologies obsolete or change their relative benefits, and iii) other relevant trials 
reporting (McKenna et al., 2015). As this is described in depth elsewhere (Claxton et 
al., 2016, 2012; McKenna et al., 2015), here we focus on illustrating where MCD 
can be used to address these judgements.  
As discussed in point 1, changes in relative price can be reflected in MCD with a 
higher price requiring a larger MCD. Therefore, future changes in relative prices (say 
due to generic entry) can also be captured by future changes in MCD. As shown, 
changes in MCD influence not only whether the treatment is expected to be 
worthwhile but also uncertainty and the potential benefits of research to future 
patients. For patented products, a significant price reduction is expected at patent 
expiry due to entry of generics (Claxton et al., 2012). This translates to a reduction in 
the MCD for the technology in the future.  
If generic entry occurs before the results of the planned research report, the expected 
benefits of research will not be realized as the decision to approve the technology 
will be less uncertain. Naturally, this reduction in uncertainty reduces the value of 
the planned research. If a technology is expected to be worthwhile, a future price 
reduction (say, due to patent expiry) will reduce the value of additional research as 
the technology will become more worthwhile at a lower price and so the uncertainty 
in the decision will fall.  
For example early PTP is expected to be just worthwhile with an MCD of 1.4%. At 
this MCD the upper bound for the value of research is 7,222 functional recoveries 
over 15 years (from Figure 6.4). If a price reduction occurred which reduced the 
MCD to 0% the upper bound for the value of research would be 6,559 functional 
recoveries over 15 years. The value of research has fallen as the decision is less 
uncertain at a MCD of 0% (reduced price makes the new treatment more attractive). 
This can affect the appropriate guidance. For example, OIR may be changed to 
Approve if the benefits of research fall such that the benefits of early approval 
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become greater than the value of additional research. For these reasons, information 
about large changes in price should be considered in decision making.  
The entry of a new technology will also influence the expected benefits of treatments 
and the value of further research. There are two extreme scenarios which may arise. 
First, a new technology may enter in the future which makes the current treatments 
obsolete. In this case the value of implementing early PTP will fall to zero at the 
point at which the new treatment enters, also the value of the research will also tend 
to zero at this point in time70. For research to be of any value, it must report before 
this point, and it will only affect patients in the window after the research reports and 
before the new product enters. The second scenario is when a technology enters 
which is similar to early PTP. In this case the value of research investigating early 
PTP vs late PTP will increase as the information gained can be used to help inform 
the decision about the new treatment too.  
Trials that are ongoing, funded, or likely to be funded are also relevant because they 
may have an influence on recruitment rates. It is also possible that the results will 
change the estimate of relative treatment effectiveness when reported (McKenna et 
al., 2015). 
To avoid complicating the illustration of methods, it is assumed that for P1 there is 
not any expected change in price, new competitors or ongoing research. 
  
                                               
70 As the entire network of evidence should be considered when considering the value of research, 
additional evidence on obsolete treatment alternatives will not have zero value if it contributes 
indirect evidence to inform relevant treatment alternatives. 
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 POINT 6 - ARE THE BENEFITS OF RESEARCH GREATER THAN THE COSTS? 
Point 6 on the checklist requires a reassessment of the potential benefits of research 
and a judgment of whether the benefits of research are likely to exceed the costs of 
research.  
The benefits of research will depend on i) the probability that the planned research 
will be carried out, ii) how long it will take for the results to report, iii) how much of 
the uncertainty is expected to be resolved , and iv) the impact of the other sources of 
uncertainty outlined in point 5. In this section, we show how the expected benefits of 
research (from point 3) can be adjusted to take account of the time to research 
reporting among other factors71.  
As discussed under point 3, the costs of research may or may not be funded by the 
health system. If the costs of research are fully borne by the private or charity sector 
then the benefits of the research will always be greater than the costs from a health 
system perspective if there is any decision uncertainty. This means that (from a 
public sector perspective) the benefits of research are always greater than the costs. 
If the new treatment is expected to be superior to the current treatment (point 1) and 
there are no significant irrecoverable costs (point 2) then, as the benefits of research 
are expected to be greater than the costs the guidance depends on whether or not the 
required research is possible with approval (point 4). If research is possible with 
approval then AWR may be appropriate (if the treatment is generally considered 
safe). Otherwise the benefits of immediate access must be compared to the benefits 
of delaying approval and carrying out additional research. This is illustrated in point 
7 and as will be shown requires an assessment of the benefits of research. 
For publically funded research, an assessment of the health benefits of research is 
always required. The health benefits of funding a particular research proposal must 
be compared to the health forgone from not funding an alternative research proposal 
and/or the alternative uses these resources could be put to in the general health 
system (as discussed in point 3).  
                                               
71 The benefits of research will also depend on the sample size with larger sample sizes reducing 
uncertainty to a greater extent than smaller samples. In this analysis, it is assumed that research 
resolves all uncertainty. Further methodological work is required to relax this assumption. 
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Whether research is funded and carried out by the private or public sector there can 
be cases in which the research does not report. This may be because of problems in 
carrying out the research such as failure of randomisation or problems with 
recruitment. A reduced probability of research reporting will reduce the expected 
value of research. Under point 3, the necessary condition for research funding (with 
total research cost borne by the health system of £2,854,000) is that research is 
worthwhile at a cost of (£2,854,000/7,222=) £395 per functional recovery. This 
assumes that there is a 100% probability of the research reporting. If there was a 
80% chance of research reporting then the upper bound for the value of research 
would be (£2,854,000/(7,222 x 0.8) =) £494 per functional recovery. Table 6.1 
illustrates how the necessary condition changes as the likelihood of reporting is 
varied from 100% to 0%. 
Table 6.1: Expected upper bound for health benefits of research for different 
likelihoods of research reporting when MCD is 1.4%. 
Likelihood of 
research reporting 
Maximum benefits of 
research in functional 
recoveries 




0% 0 NA 
10% 722 £3,952 
20% 1,444 £1,976 
30% 2,167 £1,317 
40% 2,889 £988 
50% 3,611 £790 
60% 4,333 £659 
70% 5,055 £565 
80% 5,778 £494 
90% 6,500 £439 
100% 7,222 £395 
 
As can be seen above the value of research is highest when it is certain to report and 
falls with decreasing probability of reporting.  If there is an 80% chance of research 
reporting, the maximum value of research is £494 for an additional functional 
recovery.  
In addition to the likelihood of research reporting, the potential value of research will 
depend on the time it takes for research to report. The value of the research falls as 
the research takes longer to report as the population who can benefit from the 
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information gets smaller. Table 6.2 illustrates how the expected value of research 
changes as the time to research reporting is varied from 0 to 15 years. 
 
Table 6.2: Expected upper bound for health benefits of research for different 
research reporting times when MCD is 1.4% and the likelihood of reporting is 
100%. 
Time to research 
reporting (years) 
Maximum benefits 
of research in 
functional 
recoveries 




0 7,222 £395 
1 6,616 £431 
2 6,031 £473 
3 5,465 £522 
4 4,919 £580 
5 4,391 £650 
6 3,881 £735 
7 3,388 £842 
8 2,912 £980 
9 2,452 £1,164 
10 2,007 £1,422 
11 1,578 £1,809 
12 1,163 £2,454 
13 762 £3,745 
14 374 £7,631 
15 0 - 
 
Table 6.2 illustrates that the value of research falls as the research takes longer to 
report. As the information is assumed to be relevant for 15 years, the information 
gained from the research has no value after 15 years and so the final row in Table 6.2 
has zero benefits of research. 
The above analysis assumes that research resolves all uncertainty for both the 
relative treatment effect and the baseline probability of functional recovery.  Due to 
limited sample sizes, research will not fully reduce all of this uncertainty; therefore, 
this represents an upper bound on the value of research. As described in point 5, 
research cannot completely resolve all uncertainty in a decision and there are other 
sources of uncertainty, such as patent expiry, which can have an influence on the 
expected value of research. 
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Likelihood of reporting, time to reporting, future changes and MCD should be taken 
account of when making approval and research decisions. The appropriate MCD 
value may be reasonably disputed and/or under control by the manufacturer through 
price. Therefore Figure 6.6 shows how the appropriate guidance changes for 
different MCD values when all research costs are borne by the public sector and 
AWR is possible. For Figure 6.6, the research is assumed to take 5 years as reported 
in the proposal and we assume there is a 100% likelihood of reporting. 
 
 
Figure 6.6: Cost per functional recovery gained from research for a range of MCD 
values for research which is expected to take 5 years to report and costs of £2,854,000. 
The cost per functional recovery from carrying out research reaches a minimum at a 
MCD of 1.4% which is the Approve | Reject threshold.  MCD, minimal clinical 
difference. A, approve. R, reject. OIR, only in research. 
Figure 6.6 above is the same as Figure 6.5 but adjusted for the time for research 
reporting. Note that the value of research has declined for every value of MCD in 
Figure 6.6 compared to Figure 6.5. This is because the estimate of value now takes 
into account the 5 years it takes to report. 
In the scenario illustrated above, the public sector pays for research and AWR is 
assumed to be possible, therefore research and approval decisions are independent of 
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one another72. This means there is no need to trade off the benefits of early access 
with the benefits of additional research. If the MCD is below 1.4% (left of the 
dividing line) then the appropriate guidance is grant immediate access73. Whether or 
not research should be carried out in addition (issue AWR guidance as opposed to 
Approve) depends on whether additional research is worthwhile. As shown in Figure 
6.6, this depends on the MCD. If there is little difference in the secondary outcomes 
(including relative price), then an appropriate MCD is approximately 0. As this is 
below 1.4%, immediate access is the optimal policy. From Figure 6.6, additional 
research should also be carried out (AWR) if £699 per functional recovery is 
considered value for money. The primary outcome (functional recovery) can be 
translated to QALYs to aid decision making. As each additional functional recovery 
is associated with an additional 15.86 QALYs, the upper bound for the value of 
research is approximately £699/15.86 = £44 per QALY74. This compares favourably 
with the marginal productivity of the general health system; £15,000/QALY 
(Claxton et al., 2015b), and the other research proposals considered in Chapter 3. 
Therefore AWR appears to be appropriate guidance. It should be noted that these 
arrangements have been implicitly assumed in Chapters 2, 3 and 4 with £699 per 
functional recovery estimated as the value of research in Section 2.4.5.  
If research is not possible with approval (discussed in point 4) then AWR is not a 
viable policy option and so the benefits of early access (Approve) must be traded 
against the benefits of further research (OIR). This judgement is illustrated in point 7 
of the checklist.  
 
  
                                               
72 It is possible that public sector bodies funding research on patented technologies could have an 
effect on incentives for the private sector to invest in research before launch. This would mean that 
research and approval decisions would no longer be independent. Further research is required in this 
area to understand these incentives and design appropriate policies. 
73 For private companies there is an incentive to reduce price to keep the appropriate MCD below the 
Approve | Reject threshold. 
74 Note that £44/QALY is the same value as that reported in Table 3.4. This is because calculating the 
cost per primary outcome using MCD then dividing this by the INHB (as shown here) is equivalent to 




 POINT 7 - ARE THE BENEFITS OF APPROVAL GREATER THAN THE COSTS? 
If randomised research is required then research may not be possible if the 
technology is already permitted for widespread use and/or widely used in practice. In 
this case AWR is not possible and so the benefits of early approval of the new 
treatment must be compared to the potential health benefits of research through OIR. 
OIR guidance involves withholding the technology until the results of additional 
research are clear and then reconsidering the decision. This illustrates the trade-off 
that must be made between the benefits of immediate approval to current patients 
and the benefits research which may be forgone as a result of approval (McKenna et 
al., 2015). Research, which can occur only through OIR can be funded by either the 
public or some other sector (private or charity). The specific trade-offs and 
judgements required to make decisions differ depending on the funding source and 
so are discussed separately below. 
 
6.3.7.1 Research costs not funded by the public sector  
From a public sector perspective, if the costs of research are borne by manufacturers 
or charities then they do not result in health opportunity costs75. However, trade-offs 
must be made. Choosing additional research (through OIR) means that access to the 
new technology is delayed. This delay results in foregone health when the treatment 
is expected to be effective. If research duration and likelihood of reporting are 
known, then the judgement about whether the benefits of OIR are greater than the 
costs of delay can be informed using Figure 6.7. This graph extends Figure 6.2 to 
include the value of an OIR decision in addition to the value of reject (R) and 
approve (A).  
 
                                               
75 From a charity perspective allocating limited funds to research as opposed to direct provision of 
services will come with health opportunity costs. This is not included in the current analysis as a 




Figure 6.7: Net functional recoveries for different decision options for traumatic brain 
injury when research takes 5 years to report. Net functional recoveries are expressed at 
a population level for current and future patients whose treatment choice is informed 
by the decision. Approve provides more functional recoveries if the MCD is below -
5.4%. For all other values of MCD OIR is superior. MCD, minimal clinical difference. 
Figure 6.7 illustrates the absolute benefits of approve, reject and OIR guidance for a 
range of MCD values. The payoff from OIR is calculated as the number of 
functional recoveries expected from reject in addition to the number of functional 
recoveries from research. As the benefits of research depend on MCD, the benefits 
of OIR will depend on the MCD. For example, if the MCD is 0% the value of reject 
is 55,846 functional recoveries (from point 1) and the upper bound for the value of 
research is 4,861 resulting in a value of OIR of (55,846 + 4,861=) 60,707 functional 
recoveries. This compares to 57,265 functional recoveries from approval of the 
technology. This accounts for the gap between OIR and Approve at MCD 0% in 
Figure 6.7. 
The optimal policy is given by the outer envelope in Figure 6.776. There are two 
potential policies across the MCD space; Approve (A) and OIR. From the figure, the 
                                               
76 This figure is analogous to Figure 4 from (Rothery et al., 2017) except in Rothery et al., the x-axis 
directly represents changes in price relative to a comparator technology whereas here the x-axis 
211 
 
MCD must be very negative (less than -5.4%) before immediate approval is 
appropriate. This would require the new treatment to have a very low relative price 
and/or evidence of substantially reduced side effects. If this is the case then rapid 
access to the technology provides greater benefits than carrying out research through 
OIR (which requires a delay in providing access to the new treatment). If the MCD is 
above -5.4%, then OIR provides a greater number of functional recoveries. For 
example, at a MCD of 0% OIR provides a greater total number of functional 
recoveries (3,442) than Approve. This overall difference results from a trade-off 
between the benefits of early access and the benefits of delaying for additional 
research. During the 5 years of research Approve provides 556 more functional 
recoveries than OIR as the new (more effective) treatment is implemented faster. 
After research reports, the information from OIR provides an additional 3,998 
functional recoveries compared to Approve. Overall this results in OIR providing an 
additional (3,998 – 556 =) 3,442 functional recoveries. This trade-off highlights that 
research which reports faster will be more valuable as the delay to implement the 
new treatment will be shorter. 
An implication of this approach is that in some cases only the sign of the MCD is 
required for decision making. In the present case study MCD must be negative for 
early approval to be appropriate. If it is expected that for a given treatment any 
reasonable MCD will be positive, due to high relative prices and/or uncertain side 
effects, then OIR will be appropriate. Precise knowledge about the magnitude of the 
MCD is not required for decision making only its sign. This is likely to be a common 
scenario faced by the cancer drugs fund (Grieve et al., 2016) in the United Kingdom 
and the accelerated approval program in the United States (Gyawali and Kesselheim, 
2018). 
6.3.7.2 Research costs funded by the public sector 
If research costs are borne in part or in full by the health system, then decision 
making must take account of the health opportunity costs of research funding costs. 
In point 6 we showed how to inform decision making when research is publically 
funded and AWR is an option. In this case approval and research decisions were 
independent. Here we illustrate the decision problem when AWR is not an option. 
                                                                                                                                     
represents changes in MCD relative to a comparator technology. As discussed in point 1 the MCD 
concept includes relative price in addition to other factors such as side effects. 
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As research can only be carried out through OIR, it becomes necessary to compare 
the expected gains from research (OIR) to the gains from immediate access. The 
resulting decision options and upper bound for the value of additional research for a 
range of MCD values is illustrated in Figure 6.8. 
 
 
Figure 6.8: Decision options and upper bound for the value of additional research on 
traumatic brain injury when research takes 5 years to report. Approve is optimal 
below a MCD of -5.4%. Between -5.4% and 1.4% either approve or OIR is optimal. 
OIR should be chosen over approve if the cost per functional recovery from research is 
considered worthwhile at a plausible MCD. Similarly, above 1.4% either reject or OIR 
is optimal. OIR should be chosen over reject if the cost per functional recovery from 
research is considered worthwhile. MCD, minimal clinical difference. A, approve. R, 
reject. OIR, only in research. 
In Figure 6.8 the underlying absolute benefits of approve, reject and OIR are the 
same as those in Figure 6.7. The difference is that the figure above shows the value 
of choosing research at a given cost to the health system (£2,854,000). The value of 
research (through OIR) depends on the MCD and is expressed as cost per functional 
recovery gained. The figure is divided into three sections (from low to high MCD) i) 
Approve, ii) Approve or OIR, iii) Reject or OIR. These are discussed in turn. 
Approve: below MCD -5.4% 
If the MCD is expected to be below -5.4% then immediate approval provides more 
functional recoveries than research through OIR (see Figure 6.7). This is because at 
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this MCD (low price) there is very little decision uncertainty and so delaying access 
in order to carry out more research is not worthwhile. Therefore below a MCD of -
5.4%, regardless of the cost of research, OIR offers no additional benefit and so 
research is not worthwhile at any cost per functional recovery. As shown in Figure 
6.8 the optimal guidance in this case is to Approve without further research. 
 
Approve or OIR: between MCD -5.4% and +1.4% 
For all MCD values above -5.4% OIR is expected to provide a greater number of 
functional recoveries than the other decision options (Approve or Reject) as can be 
seen in Figure 6.7. The value of research is calculated by dividing the cost of 
research by the number of additional functional recoveries through OIR compared to 
the next best alternative. For example, at an MCD of 0% the benefits of OIR are 
60,707 functional recoveries, the benefits of Approve are 57,265 and the benefits of 
Reject 55,846. This implies that at this MCD (price) research results in (60,707 - 
57,265 =) additional 3,442 functional recoveries and so has a value of 
(£2,854,000/3,442 =) £829 per additional functional recovery77. Whether OIR is 
considered good value depends on how much the health system is willing to pay for 
an additional functional recovery. Using the heuristic to translate functional 
recoveries to QALYs, the value of research is approximately £829/15.86 = £52 per 
QALY. As this compares favourably with the marginal productivity of the general 
health system; £15,000/QALY (Claxton et al., 2015b) and the other research 
proposals considered in Chapter 2, OIR appears to be appropriate guidance if AWR 
is not possible. Reducing price (and therefore MCD) will reduce the additional 
benefits of OIR and so will make Approve more likely. This can be seen in Figure 
6.8 as the cost per additional functional recovery from OIR increases as MCD 
decreases.  
An alternative to starting with a given MCD (price) and calculating whether research 
is worthwhile at this value, it can be useful to start with the maximum the health 
system is willing to pay for an additional functional recovery and use this to 
                                               
77 If costs were shared with the private sector these costs could simply be subtracted from the costs of 
research, for example if £1,000,000 was provided by manufacturers the value of research would be 
(£1,854,000/3,442 =) £539 per additional functional recovery. 
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determine the required MCD for immediate approval. For example if the health 
system was willing to pay a maximum of £2,000 per functional recovery, this 
implies that the new treatment requires a MCD below -3% for immediate approval. 
Reject or OIR: above MCD +1.4% 
Above an MCD of 1.4% OIR is expected to provide a greater number of functional 
recoveries than the second best option, which in this case is Reject. As above the 
decision about whether to carry out research or reject the treatment depends on how 




This chapter contributes to the literature in two ways. First, we show that the 
assessments required for research and early approval decisions can be informed 
without a full economic model. Second we show how early access and research 
decisions depend on whether or not research costs are borne by the public sector. 
As discussed in the introduction, full economic models are expensive and time 
consuming to construct and this can limit their use by capacity constrained decision 
making bodies. The method described here does not require a large amount of 
specialist expertise or time to carry out.  This provides three opportunities for 
supporting evidence based decision making.  
First, the method can be routinely carried out as part of reporting the results of a 
systematic review. This can allow bodies such as Cochrane to provide decision 
makers with useful metrics to understand the trade-offs involved when deciding on 
the need for further research. 
Second, this framework utilising MCD can help decision makers to inform research 
and reimbursement decisions. It provides a coherent and transparent basis to trade-
off price, uncertainty and effect size when making early access decisions and so can 
provide a basis to link evidence to pharmaceutical pricing. 
Related to the previous point, this method can be used to evaluate the policies which 
have been implemented in response to calls for earlier access to new technologies 
such as the cancer drugs fund and the accelerated access collaborative (Grieve et al., 
2016; NICE, 2016) in the United Kingdom and the FDA accelerated approval 
program in the United States (Gyawali and Kesselheim, 2018; Johnson et al., 2011). 
The methods here can be used to rapidly analyse the health consequences of the 
decisions taken by these bodies to help determine whether these policies have been 






Chapter 7  
The overall aim of this thesis is to further the use of VOI in research prioritisation by 
developing methods to calculate VOI which are feasible within the practical 
constraints of decision making. Throughout the thesis it has been argued that VOI 
methods can improve the transparency and accountability of decision making by 
bringing clarity to the discussion around the health benefits of further research and 
by making use of the available evidence. Despite the benefits of VOI, Chapter 1 
identified four barriers to the widespread of VOI methods in practice, namely i) 
human resources, ii) time, iii) computing resources and iv) familiarity with methods. 
The rapid VOI methods described in this thesis address the first three of these 
barriers as they are quick and simple to implement. The online RANE tool greatly 
reduces the time and technical barriers to carrying out VOI analysis. The final barrier 
of familiarity has not been surmounted however. This can only be overcome through 
practical applications and interaction with policy makers as will be discussed in 
Section 7.1. 
The rapid VOI approach necessarily involves simplifying complex clinical 
processes. Though there may be objections to this, the place of simplified models in 
decision making may be illustrated with a thought experiment. Imagine comparing 
VOI results from rapid models with full economic models. For a given set of 
research proposals, this exercise could compare: i) estimates of the value of research 
for each proposal and/or ii) the set of projects that would be funded given a certain 
research budget. Though interesting and potentially useful, this exercise does not 
include the policy relevant comparator. The rapid VOI methods described in this 
thesis are not being suggested as an alternative to full economic modelling, rather 
they are being suggested as a complement to current decision making processes. 
Including VOI metrics into this process through rapid VOI has the potential to 
increase the transparency and accountability of this process. Furthermore, familiarity 
with VOI can also potentially aid decision making by providing a consistent 
framework with which to think about uncertainty, opportunity costs, price and the 
role of research in the health system. 
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This thesis has developed methods for the analysis of binary, continuous and 
survival primary outcomes. The analysis for each type of primary outcome is 
illustrated using a case study from the original six NETSCC proposals. For each type 
of primary outcome more complex and potentially more realistic models could be 
used to link changes in the primary outcome to costs and QALYs. As emphasised 
throughout this thesis, the downside to using more complex models is the demand on 
time and analyst resources which makes building complex models impractical in 
many cases. In this spirit, the proper place of this thesis is to contribute to the 
development of a “toolkit” of practical methods. As discussed in Chapter 1 and 
Chapter 5 there exist methods for calculating VOI other than those discussed in this 
thesis which are less resource intensive than building a full economic model. These 
are the “minimal modelling” and “hybrid minimal modelling” methods described by  
Meltzer et al., (2011), Basu et al., (2018a), Bennette et al., (2016) and Carlson et al., 
(2018). Each approach, including the methods developed in this thesis, has different 
requirements and limitations, therefore a pragmatic approach is to see each method 
(including full modelling) as an option in the analyst’s toolbox. It then becomes a 
matter of judgement to decide which method is most appropriate in a given context.  
An additional benefit of the rapid VOI methods described in this thesis is that they 
provide a clear interpretation of MCD for a range of outcomes. MCD is defined here 
as the improvement in the primary outcome that would need to be detected for the 
new treatment to be considered worthwhile, including any additional costs or side 
effects. It is worth noting that there are many definitions of MCD in the medical 
statistics literature and in policy circles more generally (Beaton et al., 2002; Guyatt 
et al., 2008; Jaeschke et al., 1989). Importantly the definition of MCD used in this 
thesis includes both the direct health effect on the recipient of the treatment and the 
indirect health effects which result from the opportunity costs of health expenditure. 
This extension of the MCD concept is an important contribution as it can be used to 
introduce resource constraints into deliberations about “required effect sizes” which 
are used in designing non-inferiority trials and in traditional power calculations 





IMPLEMENTING RAPID VOI METHODS IN PRACTICE 
In practical policy making, research proposals are sketched out initially and are 
developed into more detailed proposals as they proceed through prioritisation stages. 
The earlier in the process that quantitative methods are used, the smaller is the 
chance of inappropriately discarding a potentially high impact research proposal. To 
generate VOI metrics to inform decision making, the required inputs could be 
requested as part of the research application process and VOI analysis carried out 
internally by the research funding body (e.g. NETSCC). Alternatively, VOI analysis 
could be incorporated into the application process and carried out by research 
funding applicants. 
The RANE tool (https://shiny.york.ac.uk/rane/) means that VOI can be more easily 
incorporated into the research funding process. However the time and resource 
constraints of research applicants and decision makers must still be considered. 
Therefore there are three important questions which must be answered when 
applying these methods in practice: (i) which type of analysis is required (cost per 
primary outcome or cost per QALY)? (ii) who should carry out the analysis 
(research funders or research applicants)? and (iii) how early in the process should 
VOI methods be used?  
 
Cost per primary outcome 
As discussed in Chapter 2, the set of inputs required to estimate the cost per clinical 
outcome (e.g. £652 per additional functional recovery) for a given research proposal 
is the minimum amount of information required to understand the health impact of 
research. Therefore it may be appropriate that this information should be required at 
the earliest stage possible. Research applicants are best placed to source these inputs 
as they have access to topic experts and should have an understanding of the 
literature and natural history of the disease. There may be concerns from research 
funders that quantitative research assessments create opportunities to selectively 
thesis or “game” the analysis if carried out by applicants. It should be noted, 
however, that these opportunities exist within the current narrative approach to the 
prioritisation of research proposals. Indeed, the requirement for a standardised set of 
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explicit inputs, which must be supported by reference to evidence, has the potential 
to decrease selective reporting and increase transparency and accountability. 
Research applicants can also benefit from VOI analysis by using it early in the 
research development process to determine whether a research idea is worth 
developing into a full grant application. A large amount of time is spent writing 
research grant applications with a success rate of approximately 20% for NIHR HTA 
funding in the UK (NIHR, 2018b). This is an important issue as the time spent 
writing failed applications could have been used in directly productive research 
activities. The RANE tool can be used early in application development to estimate 
the health impact of a given research proposal. If the proposal appears likely to be 
good value for money, then the VOI analysis can be included into the research 
proposal to increase the chances of receiving funding. If the planned research 
proposal appears to offer poor value to the health system then the proposal can either 
be modified or the organisation can save time and resources by switching to an 
alternative research proposal. 
For decision makers, presenting results in terms of cost per additional primary 
outcome may help to compare value across proposals by making the trade-offs 
between the different outcomes clearer, therefore it represents a clear improvement 
relative to implicit forms of decision making. However, significant implicit scientific 
judgements are still required to make decisions. Therefore, transparency and 
accountability to evidence can be improved by linking primary outcomes to QALYs. 
Cost per QALY 
Estimating the health impact of research in terms of cost per QALY (e.g. £44 per 
additional QALY) provides important advantages over quantifying the value of 
research in terms of cost per primary outcome (e.g. £652 per functional recovery) as 
in Chapter 2. Ideally, cost per QALY analysis would be required for all proposals 
competing for limited research funding since this make the identification of “best 
buys” more explicit. However, the additional inputs required for cost per QALY 
analysis require additional analyst time and expertise. If analyst resources are scarce 
then projects which are (i) more expensive and/or (ii) of uncertain value may be 
higher priority for cost per QALY analysis. Analyst time could be allocated 
preferentially to expensive research proposals as these are the most consequential for 
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the research budget. Intuitively, if an expensive low value project is funded this will 
consume a large portion of the available research budget which cannot be used on 
other, potentially more worthwhile, projects. Analyst time could also be focused on 
projects whose value is not clear based on the cost per natural outcome analysis. A 
project which appears to be clearly of superior value from the cost per natural 
outcome analysis may not require a full cost per QALY analysis. However, caution 
is required as it may be difficult to compare across research proposals by only 
considering their cost per natural outcome. For example, it may be difficult to know 
that P1 is a clear research priority by only looking at Table 2.3. If staged or pilot 
implementation of VOI methods for research prioritisation is considered, then large 
expensive projects may be prioritised as these are the most consequential for the 
research budget and population health. 
 DELIBERATION, DECISION MAKING AND STRUCTURAL UNCERTAINTY 
Whether the analysis carried out reports results in terms of cost per primary outcome 
or cost per QALY, deliberation and judgement will always be required for 
reasonable social decision making (Daniels, 2000; Rawlins, 2005). Deliberation is 
required because both the scientific and social value judgements embedded in an 
analysis can always be reasonably disputed (Claxton et al., 2013).  
The need for social value judgments in decision making has been discussed in the 
context of rare diseases highlighted by the P3 case study. Though there may be little 
impact in terms of population health in funding further research in rare diseases there 
may exist social value concerns that are not exhausted by impact on total population 
health (Hughes et al., 2005; McCabe et al., 2006). No analysis can fully capture 
these concerns, all that can be aimed for is that the analysis produced can help 
inform reasoned consideration of the issues. 
Scientific judgements about appropriate model structure and use of evidence are also 
required in any analysis. In some cases sensitivity analysis such as that presented in 
Section 3.3.1 can be carried out in which the value of particular inputs is varied to 
illustrate how results change under different assumptions. In other cases it is the 
structure of the model used to generate the results that is disputed. As discussed in 
Chapter 1, this “structural uncertainty” is inherent to all decision models. However 
as the rapid VOI models discussed in this thesis are designed to be simple and easy 
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to implement, there are likely important situations in which they will fail to capture 
aspects of disease natural history. In these cases more complex (and time 
consuming) modelling approach may be appropriate.  
Deciding on whether more complex modelling is required for a given proposal 
requires judgement and deliberation. This judgement will depend on a host of 
contextual factors. These factors include: the available resources for carrying out 
more complex modelling; the consequences of delaying decisions while modelling is 
taking place; the size of the population who can potentially benefit from the 
research; the budget impact of the research proposal; and the degree of complexity 
required to characterise disease natural history. Though further methodological 
research may contribute to this discussion, balancing these factors will always 
remain a matter of judgement and practical policy making. 
LIMITATIONS AND AREAS FOR FURTHER RESEARCH 
 PILOTING AND GENERALISABILITY 
As discussed in Chapter 5 there are a number of possible extensions to the current 
iteration of the RANE tool. In the spirit of letting policy needs guide methodological 
development, extensions and modifications of RANE may be best informed by 
piloting the tool with decision makers. Ideally this piloting of the tool should be one 
component of a wider effort to apply rapid VOI methods in practice. To be effective 
this work would require buy-in from a range of stakeholders involved in research 
prioritisation. It should focus on identifying barriers and implementing solutions to 
integrate VOI methods into routine policy making. Further methodological 
development may be part of this process but it is likely that efforts to understand and 
adjust institutional structures will be far more important than methodology.  
Relatedly, Section Error! Reference source not found. assesses the generalisability o
f the rapid VOI methods (and the RANE tool) by determining if it could be applied 
to a new set of NETSCC proposals. It was found that though there are is room for 
further research the tool is sufficient to provide useful analysis for each of the 
proposals in the new supporting its claim to generalisability. However this is based 
on only three proposals, more intensive piloting of the tool is required to understand 
how generalizable the tool is and to guide further development where necessary. 
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 INFORMING A JUDGEMENT ABOUT RELATIVE EFFECTIVENESS IN THE 
ABSENCE OF EXISTING EVIDENCE 
Chapter 2 highlighted the importance of methods to explicitly quantify uncertainty in 
situations in which suitable pre-existing studies do not exist. This is fundamental 
issue in the use of VOI to aid research prioritisation. Despite its importance this issue 
has received very little attention in the VOI literature. To address this, Section 2.4.4 
outlined three available options for decision makers; expert elicitation, statistical 
modelling and the use of meta-epidemiological studies. Section 2.4.4 also 
demonstrated the use of a meta-epidemiological approach related that used by 
Bennette and Carlson. Though providing a useful starting point for deliberation, this 
method could be greatly improved with further research.  
The primary limitation of the approach used is that applying a generic meta-
epidemiological estimate to inform uncertainty across all research proposals does not 
take account of contextual differences between proposals. There may be good 
scientific reasons to treat proposals differently. This contextual information could be 
incorporated by (i) integrating expert elicitation and meta-epidemiological methods, 
(ii) utilising more sophisticated statistical methods to reflect the fact that different 
disease areas and types of outcome are associated with different distributions of 
effect sizes (iii) combining approaches i and ii. Developing these methods with the 
aim of supporting research prioritisation is potentially an important and fruitful area 
of further research. 
Rapid methods of expert elicitation may be useful to develop and integrate into the 
research prioritisation process. As judgements about uncertainty must be made either 
implicitly or explicitly, expert elicitation may be especially useful in cases in which 
previous randomised trials have not been carried out and the use of meta-
epidemiological evidence is deemed inappropriate. The importance of expert 
elicitation in decision making has been increasingly recognised in recent years and 
number of user friendly tools have been developed to facilitate its integration into 
decision making (Mason et al., 2017; O’Hagan and Oakley, 2018). 
 IRRECOVERABLE COSTS AND ONLY IN RESEARCH (OIR) DECISIONS 
As in most applied VOI analysis (e.g. Bennette et al., (2016) and Carlson et al., 
(2018)), the methods illustrated in this thesis make two simplifying assumptions 
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about decision making. First, it is assumed that there are no irrecoverable costs 
associated with the treatments considered. Irrecoverable costs are those costs that, 
once committed, cannot be recovered if guidance is changed at a later date 
(Eckermann and Willan, 2007; McKenna et al., 2015; Thijssen and Bregantini, 
2017). For example, if large capital investments are required for a treatment to be 
delivered in a health system then this is associated with irrecoverable costs if the 
health system cannot easily sell the capital when guidance changes. The second 
assumption is that decisions to recommend an intervention for widespread use and 
decisions to carry out additional research on that same intervention are independent. 
This can be an issues as there are cases in which research cannot be carried out at the 
same time as the treatment is available for widespread use. In this case a conditional 
coverage option such as “Only in Research” (OIR) may be appropriate. This means 
that the use of the new treatment is only allowed in a research setting. Because an 
OIR decision restricts access to a new intervention this is associated with health 
opportunity costs of delaying access and so the value of research is affected. A 
framework exists to relax these assumptions and integrating this perspective with 
rapid VOI methods is an important area for further research (Claxton et al., 2012; 
McKenna et al., 2015; Rothery et al., 2017).  
 MARGINAL PRODUCTIVITY OF RESEARCH BUDGET 
By linking primary outcomes to QALYs Chapter 3 constructs a “bookshelf” of 
research proposals which are ranked from highest to lowest health impact. This 
framework provides a consistent approach to estimate the marginal productivity of 
the research budget. This could be estimated by calculating the value of research of 
proposals which just missed out on funding due to resource constraints (Culyer, 
2016). These are the marginal projects which would have been funded if the research 
budget was larger and so give an indication of the gains from expanding the research 
budget. In principal, the budget for direct service provision (e.g. the NHS) and the 
health research budget (e.g. NETSCC), compete for funding. Therefore estimates of 
their respective marginal productivities can be used to decide whether more 
resources should be devoted to research rather than to direct patient care (or vice 
versa). This line of inquiry fits within a wider approach to decision making which 
aims to reveal the benefits and opportunity costs of public sector expenditure across 
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multiple sectors of the economy (Claxton et al., 2007; Remme et al., 2017; Sanders 
et al., 2016).  
 RESEARCH DESIGN AND INDIVIDUALISED CARE 
The methods described in this thesis provide an expected upper bound on the value 
of research when all uncertainty is resolved. As research designs have a finite sample 
size, they will only ever partially resolve the total uncertainty. Methods to adjust 
research value for sample size and other aspects of research design are well 
developed and further work is required to incorporate this into the rapid VOI 
methods. 
Chapter 4 developed and applied a novel method for estimating the VOI provided by 
a feasibility/pilot studies. This extension allows the expected health impact of 
proposals for feasibility/pilot studies to be compared directly to proposals for RCTs 
or other comparative effectiveness research which is essential if funding for 
feasibility/pilot studies and full trials come from the same research budget. 
In addition to feasibility/pilot studies there are a number of other non-standard 
research designs. These include sequential RCTs (Wang et al., 2012), trials within 
cohorts (Relton et al., 2010) and stepped wedge designs (Hemming et al., 2015) 
among others. The P4 case study requested £3,310,883 to begin a complex adaptive 
trial. This is a trial in which modifications can be made to a trial’s design as it is 
ongoing. Outcomes are monitored over time and depending on how well or poorly 
patients perform on treatment arms, patients are preferentially enrolled to particular 
arms, or arms may be dropped, and/or entirely new treatments added (Chow and 
Chang, 2008). In principle, it is possible to adapt VOI methods to address this trial 
design. However, due to the complexity of this design, it is challenging to rapidly 
quantify the benefits of the adaptive design and so P4 was treated as a standard RCT 
design in Section 4.2.2. Other innovative research designs are also likely to emerge 
from the increased attention paid to estimating the effects of interventions on 
individual patients rather than patient populations i.e. individualised care (Basu et 
al., 2016; Espinoza et al., 2014; Love-Koh et al., 2018). These non-standard research 
designs must be funded from the same research budget as feasibility studies and 
RCTs. VOI methods provide a framework to compare the additional value added 
from these innovative designs to any additional costs, though additional research is 
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INPUTS FOR PROPOSALS 1-6 
A1. PROPOSAL 1 
Inputs used to estimate the value of research in terms of natural outcomes for 
P1 
Input Value  Reference / Justification 
Type of outcome  Binary Functional recovery. 
Outcome benefit or 
harm? 
Benefit  
Baseline probability 55% 
 
162 events 
out of 294 
at risk. 
Not reported in the proposal. Using the placebo group 
from Nichol et al., (2015), which reported 162 out of 
294 functional recoveries with standard care. 
Relative effect of 
new treatment  
Odds ratio 
with 95% 
CI from  
0.23 to 
5.24 
Not reported in the proposal. Assumption based on 
the meta-epidemiological study of 743 publically 
funded RCTs reported in Djulbegovic et al., (2012), see 
Section 2.4.4. 
 
Incidence 8,800 per 
year 
Not reported in the proposal. A study by Sauerland 
and Maegele (2004) estimates that approximately 
8,800 patients per year suffer TBI in the UK and it is 
assumed that all will receive either early or late PTP. 
Time information is 
expected to be 
valuable 
15 years Not reported in the proposal. Changes to standard 
practice in this area appear to move relatively slowly. 
Therefore, it is anticipated that the new information 
will be valuable for a long time span of 15 years.  
Duration of research  5 years From proposal. 
Cost of research to 
NETSCC 
£2,854,000 From proposal. 
Discount rate 3.5% Not reported in the proposal. Guidance from the UK 
Treasury suggests the use of a discount rate of 3.5% 
per annum (HMT Green Book, 2013). 
Current level of 
utilisation of the 
100% 
receive 
Not reported in the proposal. Late PTP is established 
practice in the UK.  Therefore, it is assumed that 100% 
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Inputs used to estimate the value of research in terms of costs and QALYs for 
P1 
Input Value  Reference / Justification 
Additional cost of 




3 days of additional doses required due to earlier 
treatment initiation (Medicines Complete).  
Probability of being 




20% and 14% 
for GOSE 
states 5-8 
Not reported in the proposal. From Nichol et al., 
(2015). 





19.23 years for 
GOSE states 5-
8 
Not reported in the proposal. From Shavelle et al., 
(2006). 
Health utility score 
for functional 
recovery 
0.7, 0.81, 0.96 
and 1 for 
GOSE states 5-
8 
Not reported in the proposal. From Fuller et al., 
(2017). 









Not reported in the proposal. From Nyein et al., 
(1999) and Wood et al., (1999). 
Probability of being 
in GOSE state if 
functional recovery 
does not occur 
29%, 7%, 41% 
and 23% for 
GOSE states 1-
4 
Not reported in the proposal. From Nichol et al., 
(2015). 
Life expectancy if 
functional does not 
occur 
0, 7.11, 12.52 
and 12.52 years 
for GOSE 
states 1-4 
Not reported in the proposal. (Shavelle et al., 
2006)  
Health utility score if 
functional recovery 
does not occur 
0, 0.11, 0.41 
and 0.58 for 
GOSE states 1-
4 
Not reported in the proposal. (Fuller et al., 2017) 
Disease related costs 
if functional recovery 






Not reported in the proposal. (Nyein et al., 1999; 
Wood et al., 1999) 
NHS support and 
treatment costs 
£490,000 From proposal. 





QALY Department of Health for use in health impact 







A2. PROPOSAL 2 
Inputs used to estimate the value of research in terms of natural outcomes for 
P2 
Input Value  Reference / Justification 
Type of 
outcome  





Benefit Pre-progression is a better state than either post-progression 














Treat for 12 
months: 
HR from 
1.05 to 4. 
 
Treat for 6 
months: 
HR from 
1.1 to 4.39 
Not reported in the proposal. The analysis of Djulbegovic et 
al., (2012) does incorporate survival outcomes and so can 
be used as a starting point in this analysis see Section 2.4.4 . 
If the primary outcome is a beneficial survival outcome and 
so this implies a hazard ratio between 0.19 and 4.39.   
However, the meta-epidemiological analysis currently does 
not address plausible results for dose reductions studies. 
The new treatments are very likely to be less effective than 
current treatment and so will be associated with higher 
hazards of transitioning out of pre-progression state to 
either progression or death; this implies a hazard ratio > 1. 
As it is very unlikely that treatment for 6 months will be 
superior to standard care we assume a range for the hazard 
ratio from 1.1 to 4.39. As treatment for 12 months is likely 
to be more effective than treatment for 6 months we assume 
a range from 1.05 to 4. Further meta-epidemiological 
research and/or expert elicitation is required to better 
characterize uncertainty in this case. 
Incidence 1,137 Not reported in the proposal. The NICE budget impact 
statements for the appraisal of nivolumab and 
pembrolizumab (National Institute for Health and Care 
Excellence, 2015) estimates that approximately 1,137 




expected to be 
valuable 
10 years Not reported in the proposal. Standard practice in this area 
appears to move at a moderate pace. Therefore, it is 
anticipated that the new information will be valuable for a 





6 years From proposal.  The primary analysis of 2 year PFS is 
planned to report after 6 years. There is also an additional 
long term follow up study which is planned to report after 
10.3 years. 
Cost of study 
to NETSCC 
£2,522,710 From proposal. 
Discount rate 3.5% Not reported in the proposal. Guidance from the UK 
Treasury suggests the use of a discount rate of 3.5% per 
annum (HMT Green Book, 2013). 
Current level 







Not reported in the proposal. Intensive treatment is the 
NICE mandated treatment in the UK (National Institute for 
Health and Care Excellence, 2015). Therefore, we assume 




Inputs used to estimate the value of research in terms of costs and QALYs for 
P2 









0.79 Not reported in the proposal. The pre progression utility 
score of 0.79 is from the NICE guidance (National Institute 
for Health and Care Excellence, 2015) and come from the 










The costs of the pre progressed state are the same as those 















6 months From proposal. 
NHS support 
and treatment 




From proposal.  
Opportunity 





Not reported in the proposal. Endorsed by the UK 
Department of Health for use in health impact assessments 




A3. PROPOSAL 3 
Inputs used to estimate the value of research in terms of natural outcomes for 
P3 
Input Value  Reference / Justification 
Type of outcome  Binary  The primary outcome for the trial is the number of 
withdrawal attributable serious adverse event (SAE) 







CI from  
5% to 6% 
In the rationale for research section of the proposal 5% is 
cited, in the scientific abstract 6% is cited. We assume 
uncertainty between 5% and 6% 
Relative effect of 
new treatment  
Odds ratio 
with 95% 
CI from  
4.39 to 
0.19 
Assumption based on the meta-epidemiological study of 
743 publically funded RCTs reported in Djulbegovic et 
al., (2012), see Section 2.4.4. Primary outcome is a 





From proposal, the number of individuals facing the 
uncertain treatment choice in the UK is estimated to be 
26.3 per year. 
 
Time information 
is expected to be 
valuable 
10 years There are a number of trials currently underway in this 
area. Therefore, it is anticipated that the new information 
will be valuable for a medium time span of 10 years.  





4 years From proposal. 
 
Cost of research to 
NETSCC 
£855,403 From proposal. 








Inputs used to estimate the value of research in terms of costs and QALYs for 
P3 
Input Value  Reference / Justification 
Cost of continuous 
treatment if SAE 
occurs 
£4,877,749 Not reported in the proposal. See Section 4.2.1 
Cost of continuous 
treatment if SAE 
does not occur 
£7,316,623 Not reported in the proposal. See Section 4.2.1 
Cost of withdrawal if 
SAE occurs 
2,643,621 Not reported in the proposal. See Section 4.2.1 
Cost of withdrawal if 
SAE does not occur 
£3,965,432 Not reported in the proposal. See Section 4.2.1 
Probability of being 
in state if SAE 
occurs 
33.3%, 33.3% 




Not reported in the proposal. Assumption. 
Life expectancy if 
SAE occurs 
0, 35.47 and 




Not reported in the proposal. If individuals 
survive we assume that they will live for their full 
additional life expectancy according to NICE 
report (National Institute for Health and Care 
Excellence, 2015), Eculizumab for treating 
atypical haemolytic uraemic syndrome. 
Health utility score if 
SAE occurs 




Not reported in the proposal. Death is associated 
with utility zero. If irreversible organ injury 
occurs we assume that utility will be 0.59 which is 
the average UK utility in diseases of kidney and 
ureters (Sullivan et al., 2011). If meningococcal 
infection occurs we assume that individuals will 
have the lower utility of 0.2 (Christensen et al., 
2013). 
Disease related costs 
if SAE occurs 





Not reported in the proposal. Death is associated 
with zero additional disease related costs. If 
meningococcal infection occurs patients incur 
disease related costs from a spell in hospital 
(£2936.2) and a follow up appointment (£279.98) 
(Christensen et al., 2013). If irreversible organ 
injury occurs we assume this will require kidney 
transplant costing £17,000 in the first year and 
£5,000 in subsequent years (NHS England, 2013). 
Individuals are assumed to survive for their 
remaining 35.47 years of life, resulting in a total 
cost of £115,503 after discounting.   
Life expectancy if 
SAE does not occur 
35.47 years Not reported in the proposal. Full additional life 
expectancy according to NICE (National Institute 
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for Health and Care Excellence, 2015), 
Eculizumab for treating atypical haemolytic 
uraemic syndrome. 
Health utility score if 
SAE does not occur 
0.59 Not reported in the proposal. 0.59 is the average 
UK utility in diseases of kidney and ureters 
(Sullivan et al., 2011). 
Disease related costs 
if SAE does not 
occur 
£0 Not reported in the proposal. Assume zero 
additional disease related costs (excluding 
treatment costs). 
NHS support and 
treatment costs 
£10,608,500 From proposal. 





Not reported in the proposal. Endorsed by the UK 
Department of Health for use in health impact 




A4. PROPOSAL 4 
Inputs used to estimate the value of research in terms of natural outcomes for 
P4 
Input Value  Reference / Justification 
Type of 
outcome  
Continuous  The primary outcome for the trial is a continuous measure 










Mean of 0 
and SE of 
0.54 
Not reported in proposal. See Section 2.4.4. 
 
MCD 1.4 MMSE 
points 
The proposal specified a required change in MMSE of 1.4 
points for all of the active treatments.  
Incidence 100,000 From proposal. 
Time 
information is 
expected to be 
valuable 
20 years Not reported in the proposal. Standard practice in this area 
appears to move slowly. Therefore, it is anticipated that the 
new information will be valuable for a long time span of 20 
years.   
Duration of 
study 
6 years From proposal.   
Cost of study to 
NETSCC 
£3,310,883 From proposal. 
Discount rate 3.5% Not reported in the proposal. Guidance from the UK 
Treasury suggests the use of a discount rate of 3.5% per 
annum (HMT Green Book, 2013). 







Not reported in the proposal. There is no treatment affecting 
disease progression, therefore, we assume that 100% of 





Inputs used to estimate the value of research in terms of costs and QALYs for 
P4 
Input  Value  Reference / Justification 
Monthly cost of 
baseline: no 
treatment 
£0 No treatment does not incur any additional costs. 
Monthly cost of 
treatment 1: 
Exenatide 
£73.36 Not reported in the proposal. From (Medicines Complete, 
2018) , Exenatide costs £18.34 per week x 4 weeks = 
73.36 per month. 
Monthly cost of 
treatment 2: 
Telmisartan 
£14.83 Not reported in the proposal. From (Medicines Complete, 
2018), Telmisartan costs £13.61 per 28 tablet pack. 
£13.61 /28 = £0.49 per day x 30.5 days in a month = 
£14.83 per month. 





Not reported in the proposal. Combination of Exenatide 
and Telmisartan (above) costs £73.36 + £14.83 = £88.19 
per month. 
How is the 
primary 
outcome 
expected to be 




utility for 1 
unit increase 
in MMSE 
Not reported in the proposal. From Technical Appraisal 
of Alzheimer’s drugs (Bond et al., 2012) see Section 
4.2.2.6. 
How is the 
primary 
outcome 





in costs for 1 
unit increase 
in MMSE 
Not reported in the proposal. Wolstenholme et al., (2002) 
estimated the relationship between disease progression 
and cost of care in dementia. Each one-point decline in 
the MMSE score is associated with a £56 increase in the 
four-monthly costs. £56/4 = £14. 
How long is the 
treatment effect 
expected to last 
12 months Not reported in proposal. Assumption, should be 
informed by expert opinion. 
NHS support 
and treatment 
costs of research  
£1,297,789 From proposal. 
Opportunity 
cost of health 
care expenditure  
£15,000 per 
QALY 
Not reported in the proposal. Endorsed by the UK 
Department of Health for use in health impact 




A5. PROPOSAL 5 
Inputs used to estimate the value of research in terms of natural outcomes for 
P5 
Input Value  Reference / Justification 
Type of 
outcome  
Binary  The proposal discusses the Positive and Negative Syndrome 
Scale (PANSS) score as an outcome in the full trial data 
could not be found to link to costs and QALYs. As relapse 
is a major concern in first episode psychosis we assume that 
the definitive trial will use relapses prevented as the primary 










out of 61 
at risk. 
Not reported in the proposal. Using the treatment as usual 
arm of a UK (London) based, RCT by Craig et al., (2004) 
we estimate that there is a (29/61 =) 47.5% risk of relapse 
with treatment as usual for young people (aged 16-40) with 









Not reported in the proposal. Assumption based on the 
meta-epidemiological study of 743 publically funded RCTs 
reported in Djulbegovic et al., (2012), see Section 2.4.4. 
 
Incidence 1,563 per 
year 
Not reported in the proposal. From Kirkbride et al., (2013), 
5,939 cases for individuals between 16-35 years old. 
Assuming constant rate of events over all age ranges: 
(5939/19 =) 312.58 cases for each year group. Number of 




expected to be 
valuable 
15 years Not reported in the proposal. Standard practice in this area 
appears to move relatively slowly. Therefore, it is 
anticipated that the new information will be valuable for a 
long time span of 15 years.   
Duration of 
feasibility study  
2 years From proposal. 
Duration of full 
trial (including 
time to apply 
for funding) 
6 years Not reported in the proposal. From Morgan et al., (2018) 
full trials funded by the National Institute for Health 
Research (NIHR) Research for patient benefit (RfPB) 
programme which arise out of feasibility studies take 42 
months on average to report (range 26 to 55). Application 
for a full trial takes an average of 10 months (range 7 – 29) 
after feasibility trial reporting and trials start an average of 
18 months (range 13 to 28) after application. Therefore the 
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average time from feasibility study report to full trial report 




£601,481 From proposal 
Discount rate 3.5% Not reported in the proposal. Guidance from the UK 
Treasury suggests the use of a discount rate of 3.5% per 
annum (HMT Green Book, 2013). 
Cost of full trial 
to NETSCC 
£1,000,000 Not reported in the proposal. From Morgan et al., (2018) 
full trials funded by the NIHR RfPB programme cost 
£1,163,996 on average (range £321,403 to £2,099,813). If 
the full trial is feasible, it will take place it is expected to 
take place 10 months after the feasibility trial reports i.e. (24 
+ 10)/12 = 2.8 years. Discounting to present value the 
expected cost of the full trial is £1,163,996/(1.035)^2.8 = 
£1,057,106. 







Not reported in the proposal. The proposal states that 
standard treatment is APs, which are chosen based on 
(National Institute for Health and Care Excellence, 2014) 
NICE guidance. Therefore, we assume that all individuals 
receive this treatment. 
Likelihood of 
delivering a 
future full trial: 
64% Not reported in the proposal. From Morgan et al., (2018) 
(57/89 =) 64% of feasibility studies were considered feasible 
by self-report of principal investigators. 20 were judged as 




Inputs used to estimate the value of research in terms of costs and QALYs for 
P5 




1 year Not reported in the proposal. Here we only consider 
differences in costs and outcomes over a 12 month period 
since there is no information reported on long term effects of 
treatment. This is an important limitation of the analysis 
(Briggs et al., 2006) since long term effects on costs and 
outcomes are not captured. 
Cost of baseline 
treatment: 
Antipsychotics  
£687 Not reported in the proposal. NICE guidance (National 
Institute for Health and Care Excellence, 2014) recommends 
that the choice of an AP for a particular individual should be 
based on its side effect profile for that individual. Since there 
is no single AP used as established standard of care in the 
UK for CYP, we use the average yearly cost over the range 
of APs listed in the NICE guidance of £687 per individual.  
Monthly costs from National Institute for Health and Care 
Excellence  (2014) guidance: £57.23 (Amisulpride), £14.35  
(Haloperidol), £85.13  (Olanzapine), £108.89  (Aripiprazole)  
£156.34 (Paliperidone),  £67.52 (Risperidone), £63.03 
(Zotepine), £6.7 (Flupentixoldecanoate). Average cost = 





£3,492 Not reported in the proposal. The psychological intervention 
(PI) is described in the proposal as up to 30 sessions of 
cognitive behavioral therapy (CBT) over 6 months, with an 
extra 6 sessions of family intervention with parents/carers.  
Based on a cost of £97 per CBT session (Curtis and Burns, 
2016) this implies a total cost of (£97 x 36 =) £3,492 per 




£4,179 Not reported in the proposal. The combination therapy (AP + 
PI) is assumed to be simply the cost of APs plus the cost of 
PI, (£3,492 + £687 =) £4,179 per individual.  
Health state 
utility if relapse 
does not occur 
0.94 Not reported in the proposal. If relapse does not occur we 
assume a similar health utility as general population below 
30 years old (Ara and Brazier, 2011). 
Disease related 
costs if relapse 
does not occur 
£5,401 Not reported in the proposal. Costs from NICE (National 
Institute for Health and Care Excellence, 2014) guidance on 
adult schizophrenia, using only outpatient, primary and 
community care costs = £5,401 per year. 
Health state 
utility if relapse 
occurs 
0.805 Not reported in the proposal. Utility during relapse estimated 
from adults with schizophrenia (0.67) (Lenert et al., 2004). 
From NICE  (National Institute for Health and Care 
Excellence, 2014) guidance on adult schizophrenia relapse is 
associated with a 6 month decrement in utility. Average 





costs if relapse 
occurs 
£19,210 Not reported in the proposal. From NICE  (National Institute 
for Health and Care Excellence, 2014) guidance on adult 
schizophrenia disease related costs are £33,018 per year for 
relapse. As above assume 6 months of increased costs 
associated with relapse and 6 months of non-relapsed costs = 





£150,000 From proposal. 
NHS support 
and treatment 
costs of full 
study  
£490,000 Not reported in the proposal. Because of similar size and 
duration of planed research, additional NHS support and 
treatment costs are assumed to be close to those of P1, which 
is £490,000.  
Opportunity cost 





Not reported in the proposal. Endorsed by the UK 
Department of Health for use in health impact assessments 




A6. PROPOSAL 6 
Inputs used to estimate the value of research in terms of natural outcomes for 
P6 
Input Value  Reference / Justification 
Type of outcome  Binary Death in preferred place. 
Outcome benefit or 
harm? 
Benefit Dying in a preferred place is considered better to dying 
in a place not of the patients choosing. 





From proposal, of those who wish to die at home 
approximately 30% achieve their wish (Office for 
National Statistics, 2015). Assume +/- 10% uncertainty. 
Relative effect of 




from  1.1 
to 5.24 
Not reported in the proposal. The analysis of 
Djulbegovic et al., (2012) can be used as a starting 
point in this analysis see Section 2.4.4. The primary 
outcome is a beneficial binary outcome and so this 
implies a hazard ratio between 0.23 and 5.24.   
 
However, the new treatment is very likely to be more 
effective than current treatment and so will be 
associated with odds achieving preference for place of 
death, this implies odds ratio > 1. Therefore we assume 
a range for the odds ratio from 1.1 to 5.24. Further 
meta-epidemiological research and/or expert elicitation 




The Palliative Care Funding Review (Tom Hughes-
Hallett et al., 2011) estimates that 355,000 patients need 
palliative care each year and 73% of these individuals 
would prefer to die at home (Macmillan, 2010). 
Therefore the population of interest is approximately 
(355,000 x 0.73 =) 259,150 individuals per annum. 
Time information is 
expected to be 
valuable 
15 years Not reported in the proposal. Changes to standard 
practice in this area appear to move relatively slowly. 
Therefore, it is anticipated that the new information will 
be valuable for a long time span of 15 years.  
Duration of research  3 years From proposal. 
Cost of research to 
NETSCC 
£882,177 From proposal. 
Discount rate 3.5% Not reported in the proposal. Guidance from the UK 
Treasury suggests the use of a discount rate of 3.5% per 
annum (HMT Green Book, 2013). 
Current level of 100% Not reported in the proposal. We assume that 0% of 
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Inputs used to estimate the value of research in terms of costs and QALYs for 
P6 
Input Value  Reference / Justification 





Assuming the estimated NHS support and 
treatment costs of £4,104 are to cover the cost of 
the booklet and advice in the treatment arm 
(n=453), this will cost the NHS an additional 
(£4,104/453 =) £9.06 per person. 
Life expectancy if 
death at home does 
not occur (death in 
hospital) 
0.3 years Those included in the trial have a prognosis of 8-
24 weeks. The midpoint in this range is 16 weeks 
which is equivalent to 16/52 = 0.3 years. 
 
Health utility score if 
death at home does 
not occur (death in 
hospital) 
0.76 Not reported in the proposal. Estimated utility of 
palliative care patients a review of utilities at the 
end of life compiled by Dixon et al., (2009). The 
average utility in this sample (extracted from 
column 7 of Table 2 of report) was 0.76. It is 
assumed that the health state utility is not affected 
by whether the patient dies at home or at hospital. 
Disease related costs 
if death at home does 
not occur (death in 
hospital) 
£3,000 Not reported in the proposal. A review carried out 
by the End of Life Care Programme (2012) 
reported the average cost of a hospital stay ending 
in death to be approximately £3,000. 
Life expectancy if 
death at home does 
occur 
0.3 years Those included in the trial have a prognosis of 8-
24 weeks. The midpoint in this range is 16 weeks 
which is equivalent to 16/52 = 0.3 years. 
Health utility score if 
death at home does 
occur 
0.76 Not reported in the proposal. Estimated utility of 
palliative care patients a review of utilities at the 
end of life compiled by (Dixon et al., 2009). The 
average utility in this sample (extracted from 
column 7 of Table 2 of report) was 0.76. It is 
assumed that the health state utility is not affected 
by whether the patient dies at home or at hospital. 
Disease related costs 
if death at home does 
occur 
£2,108 Not reported in the proposal. A review carried out 
by the End of Life Care Programme (Reviewing 
end of life care costing information to inform the 
QIPP End of Life Care Workstream, 2012) report 
provided a range of £1,415 to £2,800 for the cost 
of dying in the community. Assume the midpoint 
of this range £2,108. 
NHS support and 
treatment costs 
£4,014 From proposal. 





Not reported in the proposal. Endorsed by the UK 
Department of Health for use in health impact 
assessments (NHS England, 2015). 
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A7. R CODE TO CONVERT BETWEEN ODDS RATIO, RISK DIFFERENCE AND 
RISK RATIO 
Odds ratio (OR) to risk difference (RD) 
# Events_t0 = events in control arm 
# AtRisk_t0 = number at risk in control arm 
# OR_t1 = odds ratio for treatment effect 
OR_to_RD <- function(Events_t0, AtRisk_t0, OR_t1){ 
  set.seed(5) 
  # RD = E(P_t1) - E(P_t0) 
  # E(P_t0) = 162/294 = 0.5510204 
  E_P_t0 <- Events_t0/AtRisk_t0 
  # therefore 
  # RD = E(P_t1) - 0.5510204 
   
  # E(P_t1) = E(Odds_t1/(1 + Odds_t1)) 
  # Odds_t1 = Odds_t0*OR_t1 
  # Odds_t0 <- Prob_t0/(1 - Prob_t0) 
  Prob_t0 <- rbeta(100000, Events_t0, (AtRisk_t0 - Events_t0)) 
  Odds_t0 <- Prob_t0/(1 - Prob_t0) 
  Odds_t1 <- Odds_t0*OR_t1 
  E_P_t1 <- mean(Odds_t1/(1 + Odds_t1)) 
   
  RD_t1 <- E_P_t1 - E_P_t0 






Risk difference (RD) to odds ratio (OR) 
# Note: require: OR_to_RD() function 
# Events_t0 = events in control arm 
# AtRisk_t0 = number at risk in control arm 
# RD_t1 = risk difference for treatment effect 
# search_range = range of odds ratios tried in maximisation algorithm 
RD_to_OR <- function(Events_t0, AtRisk_t0, RD_t1, search_range = c(0, 6)){ 
  set.seed(5) 
  # minimse squared distance between OR_variable and the target RD 
  # x = OR_variable 
  f2 <- function(x) (OR_to_RD(Events_t0, AtRisk_t0, x) - RD_t1)^2 
  # optimise is for single variable minimisation:  
  # c(search_range[1], search_range[2])is the area for searching 
  r2 <- optimise(f2, c(search_range[1], search_range[2]))  # single variable 
minimisation: c(0, 2) is the area for searching 
  return(r2$minimum) 
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